Incidence and survival of prostate cancer since 1970 by Post, P.N. (Piet)
Incidence and survival of 
prostate cancer since 1970 
Piet Post 
Acknowledgements 
This study was financially supported by: 
- Netherlands Institute for Health Sciences (NIHES). 
~ Comprehensive Cancer Centre South (IKZ), Eindhoven, 
- Dr. de Grood foundatiou. 
Financial support for printing of this thesis was obtained from: 
~ Comprehensive Cancer Centre South (IKZ), Eindhoven, 
- Stichting voor Urologisch Wetcnschappelijk Ollderzoek, (SUWO) ,Rottcrdam. 
~ Zeneca Fanna B.V, 
- Abbott B.V. 
© P. N. Post, 1999. 
No part of tIus book may be reproduced in any fonn by print, microfilm or any other means 
without permission from the author or, when appropriate, from the publishers of the 
publications, 
Printed by PrintPartners Ipskamp, Enschcde, 
Incidence and survival of prostate cancer since 1970 
Incidentie en overleving van prostaatkanker sinds 1970 
PROEFSCHRIFT 
Ter vcrkrijging van de graad van doctor 
aan de Erasmus Universiteit Rotterdam 
op gezag van de Rector Magnificus 
Prof. dr. P.W.C. Akkennans M.A. 
en volgens besluit van het College voor Promoties 
De openbare verdediging zal piaatsvinden op 
woel1sdag 31 maart 1999 om 11,45 uur 
door 
Petrus Nicolaas Post 
geboren te Oudel1bosch 
Pl'omotiecolluuissie 
Promotoren: 
Overige leden: 
Co~promotor: 
Prof. dr. A. Hofman 
Prof. dr. F.H. Schroder 
Prof. dr. P.C. Levendag 
Prof. dr. Th. H. van der Kwast 
Prof. dr. P.!. van der Maas 
Dr. J. W. W. Coebergh 
CONTENTS 
Publications and manuscripts described in this thesis 
List of abbreviations 
Chapter 1 Introduction 
Chapter 2 Study populatiou and methods 
7 
8 
9 
15 
Chapter 3 Trends ill incidence and mortality 23 
3.1 Trends in incidence and mortality rates for prostate cancer, 1971-1995 25 
3.2 Striking increase in incidence of prostate cancer in men aged < 60 years 
without improvement in prognosis 37 
3.3 Increased risk of fatal prostate cancer may explain the rise in 
mortality in The Netherlands 49 
Chapter 4 Trends in prognosis 
4.1 Trends in survival of prostate cancer in southeastem 
Netherlands, 1971-1989 
4.2 Variation in survival of patients with prostate cancer in Europe 
since 1978 
61 
63 
75 
Chapter 5 Determinants of treatment oflocalized prostate cancer 87 
5.1 Trend and variation in treatment oflocalized prostate cancer 89 
5.2 Co-morbidity in patients with prostate cancer and its relevance 
to treatment choice 101 
Chapter 6 Determinants of survival of prostate cancel' 111 
'6.1 Long-tem1 survival of prostate cancer in southeastem Netherlands 113 
6.2 The independent prognostic value of co-morbidity among men 
aged < 75 years with localized prostate cancer 
Chapter 7 General Discussion 
Summ81Y 
Samenvatting (summaty in Dutch) 
Gearfetting (summalY in Frisian) 
Dankwoord 
Cuniculum Vitae 
123 
139 
149 
151 
153 
155 
157 

Publications and manuscripts based on the studies described in this thesis. 
Post PN, Kit PJM, Crommelin MA, Schapers RFM, Coebergh JWW. Trends in 
incidence and mOliality rates for prostate cancer before and after prostate-specific 
antigen introduction. A regis!ty-based study in southeastern Netherlands, 1971-1995. 
EliI' J Callcer 1998;34:705-709 (chapter 3.1). 
Post PN, Stockton D, Davies TW, Coebergh JWW. Striking increase in incidence of 
prostate cancer in men aged < 60 years without improvement in prognosis. Br J 
Callcer 1999;79: 13-17 (chapter 3.2). 
Post PN, Straatman H, Kiemeney LALM, Coebergh JWW. Increased risk of fatal 
prostate cancer may explain the rise in mortality in The Netherlands. lilt J Epidellliol 
(In press) (chapter 3.3). 
Post PN, Kil PJM, Coebergh JWW. Trends in survival of prostate cancer in 
Southeastern Netherlands, 1971-1989. lilt J Callcer (In press) (chapter 4.1). 
Post PN, Damhuis RAM, van der Meijden APM and the Eurocare Working Group. 
Variation in survival of patients with prostate cancer in Europe since 1978. The 
Eurocare s!tldy. EliI' J Callcer 1998;34:2226-2231 (chapter 4.2). 
Post PN, Kil PJM, Hendlikx AJM, POOlimans PMP, Crommelin MA, Coebergh JWW. 
Trend and variation in treatment oflocalized prostate cancer in the southern part of the 
Netherlands, 1988-1996. EliI' Urol (In press) (chapter 5.1). 
Post PN, Kil PJM, Hendrikx AJM, Janssen-Heijnen MLG, Crommelin MA, Coebergh 
JWW. Co-morbidity in patients with prostate cancer and its relevance to treatment 
choice. (submitted) (chapter 5.2). 
Post PN, Hendrikx AJM, Hansen BE, van der Heijden LH, Coebergh JWW. Long-
term survival of prostate cancer in southeastem Netherlands. (submitted) (chapter 6.\). 
Post PN, Hansen BE, Kil PJM, Coebergh JWW. Independent prognostic value of co-
morbidity among men aged < 75 years with localized prostate cancer: a population-
based study. (submitted) (chapter 6.2). 
List of frequently used abbreviations 
TURP 
BPH 
PSA 
TNM 
RR 
HR 
CI 
SE 
ESR 
WSR 
Eurocare 
IKZ 
transuretln"al resection of prostate 
benign prostatic hypelplasia 
prostate-specific antigen 
Tumour-Node-Metastasis classification 
relative risk 
hazard ratio 
confidence interval 
standard enor 
European Standardized Rate 
World Standardized Rate 
Collaborative study of European cancer registries concerning survival 
Integraal Kankercentrulll Zuid 
Chapter 1 Introduction 
10 Chapter 1 
Increased incidence or jllst a higher detection rate? 
In NOlih America and many European countries, prostate cancer has become the 
second most common and in some countries even the most common cancel' among 
men during the past two decades. I Since the age-specific incidence increases steeply 
after the age of 50 years, a considerable proportion of the increase in the cmde 
incidence rate for prostate cancer is due to the ageing of the population. Moreover, 
decreases in mOliality due to benign prostatic hyperplasia,' cardiovascular diseases' 
and lung caucer' may have increased the probability of a diagnosis of prostate cancer. 
However, the age-standardized incidence has increased considerably as weil.l 
Therefore, one might assume that the risk of prostate cancer has increased over the 
past two decades. The aetiology, however, has not as yet been clarified. 
Figl/re 1 Age-adjusted illcidellce of prostate callcer ill 1978-1983 
China (Shanghai) ~ 
Japan (Osaka) I-
india (Bombay) i-I 
Italy (Varese) 
Netherlands (Eindhoven) 
Sweden 
US Bay area (blacks) 
US Bay area (whites) 
HawaII (whites) 
HawaII (Japanese) 
HawaII (ChInese) 
0 20 40 60 80 100 
Incidence per 100 000 (WSR) 
The velY low incidence of prostate cancer among Asians as compared to populations 
in the USA and NOlihwestem Europe (Figure I) has resulted in an extensive search for 
environmental risk factors such as diet, but unfortunately so far little progress has been 
made. A role for envirOlUllental factors is supported by studies of Japanese migrants. 
Siuce both early and late migrants show prostate cancer rates that are fairly similar to 
those for US bam japanese, late-life events seem important in the aetiology.' Although 
the prevalence of latent prostate cancer is fairly similar for native Japanese and 
Japanese in Hawaii, the prevalence of the proliferative type of latent cancer was 
substantially higher among Japanese from Hawaii (19%) than those living in Japan 
(9%).' 
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Therefore, frequently used definitions of the various types of prostate cancer need to 
be distinguished. Latent prostate cancer is defined as prostate cancer found in a man in 
whom there was no clinical diagnosis or suspicion of prostate cancer before death.7 It 
can subsequently be subdivided into a proliferative (more anaplastic and invasive) and 
a nonproliferative type.' Several investigators have tried to define a tumour as 
insignificant on the basis of its morphological characteristics. Tumours with a volume 
< 0.2 ml would be unlikely to reach a clinically significant size.8•9 However, tumours 
found at autopsy are not necessarily insignificant. Focal cancer is a tumour present 
only in onesingle spot. Incidental prostate cancer is found unexpectedly in 
approximately 10% of patients who undergo transuretlnal resection of the prostate 
(TURP) for the treatment of symptoms of benign prostatic hyperplasia. 10 Increased use 
of TURP may have induced increased detection of latent tumours, thus causing an 
increase in the incidence. I I The marked improvement in survival of Swedish patients 
with prostate cancer between 1960 and 1980 has been interpreted as evidence that 
increased diagnosis of latent (,non-lethal') prostate cancer cases has occurred (length 
time bias).I2 Since the late 1980s, increased detection of 'latent' tumours may have 
been accelerated by the introduction of improved diagnostic tools such as trans rectal 
ultrasound, ultrasound-guided (random) biopsies and prostate-specific antigen (PSA) 
testing.13 Detection of prostate cancer following a positive PSA test appears to move 
the diagnosis forward by up to 5-10 years,I4.I5 also resulting in an increase in the 
incidence and improvement of survival (lead time bias). This does not, however, 
exclude a hue increase in the incidence. 
A hue increase in incidence is likely if the increase in incidence is not limited to early 
low-grade prostate cancer only and if population-based mOliality rates for prostate 
cancer have also increased. In most European countries, lTIOliality due to prostate 
cancer has increased over the past two decades, although to a lesser extent than the 
incidence. I6 MOliality is less likely to be influenced by changes in detection methods. 
Nevertheless, since all cause mortality among men has been declining over the past 
two decades, the probability that prostate cancer has been recorded as the underlying 
cause of death may have increased. Analyses of mOliality which aim to distinguish 
birth cohort effects (usually related to exposure to specific risk factors) from calendar 
period effects (usually related to changes in diagnosis or treatment) may distinguish an 
increased risk of fatal prostate cancer from increases that are due solely to increased 
detection. 
Management oflocalized prostate cancel' 
While prostate cancer is detected with increasing frequency at an early stage,13.I7 the 
often protracted nahnal history has led to doubts on the need for curative treatment in 
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these cases. Several Sandinavian studies repotied high IO-year survival rates of up to 
87% for patients with localized and low-grade prostate cancer without curative 
treatmen!."·19 However, in an American study in which all original pathological 
specimens were reviewed, patients with moderately differentiated tumours exhibited a 
significantly shotier survival than those with well differentiated tumours.'o No 
conclusive evidence is available that treatment with curative intent (radical 
prostatectomy or curative radiotherapy) will improve these results." However, patients 
with poorly differentiated tumours have a worse a poorer prognosis, which can be 
approached by radical prostatectomy when confined to the prostate.22 Radiotherapy 
with adjuvant hormonal treatment yields promising results for patients with locally 
advanced tumours.'] Nevertheless, the in 1988 by Whitmore formulated intriguing 
questions remain puzzling: 'Is cure necessary for whom it is possible?' and 'Is cure 
possible in those for whom it is necessary?,.24 Adverse effects of curative treatment are 
not negligible. Although sexual potency may be preserved after radical prostatectomy 
in 70% of patients in selected series,25 population-based estimates of partial or full 
impotence amount to 50_60%.'6 Furthermore, symptoms of urinary incontinence 
occur in 10-30% of patients.27 Impotence is less common afler radiotherapy (20-30%), 
but symptoms of urinary incontinence in 10-20% and faecal incontinence in 20% of 
patients have been reported. 27,28 Therefore, the benefits and risks of the different 
treatment options are also dependent on the patient's age and concomitant diseases and 
leave room for patients' and physicians' preferences. Many urologists who master the 
technique of radical prostatectomy advocate it only if the estimated remaining life 
expectancy of the patient is more than 10 years.'9 However, the implicit assumption 
that mortality due to prostate cancer is to be expected more than 10 years afler 
diagnosis is not undisputed. 19,]O Early mortality in elderly patients with localized 
prostate cancer might be due to concomitant diseases rather than their prostate cancer, 
which should have consequences for its management. 
Aim ofthe thesis 
The main objective of this thesis is to distinguish a spurious increase in the incidence 
of prostate cancer (due solely to a higher detection rate) from a tme increase in the 
incidence, which can be rephrased in the first central question: 
1 Was the increase in incidence of prostate cancer real or jllst dlle to improved 
detection? 
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Using regional, national and European cancer and cause of death regis hies, this 
question is addressed in studies of the incidence and prognosis of and mortality due to 
prostate cancer. 
In chapter 3.1, trends in incidence and mortality rates are described for southeastem 
Netherlands. Chapter 3.2, a collaborative study of the Eindhoven and the East Anglian 
Cancer Regishy, focuses on the age group below 60 years. In chapter 3.3, national 
mOltality rates for prostate cancer are explored in an age-period-cohOlt analysis. 
Trends in survival of prostate cancer are investigated in chapter 4.1 for southeastern 
Netherlands and in chapter 4.2 for Europe. The variation in sUlvival in Europe was 
also investigated. 
The second part of the thesis focuses on issues related to management of localized 
prostate cancer, pluased as the second central question: 
2 Wltat are tlte main determillants of treatlllellt alld slln,ival of localized prostate 
cancer? 
The changes and variation in the management of localized tumours in the southern part 
of The Netherlands is described in chapter 5.1. Factors influencing the choice of 
treatment for these patients were investigated in chaptcr 5.2. Special attention was paid 
to co-morbidity in an investigation of its prevalence and relevance to choice of 
treatment. The long-tenTI outcome of conservatively treated prostate cancer is 
described in chapter 6.1. In the last chapter bcforc the general discussion (6.2), the 
independent prognostic value of co-morbidity was investigated in a cohort of patients 
recently diagnosed with localized prostate cancer in the southem part of The 
Netherlands. 
Firstly, the study populations and general methods used for tllis thesis are discussed in 
chapter 2. 
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The questions raised in the introduction were addressed in population-based registries. 
A cancer registry collects data on all newly diagnosed cases of cancer in a defined 
population. Obviously, use of these registries is essential for calculation of incidence, 
because it is the only way to obtain all newly diagnosed patients with cancer in a 
defined area. FUlihermore, inclusion of all patients registered in a cancer registry in a 
specified period reduces selection bias in survival analyses to a minimum, provided 
that the regishy can be considered complete. Since most studies were based on the 
Eindhoven Cancer Registry, which is the only long-standing cancer regishy in The 
Netherlands, its development and methods will first be described. Specific methods of 
the East Anglian Cancer RegistlY and other European cancer registries which 
conhibuted data for two other studies in this thesis, are discussed briefly. 
The Eindhoven Cancel' Registry 
Developmellt 
This regional cancer registry stalied in 1955 as part of a progranulle for nation-wide 
cancer registration. The Eindhoven Cancer Registry has been the sole cancer registry 
in The Netherlands functioning without intcrruption from that year, whereas most 
other regional registries discontinued their activities, until a successful nation-wide 
programme was established in 1984. Registration in southeastem Netherlands started 
in three hospitals in Eindhoven, when data were collected on new cancer patients 
during the consultant's weekly meeting and, subsequently, directly from pathology 
reports and patient records. Registration activities expanded together with the 
decentralized consulting services of radiotherapists from Eindhoven, where 
megavoltage facilities were introduced in 1972. More systematic registration 
procedures were developed according to international guidelines, especially since 
1967, when a medical officer was appointed. In the early 1970s, the regishy served 13 
hospitals in a defined area in North-Brabant and middle and n0l1hern Limburg. After 
completeness and accuracy were evaluated in 1980-1983 and the data-base was 
computerized, the registry was included in the publications of the International Agency 
for Research on Cancer (tARC) conceming Cancer Incidence in Five Continents as of 
the period 1978-1982. I 
Completelless 
Although the registry stat1ed in 1955, based on analyses of referral pattems, it is likely 
that a significant prop0l1ion of several types of patients was missed by the registry for 
some types of cancer before 1971, including prostate cancer. Comparison of incidence 
with mortality rates illustrates this: only for men aged 85 or over, mortality rates 
exceeded the incidence rates in the early 1970s. Apart from some incompleteness of 
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cases diagnosed on clinical grounds only, this may also be due to misclassification of 
the underlying cause of death in this old age group with very high generalm0l1ality. 
Therefore, the registry is considered nearly complete for prostate cancer as of 1971. 
However, some increasing completcness can be assumed during the 1970s related to 
the settlement of urologists in the region. The number of urologists increased from 3 in 
1971 to 12 in 1978 and 15 in 1994 (per 500,000 men). When a nation-wide 
programme for cancer registration was stmted, the area of the Eindhoven Cancer 
Regishy enlarged and included also the central and nOlthwestern part of the province 
of North-Brabant since 1986. Registration of cancer is not obligatory by national laws, 
but contracts with the pathological laboratories, hospitals and the regional radiotherapy 
institute ensure that vh1ually all newly diagnosed cases are rep0l1ed to thc regishy. 
Cases identified on the basis of a death certificate only (DCO), of whom no clinical 
diagnosis was available, cannot be registered in The Netherlands. Moreover, autopsy 
rates are low in The Netherlands as compared to e.g. Sweden. Medical records from 
hospitals and the radiotherapy institutes have always been the basis for registration. 
Similar methods have been in use for the other cancer registries participating in the 
nation-wide Netherlands Cancer Regishy, which published its first report for the year 
1989'> Completeness of one of the participating regional cancer registries was 
estimated to be 96%_98%.3.4 Furthermore, registration of the data by trained registrars 
was shown to be of high accuracy. 5 
Characteristics of the pop Illation 
The population of southeastern Netherlands rose to almost one million inhabitants 
since the late 1970s with a pronounced ageing of the population. Probably promoted 
by the concentration of tobacco industries around Eindhoven, a high proportion of men 
in the region (>80%) used to smoke, which resulted in high mortality rates due to 
cardiovascular diseases and lung cancer. 6 Since 1960, smoking prevalences have 
decreased for men but increased for women up to the late 1960s. 
The region is characterized by good access to medical care without financial obstacles. 
The distance to a hospital has always been less than 30 kilometres. Consequently, an 
analysis of socioeconomic variations in survival of prostate cancer in southeastern 
Netherlands barely revealed any differences between the highest and the lowest 
socioeconomic levels, when the same expected survival probabilities were used (5-
year relative survival 61% vs. 59%).' The region covered by the whole Eindhoven 
Cancer Registry since 1986 is quite similar to the southeastcrn part and has a 
population of 2 million inhabitants, servcd by 16 large cOlfnlfunity hospitals and two 
radiotherapy institutes. The area does not contain university or specialized cancer 
hospitals. 
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Assessmellt of stage 
Stage has always been recorded by the regishy according to the Tumour-No de-
Metastases (TNM) classification in use. 8 In order to obtain a classification system that 
could be used through the years, this classification was simplified as localized and 
incidental finding (Tl), localized and palpablc or visible on transrectal ultrasound 
imaging (T2) or locally advanced (T3 or T4). If lymph node involvement or distant 
metastases were recorded, stage was classified as metastasized. Because absence of 
metastases was not always recorded explicitly, patients recorded as Mx were also 
included in the non-metastasized categories (MO). This seems generally justified, 
because physicians do not always make a note of evcty negative finding. Since the 
introduction of PSA testing (betwccn 1990 and 1993 in southeastern Netherlands) this 
may have increasingly taken place, since patients with PSA < 10 ng/ml are unlikely to 
show positive signs on bone scan present with a positive bone-scan imaging: On the 
other hand, part of the patients did probably not undergo bone scanning, because their 
high PSA level indicated a velY high probability of metastases. 10 Because bone scan 
imaging did not bccome widely available until the late 1970s, almost 70% of the 
patients diagnosed between 1971 and 1979 were classified with an unkown stage. 
Therefore, stage inf0l1l1ation is used only for patients diagnosed since 1980. 
Since about 98% of cases comprise adenocarcinoma, no subdivison according to 
histological type is made generally. Histological grade of adcnocarcinoma has also 
been registered routinely in the Eindhoven Registry since 1980. Grade information of 
patients diagnosed in the 1970s is not used, because it was registered infrequently in 
this period. Grade was scored according to the TNM classification of malignant 
tumors' by various pathologists from three Departments of Pathology in the eastem 
part and another three in the westem part of the Eindhoven Cancer Regishy. The 
Gleason score is not recorded routinely. 
Assessmellt of co-morbidity 
Since 1993, the Eindhoven Cancer Registry has documented serious co-morbidity in 
patients with newly diagnosed cancer. The main objectives were to describe the 
prevalence and prognostic value of this major prognostic indicator and to illustrate the 
complexity of care among patients with cancer and serious co-morbidity. Charlson and 
colleagues proposed a new method of classifYing prognostic co-morbidity and 
developed a list of serious concomitant diseases. II This list has been the model for 
registration of serious co-morbidity in the Eindhoven Cancer Regishy since 1993 
(Table 1), but it was not possible to subdivide these diseases according to severity, as 
suggested by Charlson. Co-morbidity is scored at the same time when the cancer is 
registered, usually within 4-6 months of diagnosis. For co-morbidity, the trained 
registrars use medical records, including correspondence from specialists and general 
practitioners. As such, the reliability of co-morbidity registration is dependent on the 
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accuracy with which these diseases were documented. Fmihermore, the accuracy may 
vary between physicians. Because a valid registration is also dependent on the quality 
of the registrars, a validation study was started in six hospitals to assess if they 
subtracted concomitant diseases correctly from the medical records. This was done in 
a random sample of 150 patients fi'om six urologist finns diagnosed with prostate 
cancer in 1995. Urologists from the involved finns where the patients were diagnosed 
were asked to score co-morbidity according to the list used by the registty. 
Table 1 Classification of co-morbidity, according to an adapted list of 
Charlson et al. II 
Cardiovascular diseases 
(myocardial infarction, heart failure, angina pectoris, intennittent claudication, 
abdominal aneurysm, previous CABG or PTCA) 
Cerebrovascular diseases (cerebrovascular accident, hemiplegia) 
Diabetes Mellitus (medically treated) 
Other malignancies (except basal skin carcinoma) 
Chronic obstructive pulmonary diseases (COPD) 
Dementia 
Tuberculosis and other chronic infections 
Connective tissue diseases 
(Besnier Boeck's disease [sarcoidosis], systemic lupus erythematosus [SLE], 
\Vegener's granulomatosis) 
Rheumatoid arthritis (only severe) 
Kidney diseases (chronic glomerulonephritis, chronic pyelonephritis) 
Bowel diseases (Chrolm's disease, colitis ulcerosa) 
Liver diseases (cirrhosis, hepatitis) 
Stomach disease (patients who received major surgery for ulcerative disease: Billroth II) 
In case of disagreement, the author checked the medical records personally. 
Registration of co-morbidity was conect for 87% of patients. When the type of disease 
was examined, only 20% of diseases was registered inconectly (Table 2). In most of 
these cases, serious co-morbidity was usually present, but the wrong type of disease 
was chosen from the list. Another pali of this misclassification was due to 
unfamiliarity of the registrars with isolated tenns such as CABG (Coronary ArtelY 
Bypass Grafting), PTCA (Percutaneous Transluminal Coronary Angioplasty), etc. This 
resulted in an underestimation of cardiovascular disease of 28%. This underestimation 
was also observed in similar validation studies for patients with lung cancer and for 
women with endometrial cancer. The categOlY "co-morbidity not assessable" appeared 
to represent largely patients without any co-morbidity. 
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It is important to realize that these figures are dependent on the accuracy with which 
these diseases were documented in the medical records. Therefore, some additional 
underestimation of the prevalences is possible, although severe concomitant diseases 
are likely to be documented by most physicians, because they affect treatment choice 
and supportive care. 
Table 2 Percentages correctly registered by the Eindhoven Cancel' Registl)'. 
Correct Overestimation Underestimation Total 
N % N % N % (100%) 
COPD 15 (83) 2 (II) (6) 18 
Cardiovascular diseases 35 (70) 2 (2) 14 (28) 51 
Other malignancy 12 (100) 0 (0) 0 (0) 12 
Diabetes mellitus 9 (80) 0 (0) 2 (20) II 
Other diseases 4 (44) 3 (22) 3 (33) 10 
Total 75 7 20 102 
When 34 patients correctly registered as having no co-morbidity were included, the % correctly registered was 
(75+34)/(102+ 34)~80%. 
East Anglian Cancel' Registry and other European cancel' registries 
The East Anglian Cancer Regishy covers a defined region in and around the cities of 
Cambridge, lpswhich and Norwhich in the UK and uses similar methods of data 
collection as the Eindhoven Cancer Registry. In addition to active follow up, the East 
Anglian Registry receives notification of deaths from the Office of National Statistics. 
All 45 registries fi'om 17 countries participating in the EUROCARE study (chapter 
4.2) are comparable to the aforementioned and comply with the standards required by 
the lARC. 12 Because differences exist between countrics in the proportion of patients 
registered by a death certificate only (DCO), these are excluded from the analyses in 
the specific studies. 
Data-analysis 
Calculation of incidence and mortality 
Most of these calculations were based only on the southeastern part of the registry. 
Population data for each 5-year age group were obtained from Statistics Netherlands. 
The midyear population estimates were used for each individual year included in the 
study, to obtain the population at risk. Data on mortality due to prostate cancer were 
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also obtained from Statistics Netherlands. Because the age distribution of the region 
vmies over time and between cQunhies, incidence and modality ratcs were age 
standardized by direct standardization to the European (ESR) or World (WSR) 
Standard population. 
Caiclilation of s/ln,ival 
Most survival analyses were based on incident cases diagnosed in the long-standing 
southeastern pad of the Eindhoven Cancer Registry. Apart from passive follow up, the 
vital status of all patients registered between 1955 and 1992 was actively followed up 
through municipal civil registries up to 1 April 1994. The cause of death could not be 
obtained in this way. Of all patients with prostate cancer diagnosed between 1955 and 
1992, 51 (1.5%) were untraceable (mostly due to repeated moving) and 38 (1.1%) 
were lost to follow-up before the closing date, 1 April 1994. Becausc there is no 
unique personal number for evelY Dutch citizen, the registlY call1lot be linked with the 
national cause of death register. Therefore, relative survival was calculated generally. 
Relative survival is the ratio of the cl1lde to the expected survival and its complement 
can be regarded as an estimate of mortality attributable to the disease studied, unless 
the study cohOlt differs substantially from the general population apmt from the 
disease studied. 13 Expected survival probabilities were derived from life tables for the 
regional male population supplied by Statistics Netherlands. 
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Chapter 3 Trends in incidence and 1l10liaiity 
3.1 Trends in incidence and mortality rates for prostate cancer before and 
after prostate-specific antigen introduction. 
3.2 Striking increase in incidence of prostate cancer in men aged < 60 
years without improvement in prognosis. 
3.3 Increased risk of fatal prostate cancer may explain the rise in 
mortality in The Netherlands. 
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3.1 Trends in incidence and mortality rates for prostate cancel' 
before and after prostate-specific antigen introduction. A 
registry based study in southeastern Netherlands, 1971-1995: 
Abstract 
The incidence of prostate cancer has increased considerably over the past decades 
pattly due to increased detection of subclinical cases. In Southeastern Netherlands, a 
region of almost 1 million inhabitants with good access to specialized medical care, 
prostate specific antigen (PSA) assays were not introduced until 1990, allowing us to 
investigate the nature of the increascs in incidence. Age-adjusted (European 
Standardized Rate) and age-specific rates were calculated using incidence data from 
the population-based Eindhoven Cancer Registry and mortality data from Statistics 
Netherlands. The age-adjusted incidence, which increased from 36 in 1971 to 55 per 
100,000 in 1989, included all grades as well as metastasized prostate cancer. The age-
adjusted mortality mainly fluctuated in this period but increased among men aged 55-
64 years from 12 in 1980 to 25 per 100,000 in 1989. After 1990, the age-adjusted 
incidence further increased to 80 per 100,000 in 1995, the increase representing mainly 
low-grade localized prostate cancer presumably due to increasing oppOliunistic PSA 
testing, especially after 1993. 
A real increase in incidence may have occUlTed before 1993; on the other hand, 
pending results of randomized trials, judicious application of PSA testing seems 
justifiable to avoid unnecessary intervention without reducing mortality . 
• Post PN, Kil PJM, Cronullelin ~ ... IA, Schapers RFM, Coebergh J\vw. Eur J Callcer 1998;34:705-709. 
Reproduced with permission from Elsevier Science. 
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Introduction 
The incidence of carcinoma of the prostate has increased over the past two decades, 1 
although a large propOliion of the increase seems to represent subclinical cases which 
fonnerly remained undetected.' This fits in with the worldwide observcd high 
prevalence of prostate cancer at autopsy of 10-40% and the increase in diagnostic 
procedures over time:3 in the USA between 1973 and 1986, a 30% increase in 
incidence appears to be partly attributable to an increase in trans-urethral resection of 
the prostate (TURP).' This is a surgical procedure for the treatment of symptoms of 
urinary obstmction due to prostate cancer as well as benign prostatic hypetplasia 
(BPH). TURP in BPI-! patients is known to result in the incidental detection of prostate 
cancer in approximately 10% of cases.' Subscquently, the incidence in the USA 
increased by 82% from 1986 to 1991, due to an exponential increase in Prostate 
Specific Antigen (PSA) testing." Several authors repOlied that an elevated sennn PSA 
may precede prostate cancer by up to 5-10 years.7•S Increased detection of prevalent 
subclinical prostate cancer should be followed by stabilization or a subsequent decline. 
Indeed, in some areas of the USA a decline in incidence has now been absclved. 9,10 
Similarly, increased diagnosis during TURP should have been followed by 
stabilization of the incidence. However, the exponential rise in PSA testing as of 1986 
may have obscured the expected changes. Nevertheless, Potosky et al. made it 
plausible (by recognition of overestimation due to multiple hospitalizations and by 
mortality patterns) that there was in pati a tme increase in risk between 1973 and 
1986.' 
In contrast to the USA, II prostate cancer screening progrmmnes have not been 
introduced in Europe yet, but a European randomized study of screening for prostate 
cancer has been started. I' Opportunistic PSA testing has been introduced in some parts 
of Europe, e.g. in Isere, France. 13 In Southeastern Netherlands, PSA testing was not 
introduced until 1990, giving us the opportunity to investigate the possible nature of 
changes in incidence. We studied trends in incidence and mortality rates and provided 
insight into the nature of these trends by describing changes in the distribution of stage 
and grade. Also, we estimated the contribution of the increase in TURP procedures by 
relating its application to the mode of diagnosis. 
Methods 
Study population 
We calculated incidence rates using data from the Eindhoven Cancer RegistlY, which 
covers a region with almost one million inhabitants in Southeastern Netherlands. The 
development of this registry, which stalied in 1955, is described in detail elsewhere. 14 
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Registration is not obligatory by national laws, but contracts with the pathological 
laboratories, hospitals and regional radiotherapy institute ensure that virtually all 
newly diagnosed cases are reported. Analysis of referral patterns and comparison with 
regional mortality statistics, derived from the Netherlands Statistics, indicate that 
prostate cancer data can be considered nearly complete as of 1971. Although 
representing less than 5%, non-pathologically confirmed cases are also registered. 
Cases identified by 'death certificate only' are not registered in the Netherlands due to 
privacy regulations. After notification, data are collected by trained registrars from 
patient records in connl1tmity hospitals. The region offcrs good access to medical care 
with seven large community hospitals (originally 13), to which the distance has always 
been less than 25 kilometres. The number of urologists increased from 4 in 1971 to 12 
in 1978 and 15 in 1994. National hospital discharge data show that the number of 
TURP increased from 1900 in 1971 to 12326 in 1985. PSA assessment was not 
introduced until 1990. In the seventies, prostate cancer patients were usually treated 
symptomatically (TURP), often supplemented with anti-androgen or oestrogen 
treatment or castration. Since the early eighties an increasing prop0l1ion has undergone 
radiotherapy, but radical prostatectomy was only rarely applied before 1990 and by 
specialists outside the region. Regional urologists increasingly performed this 
procedure in the nineties. 
Stage and grade 
Stage is recorded in the registry according to the TNM classification in use. IS•16 On the 
basis of the registered information, we classified stage as localized and incidental 
finding (TI), localized and palpable or visible on transrectal ultrasound imaging (T2) 
or locally advanced (T3-4). If lymph node involvement or distant metastases were 
recorded, stage was defined as metastasized. Because absence of metastases was not 
always recorded explicitly, we included both MO and Mx in the non-metastasized 
categories. Since bonescan imaging became widely available in the late 1970s, stage is 
presented as of 1980. 
Histological grading recorded according to the TNM classification of malignant 
tumours l6 was scored by up to 10 pathologists of three Departments of Pathology 
serving seven hospitals. Poorly and undifferentiated tumours were considered as one 
categOlY. Because grade was unkoown for a large prop0l1ion of cases in the 1970s, 
grade too is presented as of 1980. 
Urological care 
Data on regional use of PSA assays were supplied by clinical chemists of the various 
community hospitals. We related TURP procedures to stage at diagnosis as of 1988 
(when registration of treatment became more detailed). 
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Data allalysis 
We calculated age-specific rates (for 10-year age groups) as well as age-adjusted rates 
(European Standardized Rate) per 100,000 person-years. Furthermore, we calculated 
incidence rates according to stage and grade. Alll1ual incidence and mOliality rates are 
presented as 3-year moving averages: the incidence for a specific year is calculated as 
the mean for that year and the preceding and succeeding years. 
Figure 1 Trellds ill age-adjusted illcidellce alld /IIortality rates for prostate callcer 
(Europeall Stalldardized Rates) ill Southeastern Netherlallds per 100,000 
persall-years, 1971-1995 (3-year /IIovillg averages). 
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Between 1971 and 1995, 4205 patients with newly diagnosed prostate cancer were 
registered, The mean age, 73 years, barely changed during the study period: 18% of 
patients were below 65 years and 40% were aged over 75. In total, 95% of all patients 
were diagnosed by histological examination of biopsies or TURP specimens, less than 
1 % on the grounds of cytological examination, 1% as a result of post mortem 
examination and 3%, mainly older men, only on clinical evidence. 
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Figllre 2 Trellds ill age-specific incidence alld mortality rates for prostate cancer ill 
Southeastern Netherlallds per 100,000 persoll-years, 1971-1995 (3-year 
movillg averages). 
Incidence 
1.000,--------------"" 
ID 
1'i 100 
<J) 
0) 
0 
= 
0 
0 
0 
c5 
0 
Q; 10 
c. 
1L---------------------~ 
1970 1975 1980 1985 1990 1995 
year of diagnosis 
Mortality 
10.000,----------------, 
1.000 
Qi' 
(ij 
0 
<J) 
0) 100 
0 
= 
0 
0 
0 
c5 10 0 
~ 
., 
c. 
0,1 '---L-1-__ --'-"-______ -' 
1970 1975 1980 1985 1990 1995 
year of death 
-45·54 yrs 
+55·64 yrs 
'*-65-74 yrs 
~ 75-84 yrs 
*85 + yrs 
-45-54 yrs 
+55-64 yrs 
'*-65-74 yrs 
~75-84 yrs 
*85 + yrs 
30 Chapter 3 
Incidence 
The age-adjusted incidence increased in the seventies from 37 in 1975 to 46 per 
100,000 in 1980 (Figure I). After 1985, the incidence fhrther increased to 55 per 
100,000 in 1988. An exponential increase in incidence was observed after 1991, 
resulting in an incidence rate of80 per 100,000 in 1995. The increase in incidence was 
observed at all ages (Figure 2), but before 1990 it was more pronounced in the 
youngest age groups (below 65). The incidence among men over 85 showed marked 
fluctuations. Random valiation due to the small number of men in this age group plays 
probably a role. In the early eighties, the incidence of patients with unknown grade 
decreased markedly (Figure 3). The increase in incidence in this period included all 
grades but after 1985 mainly moderately differentiated tumours. The exponential 
increase after 1991 was initially largely due to poorly and modcrately differentiated, 
but after 1993 it could be explained solely by well and moderately differentiated 
cancer. 
Figure 3 
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The increase in patients with incidental localized cancer parallelled a decrease in 
patients with unknown stage, but the incidence of metastasized cancer also increased 
in the late eighties (Figure 4). Although patients with lymph node but no distant 
metastases were included in the category 'metastasized', only 7% of the metastasized 
patients between 1985 and 1989 were diagnosed without distant metastases. 
Subsequently, the incidence of metastasized cancer stabilized and decreased, although 
it continued to represent some 15% of the incidence in the nineties. After a transient 
increase due to temporarily stricter registration practices around 1990, the incidence of 
patient with unknown tUlllour size has declined again. The exponential increase in 
incidence after 1991 can be attributed to incidental cases but also to suspected 
localized prostate cancer. 
Figure 4 Trel/ds il/ prostate cal/cer il/cidel/ce (European Stal/dardized Rate) 
accordil/g to stage il/ Southeastel'll Netherlal/ds, 1980-1995 (3-year movil/g 
averages). 
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The age-adjusted mortality declined initially in the early seventies but increased 
slightly from 22 in 1975 to 26 per 100,000 in 1980 (Figure 1). This increase was 
apparent for all age groups (Figure 2). 
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In the eighties, the age-adjusted mortality increased again slightly, mainly due to an 
increase among men aged 55-64 years from 12 in 1980 to 25 per 100,000 in 1989. 
Finally, a small increase in the age-adjusted mortality from 26 in 1990 to 32 per 
100,000 in 1995 was noted mainly for older age groups. 
PSA 
PSA assays were introduced in two community hospitals in 1990 but did not become 
routine in all hospitals until 1993. The number of assays increased from 1,449 in 1990 
to 13,506 in 1993, for which the propOliion requested by general practitioners 
increased from 7 to 22%. 
Role of TURP 
In the Netherlands, the national number of TURP procedures increased sixfold 
between 1970 and 1990, whereas the number men aged 65 years or more (who 
underwent the majority of transurethral resectious) only increased by 30% in the same 
period. Of the 408 prostate cancer patients undergoing TURP in Southeastem 
Netherlands between 1988 and 1991, only 38% were detected by this procedure, 29% 
had palpable localized cancer and 20% even exhibited metastasized prostate cancer 
(13% were registered as having an unknown stage). Moreover, the distribution of 
stage between 1980 and 1987 points in the same direction: 28% were staged as 
incidentally detected, 26% were localized palpable and up to 30% were metastasized 
at diagnosis (17% were recorded as unknown). 
Discussion 
We report a 56% increase in the incidence of prostate cancer in Southeastem 
Netherlands between 1971 and 1989 and a 43% increase in 5 years after PSA 
introduction as of 1990. Increases in incidence before introduction ofPSA testing have 
been reported in other European couutries 17.18 and the USA.' The increase in incidence 
in Northem Sweden was due to low grade cancerl7 but iu Norway, the increase in the 
incidence of metastasized cancer was similar to that found for localized cancer. 
Moreover, a concomitant increase in 1ll0l1ality was observed. IS In the USA, the 
increase involved mainly localized prostate cancer.' An increase in incidence of 6.3% 
per year, mainly due to non-metastasized prostate cancer, was observed after PSA was 
introduced in Ishe. J3 In the USA, an even more pronounced increase in was reported." 
This dramatic rise has now beeu followed by a decline in different paris of the USA, 
especially among older men.9,JO 
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Validity alld completelless 
EvelY pathologically can finned prostate cancer is reported to the registlY. 
Furthermore, clinical cases are notified through medical records offices and the 
regional radiotherapy institute. Nevertheless, there may have been increasing 
ascertainment in the seventies, related to the marked increase in the number of 
urologists. 
It is not likely that changes in the mOlphological interpretation of histological 
specimens influenced the incidence. Moreover, no changes occulTed in the 
classification of grade. 
Because patients recorded as Mx were included in the non-metastasized categories, a 
few Mx cases may have been misclassified. It is not likely that stage migration due to 
improved diagnostic techniques played an important role, because an increase in the 
categOlY 'locally advanced' would then have been expected. 19 F1ll1hermore the clinical 
stage was used. 
Cardiovascular disorders generally tend to be recorded as the underlying cause of 
death more often than other chronic diseases such as cancer.'o Since mortality from 
cardiovascular causes has decreased over the past decades (in Southeastern 
Netherlands from 258 in 1973-1982 to 192 per 100,000 in 1983-1992)," the 
probability that prostate cancer was recorded as the cause of death may have increased. 
Moreover, the decline in mortality due to BPH (in The Netherlands from 6.3 in 1970-
1974 to 1.5 per 100,000 in 1985-1989) 22 may have resulted in an increase in m0l1ality 
due to prostate cancer. Finally, the decline in incidence of male lung cancer since 1978 
in Southeastem Netherlands may have had a similar effect. 2J Increased mortality due 
to prostate cancer should, therefore, be interpreted with caution, especially that found 
for males aged 75 years or more. 
Increased incidence 01' higher detection rate? 
The increase in incidence in the eighties was not only represented by low grade but 
also by metastasized prostate cancer, suggesting a genuine increase. Fmihennore, less 
than 30% of all cases were detected incidentally during a TURP procedure. Regional 
mortality also increased in Southeastem Netherlands, albeit to a lesser extent. 
Moreover, analysis of national mortality data revealed a 20% increase in the age-
adjusted mortality between 1970 and 1989, presumably due to an increased risk in 
consecutive birth cohorts up to men born in 1925. 24 
Despite the increased TURP rates, only 38% of the prostate cancer patients undergoing 
TURP, were diagnosed as a result of this procedure. The majority of patients 
underwent the TURP procedure for symptomatic relief of symptoms of urinary 
obstruction after cancer was suspected or already confinned. Increased number of 
TURP procedures may, therefore, partly be a consequence of the increased incidence 
of prostate cancer rather than a cause. 
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A tnle increase in incidence would be in agreement with an increase in mOtiality due 
to prostate cancer in many countries [I], which is unlikely to be entirely an artifact." 
Nevertheless, the marked improvements in survival of prostate cancer in Sweden 
between 1960 and 1980 suggest increased diagnosis of nonlethal prostate cancer. 2 
Therefore, it is likely that the increase in incidence between 1971 and 1990 reflects 
both a higher detection rate and a true increase in incidence. 
In contrast, the rapid increase in the incidence of prostate cancer after the introduction 
of PSA is most likely an artifact caused by accelerated diagnosis. Although a further 
increase in incidence may have occurred, the diagnosis of prostate cancer has most 
likely been advanced recently by several years, in agreement with studies linking 
serum banks with subsequent cancer diagnosis.7., This would mean that more elderly 
men will live for several years with the knowledge of a diagnosis of prostate cancer 
before it eventually may lead to symptoms. 
As yet, the benefits of early detection by PSA have not been proven. A European 
randomized screening trial is on its way, 12 but conclusive results will not be available 
for several years. Judicious application of PSA testing seems justifiable, in order to 
control the cycle of increasing intervention without evidence of reducing mortality.2' 
For the time being, it may be useful to follow the recommendations of Kramer and 
associates: "inform each man about the cutTcnt state of uncertainty, detail the risks and 
theoretical benefits ... Outside of the study setting, screening blood tests should only 
be done once the man is engaged in the decision process".'7 The Dutch Society of 
General Practitioners advises PSA detetlnination only if the rectal examination is 
difficult to interpret and only if the man still has a considerable life expectancy. Case 
finding is discouraged.28 
In conclusion, our results suggest that the increase in incidence of prostate cancer in 
Southeastern Netherlands before 1990 partly represents increased detection and partly 
reveals a true increase in incidence. The exponential increase in the incidence of low-
grade localized prostate cancer after 1990 seems to be attributable mainly to advanced 
diagnosis due to opportunistic PSA testing. 
References 
I. Arslan A, Renard H. Trends in cancer incidence and mortality. Lyon: IARC Scientific 
Publications No. 121, 1993, pp. 499-520. 
2. Helgesen F, Holmberg L, Johansson ill, Bergstrom R, Adami HO. Trend in prostate cancer 
survival in Sweden, 1960 through 1988: evidence of increasing diagnosis of nonlethal hUllOurS. J 
Natl Callcerlllst, 1996; 88: 1216-122l. 
3. Breslow N, Chan CE, Dhom G. Latent carcinoma of prostate at autopsy in seven areas. Jilt J 
Callcer 1977; 20: 680-688. 
Trellds ill illcidellce alld mortality 35 
4. POlosky AL, Kessler L, Gridley G, Brown ee, Homt J\V. Rise in prostatic cancer incidence 
associated with increased use of transurethral resection. J Natl Cancer Inst. 1990; 82: 1624~ 1628. 
5. Rohr LR. Incidental adenocarcinoma in transurethral resections of the prostate. Am J Surg Pallial. 
1987; 11: 53-58. 
6. Potosky AL, Miller BA, Albertsen PC, Kramer BS. The role of increasing detection in the rising 
incidence of prostate cancer. JA.A1A 1995; 273: 548-552. 
7. Gallll PH, Hennekens CH, Stampfer MJ. A prospective evaluation of plasma prostate-specific 
antigen for detection of prostatic cancer. JAMA 1995; 273: 289-294. 
8. StcIIDlan UH, Hakama M, Knekt P, Aromaa A, Tcppo L, Leinonen 1. Serum concentrations of 
prostate specific antigen and its complex with al-antichymotrypsin before diagnosis of prostate 
cancer. Lallcet 1994; 344: 1594-1598. 
9. Jacobsen SJ, Katusic SK, Bergslralh EJ, et aJ. Incidence of prostate cancer diagnosis in the eras 
before and after prostate-specific antigen testing. JAAIA 1995; 274: 1445-1449. 
to. Stephenson RA, Smart CP, Mineau GP, James BC, Janerich DT, Dibble RL. The fall in incidence 
of prostatic carcinoma. On the down side of a Prostate Specific Antigen induced peak in 
incidence- data from the Utah Cancer Registry. Cancer 1995; 77: 1342-1348. 
11. Mettlin C, Lee F, Drago 1. The American Cancer Society national prostate cancer detection 
project. Findings on the detection of early prostate cancer in 2425 men. Cancer 1991; 67:2949-
2958. 
12. Schroder HI, Damhuis RAM, Kirkels \VJ et a1. European randomized study of screening for 
prostate cancer- The Rotterdam pilot studies. lilt J Cancer 1996; 65: 145-151. 
l3. Menegoz F, Colonna M, Exbrayat C, Mousseau M, Orfeuvre H, Schaerer R. A recent increase in 
the incidence of prostatic carcinoma in a French population: role of ultrasonography and prostate-
specific antigen. Ellr J Callcer 1995;31A:55-58. 
14. Parkin DM, Muir CS, Whelan SL, Gao YT, Ferlay J, Powell J. Cancer incidence in fivc 
continents. Vol VI. Lyon, IARC No. 120, 1992, p. 666. 
15. Harmer:MH (ed.). TNM classification of malignant tumours, 3rd ed, Geneva, International Union 
Against Cancer, 1978. 
16. VICe. TNM Atlas Illustrated guide to the TNi',lIpTNM-ciassification of malignant tumours. 4th 
cd. 2nd rev. Berlin, Springer Verlag, 1992, pp. 141-144. 
17. Gronberg I-I, Bergh A, Damber JE, Jonsson H, LeImer P, Angstrom T. Prostate cancer in northern 
Sweden. Incidence, survival and mortality in relation to tumour grade. Acta OJ/col 1994;33:359-
363. 
18. Harvei S, Tretli S, Langrnark F. Cancer of the prostate in Norway 1957-1991- A descriptive study. 
EIII" J Calleel" 1996; 32A: 111-117. 
19. Feinstein AR, Sosin DM, \Vells CK. The Will rogers phenomenon. Stage migration and new 
diagnostic techniques as a source of misleading statistics for survival in cancer. N Engl J l\1ed 
1985; 312:1604-1608. 
20. Goldacre MJ. Cause-specific mortality: understanding uncertain tips of the disease iceberg. J 
Epidemiol Community Health 1993;47:491-496. 
21. Coebergh J\VW, van der Heijden LH, Janssen-Heijnen MLG (eds.). Cancer incidence and survival 
in the Southeast of the Netherlands, 1955-1994: a report from the Eindhoven Cancer Registry. 
Eindhoven: Comprehensive Cancer Centre South, 1995, p. 116. 
22. La Vecchia C, Levi F, Lucchini F. Mortality from benign prostatic hyperplasia: worldwide trends 
in 1950-92. J Epidemiol Commullity Health 1995;49:379-384. 
23. Janssen-Heijnen MLG, Nab HW, van Reek J, Van der Heijden LH, Schipper R, Coebergh J\VW. 
Striking changes in smoking behaviour and lung cancer incidence by histological type in 
Southeast Netherlands, 1960-1991. EIII" J Calleel" 1995;31 A:949-952. 
24. Van der Gulden J\VJ, Kiemeney LALM, Verbeek ALM, Straatman H. Mortality trend from 
prostate cancer in the Netherlands (1950-1989). Prostate 1994;24:33-38. 
25. Boyle P, Maisonneuve P, Napalkov P. Geographical and temporal pattems of incidence and 
mortality from prostate cancer. Urology 1995;46:47-55. 
26. Black \Ve, \Velch HG. Advances in diagnostic imaging and overestimations of disease prevalence 
and the benefits oftherapy. N Ellg/ J Med 1993;328: 1237-1243. 
36 Chapter 3 
27. Kramer BS, Gahagan JK, Prorok PC. Is screening for prostate cancer the current gold standard?~ 
'No'. ElIr J Callcer. 1997;33:348-353. 
28. Klomp MLF, Gcrcama AJ, De Jongc-\Vubben JOM ct a!. NHG Standaard bemoeilijkte mictie bij 
oudere mannen. Eerstc herziening (in Dutch). Hu;sarts Wet t 997;40: 114-124. 
Trends in incidence and mortality 37 
3.2 Striking increase in incidence of prostate cancer in men 
aged < 60 years without improvement in prognosis: 
Abstract 
Increased awareness and improved diagnostic techniques have led to earlier diagnosis 
of prostate cancer and increascd detection of subclinical cases, resulting in improved 
prognosis. We postulated that the considerablc increase in incidence under age 60 is 
not only attributable to increased detection. To test this hypothesis, we studied 
incidence, mortality and relative survival for middle aged patients diagnosed in 
Southeastem Netherlands and East Anglia (UK) between 1971 and 1994. Prostate-
specific antigen (PSA) testing did not occur before 1990. Between 1971 and 1989, the 
age-standardised incidence at ages 40-59 increased from 8.8 to 12.5 per 10' in the 
Netherlands and from 7.0 to 11.6 per 10' in East Anglia. Five-year relative survival did 
not improve in East Anglia and even declined in Southeastem Netherlands from 65% 
(95% Confidence Interval [CIJ47-83) in 1975-1979 to 48% (CI 34-62) in 1985-1989. 
Mortality due to prostate cancer among men aged 45-64 years increased by 50% in 
Southeastem Netherlands and by 61% in East Anglia between 1971 and 1989, but 
decreased slightly in the 1990s. Because other factors adversely influencing the 
prognosis are unlikely, our results indicate an increase in the incidence of fatal prostate 
cancer among younger men in the era preceding PSA testing. 
Post PN, Stockton D, Davies TW, Coebergh JWW, HI' J Callcer 1999;79:13·17. Reproduced with pemlission 
from Churchill Livingstone. 
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Introduction 
Worldwide, prostate cancer has been diagnosed with increasing frequency over the 
past decades. I This increase is partly due to increased application of transurethral 
resections of the prostate (TURP), 2 a procedure to treat symptoms of benign prostatic 
hyperplasia (BPR) and resulting in incidental detection of subclinical prostate cancer 
in approximately 10% of cases.3 More recently, case finding by prostate-specific 
antigen (PSA) testing resulted in a fhrther increase in the incidence. 4 
As a consequence, the prognosis of prostate cancer patients has improved in many 
countries,5.6,7,8 because an increasing proportion was detected at a preclinical stage. In 
Southeastem Netherlands, overall 5-year relative survival improved modestly fi'OITI 
57% in 1970-1979 to 61% in 1987-1992, but the improvement occulTed largely in 
elderly patients.9 In the youngest age groups, the highest increase in incidence was 
obselved in the 1980s in Southeastern Netherlands. lo As TURP is about seven times 
less frequently applied in men under age 60 than in men over age 75" because of the 
lower prevalence of BPR 12 and the much lower incidence of cancer, it seemed that the 
increase in incidence at younger ages might not be caused by a higher detection rate, 
We studied trends in incidence and prognosis of patients with prostate cancer aged 40-
59 years in Southeastern Netherlands and for comparison also in East Anglia, UK, 
which has a similar system of data collection and a more or less comparable system for 
health care provision, We also studied trends in mortality due to prostate cancer and 
analysed the changes in the distribution of grade, stage and the initial treatment 
applied. The main study period (1971-1989) is the time before the introduction ofPSA 
testing, data for 1990-1994 are also included to provide some insight into more recent 
trends. 
Patients and methods 
Study populatioll 
We used data from two cancer registries, the Eindhoven Cancer Registry in 
Southeastern Netherlands and the East Anglian Cancer Registry in the United 
Kingdom. In both registries, most cases were identified by pathology reports, which 
are always sent to the registries, the remainder by medical record departments in the 
regional hospitals and the regional radiotherapy institute (Eindhoven) or the district 
general hospitals (East Anglia). Southeastern Netherlands has a population of almost 1 
million inhabitants and is characterized by good access to specialized medical care 
provided in eight large community hospitals. National data show that TURF was 
increasingly applied between 1970 and 1990 and it was the main treatment modality 
for both cancer of the prostate and BPR in the 1970s. Radiotherapy was applied 
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increasingly after 1980, but radical prostatectomy rarely. PSA assessment was not 
introduced until 1990. In the Eindhoven Registry, vital status of all cases was followed 
up through municipal civil registties until 1 April 1994. Five patients (2.8%) were lost 
to follow-up before this date (mostly due to repeated moving home), and so were 
censored in the analysis. East Anglia has a population of around 2.2 million 
inhabitants and has three specialist hospitals with Oncology centres and a further six 
district general hospitals. The majority of the population lives in and around the threc 
major cities of Cambridgc, Ipswich and Norwich, guaranteeing them good access to 
spccialised medical care. PSA assays were introduced in 1991. Thc East Anglian 
Rcgistry receives notification of deaths of all individuals flagged as having cancer or 
where cancer is mentioned on thc death certificate, from the Office of National 
Statistics. In addition, it actively follows up its patients 3 years after diagnosis and then 
every 5 years until death, guaranteeing nearly complete follow-up. Mortality data were 
obtained from Statistics Netherlands and the British Office of National Statistics. 
The midyear population estimates were used for each individual year included in the 
study. 
Allalysis 
The incidence rates per 100,000 person-years for the age band 40-59 were 
standardized to the European Standard Population. Since the median survival time is 
approximately 5 years, we calculated the age-standardised mortality rates for the age 
band 45-64 years. Poisson regression analysis was applied to model incidence and 
mOliality, 13 using the GENMOD procedure of the statistical package SAS. The data 
were grouped in 5-year age groups and calendar periods for each registry, before they 
were pooled. Significance of temls in the models was tested with the likelihood-ratio 
test. 
We calculated clUde and relative survival rates using the acttmrial (life-table) method. 
Relative survival, the ratio of the clUde to the expected survivaL 14 The expected 
survival was calculated from life tables derived from the regional mortality statistics 
and data were compiled into five year age groups and calendar year. A software 
package from the Finnish Cancer Registry was used to calculate the survival rates." 
The rates were adapted during the course of the follow-up according to the changing 
age disttibution of the patient groups (Ederer II option). Cases identified at death were 
excluded from the analyses. We used grade information as it was registered, scored 
according to the classification of malignant tumours,I6 Info1111ation about stage was 
only available in the Eindhoven Cancer Registty. Based on clinical TNM 
assessment,17 we classified stage in 3 categories: small tumours confined to the 
prostate (Tl-T2) without evidence of metastases were classified as localized; tumours 
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which invaded surrounding stmcturcs (T3-T4) but without evidencc of metastases 
were classified as locally advanced; patients with distant or lymph node metastases 
were classified as metastasized. Grade and stage, both available as of 1980, are 
presented both with and without inclusion of the unknown cases. Differences in 
proportions were tested with the chi-square test (excluding unknown cases). 
We classified initial treatment as TURP (including patients detected incidentally due 
to TURP); honnonal treatment; honnonal treatment after TURP; radiotherapy. 
(patients receiving radiotherapy after TURP or radiotherapy and honnonal therapy 
were included in the radiotherapy group) Treatment information was available for the 
main study period (1971-1989) in The Eindhoven Regislty and from 1980 to 1989 in 
East Anglia. 
Results 
The number of patients aged 40-59 diagnosed with prostate cancer between 1971 and 
1989 was 181 in Southeastern Netherlands and 384 in East Anglia, being 7% and 4% 
respectively of all patients with prostate cancer diagnosed between 1971 and 1989. 
The proportion of patients with a histologically confimled diagnosis at ages 40-59 was 
more than 95% during the whole study period in both populations. 
Table 1 Risk ratios and 95% confidence intervals for incidence (40-59 years) of and 
mortality (45-64 years) dlle to prostate cancer in SOlltheastern Netherlands 
and East Anglia. 
Incidence (40-59 yrs) Mortality (45·64 yrs) 
Risk ratio (95% CI) No. of cases Risk ratio (95% CI) No. of cases 
1971-1974 (ref) I 82 I 82 
1975-1979 1.11 (0.84, 1.47) 127 1.02 (0.77,1.36) 108 
1980-1984 1.33 (1.02, 1.73) 162 1.24 (0.95, 1.63) 140 
1985-1989 1.53 (1.19, 1.99) 194 1.63 (1.26, 2.12) 195 
1990-1994 1.91 (1.49,2.46) 255 1.53 (1.18, 1.98) 191 
p-value trend 0.0001 0.0001 
Between 1971 and 1989, the age-adjusted incidence rate for men aged 40-59 increased 
from 8.8 per 10' to 12.5 per 10' in Southeastern Netherlands and from 7.0 per 10' to 
11.6 per 10' in East Anglia (Figure I). The mean age at diagnosis of the patients in this 
age group barely changed over the study period, being 55.4 years in the Netherlands 
and 55.6 in East Anglia. 
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A multivariate model for the incidence up to 1994 was built containing age group, 
registry and calendar period (deviance 35.0; 34 degrees offreedom [df]). The risk ratio 
of the incidence increased for each subsequent period lip to 1990-1994 (Table I). The 
test for trend was significant (p = 0.0001) and the trend was similar in both registries. 
A similar result was obtained when the period 1990-1994 was excluded. The age-
standardized mortality rate for prostate cancer among men aged 45-64 years increased 
between 1971 and 1989 from 7.4 to 11.1 per 10' in Southeastern Netherlands and from 
7.5 to 12.1 per 105 in East Anglia. A model was built containing age group, calendar 
period and registry (deviance 47.1; 34 d£). The risk ratio increased with each 
subsequent period up to 1985-1989, followed by a slight decline in 1990-1994 (Table 
I). Nevertheless, the test for trend was significant (p=O.OOOI) and the trend was 
similar in both registries. 
Figure 1 Illcidellce rates per J 00 000 persoll years (Europeall Stalldardized Rate) 
(top) alld 5-year relative sUI1'ival rates (bottom) Jor prostate callcer 
patiellts aged 40-59 ill Southeastem Netherlallds alld East Allglia. 
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In Southeastern Netherlands, 5-year relative survival improved slightly in the early 
seventies, but declined from 65% (95% CI 47-83) in 1975-1979 to 48% (CI 34-62) in 
1985-1989 (Figure 1). In East Anglia, 5-year relative survival was initially 
considerably lower, being 48% (CI 34-62) in 1971-1974 and slightly decreased to 46% 
(CI 36-56) in 1985-1989. The cmde survival followed a similar trend. 
Table 2 Trelld ill stage distributioll (lVith alld lVithout ullkllOlVll cases) of prostate 
callcerpatiellts aged 40-59 ill Southeastel'll Netherlallds, 1980-1989. 
1980-1984 1985-1989 1990-1994 
Number of cases 51 65 108 
% within petiod % % 
Localized 40 53 57 
Locally advanced 8 12 12 
Metastasized 39 29 18 
Unknown 13 6 13 
Localized 47 56 66 
Locally advanced 9 13 13 
Metastasized 44 31 21 
p-value X2 0.07 
In spite of an increase in the estimated proportion of patients with localized cancer 
from 47% in 1980-1984 to 56% in 1985-1989 in Southeastern Netherlands (Table 2), 
the estimated propOliion of patients with poorly differentiated tumours increased from 
15% to 25% (Table 3). The proportion of patients aged 40-59 years receiving 
radiotherapy increascd from 21% in 1975-79 to 55% in 1985-89 in Southeastern 
Netherlands and radiotherapy has also been the main treatment modality in East 
Anglia between 1980 and 1989 (Table 4). The remainder of patients received 
endocrine therapy or TURP. Radical prostatectomy was only rarely applied before 
1990 in both populations. 
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Table 3 Trelld ill grade distributioll (with alld without ullkllowlI cases) of prostate 
callcer patiellts aged 40-59 ill Southeastern Netherlallds alld East Allglia, 
1980-1994. 
Southeastern Netherlands East Anglia 
1980-84 1985-89 1990-94 1980-84 1985-89 1990-94 
n 51 65 108 111 129 147 
% % % % % % 
Well 36 34 41 24 22 25 
Moderately 31 37 31 18 24 29 
Poorly 12 23 22 18 21 22 
Unknown 20 6 6 40 33 24 
Well 46 36 44 40 33 33 
Moderately 39 39 33 30 36 38 
Poorly 15 25 23 30 31 29 
p-value X' 0.6 p>O.1 
Discussion 
We repOli a similar rise in the incidence of prostate cancer among men aged 40-59 
years ill Southeastel11 Netherlands and East Anglin and no improvement in prognosis 
in the era preceding the introduction of PSA testing. Improved diagnosis might explain 
the rise in incidence, but this does not seem to play an imp0!1ant role, because it 
should have resulted in the inclusion of more non-aggressive cases resulting in 
improved survival. Moreover, in spite of a more favourable stage distribution, we did 
not observe an increase in well differentiated tumours in tItis period. 
Our findings are conditional on the accuracy of the cancer registries. Based on a 
comparison with 111011ality data and analysis of referral patterns, both registries can be 
considered virtually complete for prostate cancer as of 1971 and comply with the 
standards of the Intemational Agency for Research on Cancer. l7 Few patients were lost 
to follow up, so that selective loss to follow-up is not likely to be an issue. 
Nevertheless, the study population was relatively small, especially in southeastern 
Netherlands. However, our findings are not compatible with a significant 
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improvement. Moreover, registry-based studies in other countries provided similar 
results. 
In Sweden, 5-year relative survival for prostate cancer patients aged 45-54 improved 
from 42% in the early 1960s to 62% in the late 1970s, but it declined to 50% in the 
early 1980s. 5 In Scotland, it declined from 47% in 1978-1982 to 32% in 1983-1987 6 
In Switzerland (Vaud), the relative survival for patients aged below 60 slightly 
improved from 39% in 1974-1978 to 41% in 1979-1983,' whereas it also slightly 
improved for Fhmish patients. 18 We do not know why the prognosis barely changed in 
East Anglia but deteriorated in Southeastern Netherlands. Lesser access to specialised 
care may have played a role in the initially lower survival in East Anglia, because the 
EUROCARE study showed that similar differences in survival existed between 
Southeastern Netherlands and Great Britain for patients with lung-, breast- and 
colorectal cancer, which may be related to differences in stage at diagnosis. 19 
Increasing awareness of prostate cancer and early diagnosis did probably not become 
apparent before 1980 in East Anglia. 
Table 4 Trelld ill illitial treatmellt of prostate callcer patiellts aged 40-59 ill 
SOlltheastem Netherlallds alld East Allglia. 
Eindhoven 
Radiotherapy 
Endocrine therapy 
Endocrine + TURP 
TURP 
None 
East Anglia 
Radiotherapy 
Endocrine therapy 
Endocrine + TURP 
TURP 
None /Unknown 
1971-1974 1975-1979 1980-1984 1985-1989 
% 
o 
32 
36 
28 
4 
% 
21 
24 
7 
48 
% 
38 
4 
13 
40 
5 
% 
42 
12 
15 
26 
5 
% 
55 
22 
9 
14 
% 
46 
6 
15 
26 
7 
Our hypothesis, that a genuine increase in incidence has occulTed, is also supported by 
the increase in mortality due to prostate cancer below 65 years, which was similar in 
both populations, although it was followed by a small decline in 1990-1994. An 
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analysis of national mortality data of 1950-1989 showed an increase of mortality due 
to prostate cancer in consecutive birth cohOl1s up to men born around 1925 in The 
Netherlands. '0 In Norway, the increase in both incidence and mOl1ality due to prostate 
cancer between 1957 and 1991 was highest in men below 60 years." In the USA, 
mOl1ality due to prostate cancer has started to decline since 1991-1995, in particular 
for men under age 75,22 whereas it had increased slightly under age 65 in the years 
beforehand. 7 The decline, however, may be related to widespread introduction of early 
detection and intervention. Although we observed a considerable increase in cause-
specific mortality, changes in mOl1ality should be interpreted with caution. All cause 
mortality has been declining in both populations, also in this age group and in 
particular mortality due to cardiovascular causes declined in the Netherlands from 499 
per 10' in 1970 to 301 per 10' in 1990 for men aged 45-64 years.2J Due to the decrease 
in conCUlTent causes of death, the probability that prostate cancer was recorded as the 
cause of death may have increased. Howcver, this explanation would be more 
plausible for mortality in older age groups. 
Therefore, an increased lisk of prostate cancer is not unlikely. As far as we know, only 
one etiologic study has focused on the age group below 60 years. This reported a 
relative risk (RR) of 1.9 for cigarette smoking, a RR of 1.4 for vasectomy, and a RR of 
2.3 for early age at first sexual intercourse." Recently, Rodriguez et al. repOl1ed a 
significant association of CUlTent smoking with fatal prostate cancer (RR 1.34) which 
was highest among men below 60 years (RR 1.83) but there was no association with 
the number of cigarettes smoked or with the duration of smoking at baseline for the 
cohort in 1982. Nor was there any increased risk for fonner smokers." This, as well as 
results from other large studies, suggests that smoking adversely affects survival. 
Increased occurrence of a factor associated with a worse survival could be an 
alternative explanation of our findings. Smoking, however, is not a likely candidate, 
because the proportion male smokers decreased markedly from 95% in 1960 to 40% in 
1981 in The Netherlands'· and also in England.' Unfavourable changes in the health 
care system do not seem to playa role, because a larger propOliion of the recent cases 
was detected at an earlier stage, at least in Southeastern Netherlands. Furthennore, 
radiotherapy was applied increasingly during the study period. Although a beneficial 
effect of radiotherapy on survival has not been proven defintively,27 it seems unlikely 
that radiotherapy has been detrimental for prostate cancer patients. We, therefore, 
assume that increased incidence of fatal prostate cancer, of which the cause still needs 
to be unravelled, should explain our findings. 
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Although the incidence continued to increasc, mortality due to prostate cancer 
decreased slightly in the 1990s. This could mean that the suggested genuine increase in 
incidence has come to a halt in the 1990s. Continuing studies of incidence and survival 
may provide morc insight into the nature of the most recent increase in incidence. 
From thc current study, we conclude that increased detection of prostate cancer by 
TURP cannot explain the considerable increase in incidence between 1971 and 1989 in 
the age group below 60 years. 
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3.3 Increased risk of fatal prostate cancel' may explain the rise in 
mortality in The Netherlands: 
Abstract 
Backgrolllld. Several lines of evidence suggest that, as a result of improved diaguostic 
techniques, the increase in incidence of prostate cancer is due largely to increased 
detection of subclinical cases. Between 1971 and 1989, a considerable increase in 
incidence was found in Southeastem Netherlands among men aged below 60 years 
without an improvement in prognosis. We hypothesised that in addition to the increase 
due to increased detection, a genuine increase in incidence has occurred in the last two 
decades and that this should be reflected in nationallllortality rates. 
Methods. Age-specific and age-adjusted mortality rates were calculated to detennine 
whether mortality due to prostate cancer continued to increase after 1990. Using log-
linear Poisson modelling according to Clayton & Schifflers, we estimated the 
contribution of period and cohort effects to prostate cancer lllot1ality between 1955 
and 1994. 
Results. The age-adjusted Illortality increased from 22 in 1955-1959 to 33 per 10' in 
1990-1994 (European Standardised Rate). For men under the age of 65, the rates 
stabilised after 1989. The age-cohot1 model fitted the data better than the age-period 
model. Therefore, the increase in mot1ality can be explained largely by the increasing 
risk for successive birth cohot1s for men bom until 1930. However, more frequent 
repm1ing of prostate cancer as the underlying cause of death (partly attributable to a 
decline in competing causes of death) Illay have occurred as well. 
COIlc/IISioIlS. Our findings suggest an increased risk of fatal prostate cancer in The 
Netherlands between 1955 and 1994 . 
• Post PN, Straatman H, Kiemeney LAU..1, Coebergh JWW. Jilt J Epidemio/ (In press). Reproduced with 
pcmlission from Oxford University Press. 
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Introduction 
The incidence of prostate cancer has increased considerably over the past decades in 
most industrialised countries,' including The Netherlands.'·3 M0l1ality rates for 
prostate cancer have increased to a lesser extent. I.' More than 6300 cases of prostate 
cancer are now detected yearly in The Netherlands, whereas the number of deaths due 
to prostate cancer amounted to 2374 in 1994.3 An increase in m0l1ality due to prostate 
cancer was found in consecutive bil1h cohorts, on the basis of m0l1ality data up to 
1989.' The prognosis for prostate cancer patients has improved in several countries, 
e.g. the USA' and Sweden,. presumably due to earlier diagnosis and increased 
detection of pre-clinical cases. In Southeastern Netherlands, the overall 5-year relative 
survival improved slightly, but it declined for patients aged 40-59 from 65% (95% 
confidence interval [CI] 47-83) ill 1975-1979 to 48% (CI 34-62) in 1985-1989.' A 
decline ill survival of prostate cancer patients below 60 years of age was also observed 
in other countries in this period, e.g. in Sweden. 6 We hypothesised that a real illcrease 
in risk may have occurred in the 1980s in the most recent bit1h COh0l1s, i.e. men born 
between 1920 and 1935. We chose to analyse m0l1ality data, because trends in 
mortality due to prostate cancer are less likely to be influenced by changes in 
diagnostic procedures than trends in the incidence. III addition to calculation of age-
specific and age-adjusted mortality trends, we performed all age-period-cohort analysis 
using national data up to 1994 to deternline whether mortality due to prostate cancer 
continued to increase afier 1989 in The Netherlands and whether this can be explained 
by either period or bit1h cohort effects. 
Methods 
The underlying cause of every death has been reported to Statistics Netherlands since 
1900. The number of men recorded as having died of prostate cancer and the age-
specific number of males in the Dutch population were abstracted from the annual 
publications of Statistics Netherlands for the years 1955-1994.'·9 Four revisions of the 
International Classifications of Disease (lCD) were used in this period. In the sixth and 
seventh revisions, ICD code 177 was used as the definition for prostate cancer, in the 
eighth and ninth revisions ICD code 185. The definitions for the two codes were 
essentially the same. For statistical analysis, the number of deaths and the number of 
males in The Netherlands were compiled into five-year age groups and five-year 
calendar periods of death (Table I). 
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Table 1 Number of deaths due to prostate callcer alld persall years of observatioll 
ill the Netherlallds, 1955-1994 
a) Number of deaths 
55-59 60-64 65-69 70-74 75-79 80-84 
1955-59 95 229 514 837 1036 867 
1960-64 116 245 591 898 1299 1133 
1965-96 132 325 654 1078 1512 1425 
1970-74 138 314 689 1089 1553 1514 
1975-79 140 339 799 1338 1693 1674 
1980-84 163 410 879 1433 1889 1832 
1985-89 210 529 919 1581 2116 2112 
1990-94 195 519 1062 1766 2319 2496 
b) Person years of observation 
55-59 60-64 65-69 70-74 75-79 80-84 
1955-59 1244347 1055747 845088 640646 423388 218827 
1960-64 1382245 1156572 940699 707939 475594 257087 
1965-69 1462469 1274451 1015380 771006 521280 290946 
1970-74 1506338 1343825 1110544 819823 554929 316949 
1975-79 1580498 1388582 1171273 895203 588620 336228 
1980-84 1710417 1462326 1218130 948617 644259 360135 
1985-89 1757563 1588469 1284758 997095 688909 386452 
1990-94 1821150 1369635 1417716 1073638 736525 424506 
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MOliality rates were calculated for these groups per 100,000 person years. We adjusted 
the rates for age according to the European Standard Population. Ages below 55 were 
ignored in the analysis, because less than 1 % of prostate cancer deaths occur in this 
group.3 The relation between the indexed age groups (a~I-6), periods (IFI-8) and 
COhOlis (c~I-13) is shown in table 2. To estimate the separate effects of age, calendar 
period and birth COhOli on the trend in mOliality, a series of models containing the 
terms listed in table 3 was fitted sequentially, using the methods described by Clayton 
& Schifflers.lO.l! The GENMOD procedure of the statistical package SAS was used. 
To test the goodness-of-fit of the models with the obselved mortality rates and to test 
the models against one another, deviances and differences of deviances with 
appropriate degrees of freedom were used.lO.l! We allowed for extra Poisson variation 
in the final age-cohort model. l2 
Results 
The number of cases and person years of all obselvations used in the analyses are 
displayed in table 2. The age-adjusted mortality due to prostate cancer increased 
gradually from 22 in 1955-1959 to 26 in 1965-1969, stabilised in the early seventies 
and then further increased to 33 in 1990-1994 (Figure I). The increase occulTed 
initially in all age groups, but after 1989 only in the oldest age groups (Figure 2). The 
age-specific mortality rate declined slightly in 1990-1994 for men under the age of 65. 
The results of statistical modelling of the obselved rates arc summarised in table 4 and 
5. If a model is valid, the deviance is chi-square distributed with DF degrees of 
freedom. Large values of the deviance compared with DF indicate a lack of fit. The 
age-period model gave a poor fit, resulting in a p-value for the goodness of fit of 
0.014. The AC-model fitted somewhat better (p~0.038) than the AP-model. 
The fully parameterised age-period-cohort model did not fit the data better than the 
age-cohort model: the difference in deviances was not significant (p~0.088) (Table 4). 
The age-period-cohort model fitted the data better than the AP-model (p~0.026), but 
not better than the AC model, also when allowing for extra-Poisson variation (F-test: 
p~0.30) (Table 6). We, therefore, conclude that the AC-model with extra-Poisson 
variation provided a good description of the data (Figure 3). The plot of the 
standardised deviance residuals of the AC-model with extra-Poisson variation and the 
AC-model without extra-Poisson variation showed only small differences in the two 
types of residuals and no (extreme) outliers (Figure 4). 
Table 2 Relationship between age, period and cohort. (For illustration, birth cohort 1900-1909 is shown in Italic). 
Period 1955-1959 (1) 1960-1964 (2) 1965-1969 (3) 1970-1974 (4) 1975-1979 (5) 1980-1984 (6) 1985-1989 (7) 1990-1994 (8) 
Age 
55-59 (1) 1895-1904 (6) 1900-1909 (7) 1905-1914 (8) 1910-1919 (9) 1915-1924 (10) 1920-1929 (11) 1925-1934 (12) 1930-1939 (13) 
60-64 (2) 1890-1899 (5) 1895-1904 (6) 1900-1909 (7) 1905-1914 (8) 1910-1919 (9) 1915-1924 (10) 1920-1929 (11) 1925-1934 (12) 
65-69 (3) 1885-1894 (4) 1890-1899 (5) 1895-1904 (6) 19011-1909 (7) 1905-1914 (8) 1910-1919 (9) 1915-1924 (10) 1920-1929 (11) 
70-74 (4) 1880-1898 (3) 1885-1894 (4) 1890-1899 (5) 1895-1904 (6) 19011-1909 (7) 1905-1914 (8) 1910-1919 (9) 1915-1924 (10) 
75-79 (5) 1875-1884 (2) 1880-1889 (3) 1885-1894 (4) 1890-1899 (5) 1895-1904 (6) 1900-1909 (7) 1905-1914 (8) 1910-1919 (9) 
80-84 (6) 1870-1879 (1) 1875-1884 (2) 1880-1889 (3) 1885-1894 (4) 1890-1899 (5) 1895-1904 (6) 1900-1909 (7) 1905-1914 (8) 
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Table 3 List of models fitted consecutively using methods described by Clayton & 
SchifJlers. 10,/ 1 
TI,e mortality rate Yap is fully specified as being the rate for age group a alld cohort c,sillce 
c=A-a+p, where A is the lIumber of age groups. 
17,e left hand side of the equation is the expected value of the lIa/lirallag a/the mortality rate. 
n,e right halld side of the equation is a linear combination of the effects 0/ SOlJIe or all o/the factors: 
age, period and cohort. 
IHodcls considered 
AGE (A) 
AGE+DRIFT (AD) 
AGE+PERIOD (AP) 
AGE+COHORT (AC) 
AGE+PERIOD+COHORT APC) 
Equations of the model 
B[InY,,] =aa 
E[ln Yap1=aa +3p or 
E[ln Yac]=aa +Sc 
E[ln YapJ=aa+1tp 
E[In Y "l~a,+~, 
E[In Y,p,l~a, +np +1, 
Values of ill dices 
a = 1,2, ... ,5,6 
P = 1,2, ... ,7,8 
c = A~a+PJ c=I, .... 13 
as before 
as before 
as before 
Figure 1 Age-adjusted mortality due to prostate cancer in The Nether/ands, 
1955-1994. (European Standardized Rate) 
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Table 4 
Model 
Age 
Age+Drift 
Age+Period 
Age+Cohort 
A+P+C 
Age-specific mortality rates for prostate cancer in The Netherlands, 
1955-1994. 
-" 
1960-64 1965·69 1970-74 1975-79 1980-84 1985-89 1990-94 
Period of death 
Goodness offit tests of the models 
Deviance Degrees freedom p-value 
418.5 42 < 0.001 
75.2 41 < 0.001 
55.9 35 0.014 
45.1 30 0.038 
34.1 24 0.083 
-80·84 
+75·99 
.... 70·74 
...... 65-69 
*60·64 
+55·59 
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Table 5 Successive testillg oflllodeis' 
Testing models Difference in deviance Degrees of freedom p-value 
Age+drift vs. Age 343.3 I < 0.001 
AP vs. Age+Drift 19.3 6 0.004 
AC vs. Age+Drift 30.1 II 0.002 
APCvs.AP 21.8 II 0.026 
APCvs. AC 11.0 6 0.088 
*The F-value Jar a lest of the APe-model verslls the AC-mode/ ill the presence of exira 
Poisson variatio1l12 was [(45.1~34.1)/6]1[34.1/24J = },29 with 6 degrees affreedom/or the 
lIumerator and 24 degrees a/freedom/or the denominator (p-vaille is 0.30). 
17,e F-vafue for a lest oJ the APe-model versus the AP-model ill the presence of extra 
Poisson varia/ioll 11 was [(55,9-34./)/1l]/[34.1I24J = 1.39 with 11 degrees ofFeedomJor (he 
numerator and 24 degrees affreedom/or the del/omillator (p-value is 0.24). 
Figure 3 Relative risk of 1II0rtaiity due to prostate cancel' pel' birth cohort in The 
Netherlands + 95% confidellce intervals, based all the Age-Cohort model (birth cohort 
1935 is reference cohort). 
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Table 6 Paramelers of Ihe Age-Cohorl model on Ihe log scale (see Table 2) wilh 
and without extra Poisson variation. 
Age para- standard Se (extra Poisson Cohort para- Se Se (extra Poisson 
meters error (Se) variation} meters variation) 
55-59 -9.14 0.072 0.088 1875 -0.56 0.087 0.106 
60-64 -8.08 0.081 0.099 1880 -0.45 0.082 0.101 
65"69 -7.09 0.080 0.098 1885 -0.35 0.081 0.099 
70-74 -6.28 0.080 0.098 1890 -0.34 0.081 0.099 
75-79 -5.56 0.080 0.098 1895 -0.31 0.080 0.098 
80-84 "4.97 0.080 0.098 1900 -0.31 0.080 0.098 
1905 -0.25 0.080 0.098 
1910 -0.20 0.080 0.098 
1915 "0.18 0.080 0.098 
1920 -0.13 0.080 0.099 
1925 -0.06 0.081 0.099 
1930 0.04 0.085 0.104 
1935 0.00 
Fignre 4 Pial of slandardized deviance residuals of Ihe Age-Cohorl-model withoul 
exira-Poisson varialion (Res-ac) (,-axis) and Ihe Age-Callari-model with 
exlra- Poisson varialion (Res_ace) 6'-axis). 
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Discussion 
Two main findings can be derived from our analyses. Firstly, mOltality due to prostate 
cancer in The Netherlands continued to increase up to the period 1990-1994 and this 
increase can be described largely by an increased risk for consecutive bilth cohorts 
since 1875. Secondly, prostate cancer mortality ceased to increase for men under the 
age of65 after 1989. 
The poor fit of the Age-Drift model indicated non-regular period and cohort effects. 
Although the fully parameterised Age-Period-Cohort model gave the best description 
of the data, this model is difficult to intetpret. Because there are too many parameters 
in this model, age, period and cohort effects cannot be distinguished. t t Since the Age-
Cohort model was not significantly worse, an age-cohOlt model with extra Poisson 
variation describes the data reasonably well, suggesting bilth cohOlt effects. 
Mortality due to prostate cancer increased between 1975 and 1988 in most European 
countries (by 5-10% per 5-year period), except for POliugal, Spain and Yugoslavia.' 
This increase did not occur in a specific age group. Furthennore, an increasing 
cumulative mortality risk (30-74 years) was found for consecutive birth cohOtts after 
1910 (up to the 1940 birth cohOlt) in Denmark and Norway and to a lesser extent in 
Gennany, Belgium, United Kingdom and The Netherlands. t In Norway, mortality due 
to prostate cancer increased to a similar extent as the incidence between 1957 and 
1991, which was more pronotlllced in men under 60 years of age, but without a bitth 
cohort effect. 13 On the other hand, no notable increases in mortality were reported for 
Northem Sweden between 1974 and 198914 or Isere (France) between 1979 and 
1990." 
Analyses with mortality data available up to 1983 in Spain showed an increase in the 
risk for men bam before 1891-1896, followed by a stabilization.'6 On the basis of 
mortality data up to 1991 from the database of the World Health Organisation, a 
pattenl of an increasing risk was shown for men horn around 1910 and earlier, 
followed by a slow increase (France, Canada, Australia) or stabilisation (USA, UK)." 
In a recent repOli concerning mortality in Europe, a cohort effect was found in most 
countries, which was most pronounced in Poland, Hungary, Greece and Spain. In some 
countries (e.g. Belgium, Denmark) there was a hint of reversal of trends in the cohOtts 
of men born around 1940. Calendar period effects were negligible in most countries." 
Our results suggest that the risk of clinical prostate cancer has increased in The 
Netherlands. There could, however, be other reasons for our findings. Because the 
unequivocal detelmination of the cause of death is particularly difficult for the oldest 
subjects, changes in coding practices may have influenced the frequency of reporting 
prostate cancer as the underlying cause of death, against the background of the rising 
incidence of prostate cancer and the decline in mortality due to cardiovascular 
disease,l9 male lung cancer'o and benign prostatic hyperplasia." 
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This would, however, have resulted in stronger period than coh01t effects. 
Nevertheless, the finding of an age-coh01t model that fits might be explained in a 
different manner. If increased detection and consequently increased rep01ting of 
prostate cancer as the cause of death affect successive birth cohorts to different 
extents, changes in diagnostic procedures could mimic a cohort effect under some 
circumstances. For prostate cancer, incidence rates would have been more prone to 
spurious coh01t effects, because increasing detection of subclinical prostate cancer is 
more likely to affect the incidence of prostate cancer than mortality. Since the 
prevalence of 'latent' prostate cancer at autopsy increases rapidly with age,22 a higher 
detection rate is, indeed, likely to be more pronounced for older than younger ages. A 
spurious cohort effect on m01tality rates could only be found if the vast majority of 
'latent' cases of prostate cancer resulted in the rep01ting of prostate cancer as the 
underlying cause of death, but this does not seem to be a plausible assumption. 
Delayed diagnosis resulting in a worse prognosis is not a likely explanation for 
increased mortality because, in fact, an increasing prop01tion of cases was detected at 
an organ-confined stage.' FlIlthermore, curative radiotherapy was applied increasingly. 
If the m01tality rate for prostate cancer has increased over the past decades, it seems 
that the contribution of increased detection to the increase in incidence is generally 
overestimated. However, the incidence of prostate cancer has been higher than the 
mortality attributable to this disease since the seventies and the trend has been a steady 
increase. ' As a consequence, the mortality/incidence ratio in The Netherlands was 
0.52 in 1990 and 0.38 in 1994.3 Therefore, it seems likely that an increase in the risk of 
clinical prostate cancer has occuned in addition to a considerable at1ificial increase in 
the incidence. 
However, a cause for this increased risk has not been established yet. Major genetic 
factors are responsible for approximately 9% of cases.23 High dietary fat intake is one 
of the few rather consistently rep01ted risk factors, but the evidence on alcohol intake, 
physical activity, vitamin D and risk factors in utero is still inconclusive.24,25 
In conclusion, mortality due to prostate cancer has continued to increase, which can be 
explained to a large extent by an increasing risk for successive birth coh01ts up to 
those bom around 1930. Analyses of mortality in other European countries point into 
the same direction. 
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Chapter 4 Trends in prognosis 
4.1 Trends in survival of prostate cancer in southeastern Netherlands, 
1971-1989. 
4.2 Variation in survival of patients with prostate cancer in Europe since 
1978. 
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4.1 Trends in survival of prostate cancel' in southeastel'll 
Netherlands, 1971-1989: 
Abstract 
The increase in the incidence of prostate cancer over the past two decades is suggested 
to be due largely to increased detection of subclinical tumours. 
To explore this assumptioll, we investigated trends in survival of prostate cancer in 
southeastelll Netherlands, an area with almost 1 million inhabitants, where the age-
adjusted incidence of prostate cancer increased by 53% between 1971 and 1989, i.e. 
before the introduction of prostate-specific antigen testing. Survival was calculated for 
all patients registered in the Eindhoven Cancer Registry bctween 1971 and 1989 
(IF2562). In spite of earlier diagnosis, survival barely changed during tlus time period. 
Five-year relative survival improved slightly from 53% (95% confidence interval [CI] 
47,59) in 1975-1979 to 56% (CI 51-61) in 1985-1989. Stratified analyses suggested 
an improvement since 1980 for patients below 75 years ,,,ith localized hllll0urs but, 
despite possible stage migration, decreased survival for those with metastasized and/or 
poorly differentiated tumours. Paticnts below 75 years whose tumours were diagnosed 
unexpectedly during transurethral resection exhibited a relative survival of 85% 5 
years and 68% 10 years after diagnosis. 
Less extensive application of transurethral resection in The Netherlands might explain 
why our findings do not agree with those found in Sweden and the USA. Inference 
from counby-specific trends in survival appears not necessarily generalizable to other 
countries with a similar increase in the incidence of prostate cancer. 
We conclude from our study that earlier diagnosis of prostate cancer between 1971 
and 1989 may be accompanied by an increased incidence of the aggressive variant. 
• Post PN, Kil PJM, Coebergh JWW. lilt J Cancer (in press). Reproduced with pemlission from John Wiley & 
Sons, Inc. 
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Introdnction 
Investigation oftrends in survival of prostate cancer may provide insight into the 
nature of recent increases in incidence. The considerable increase in incidence over the 
past two decades! is probably attributable to increased detection of subclinical cases 
that fonnerly remained undetccted. This seems plausible, becanse a high prevalence of 
'latent' prostate cancer (of up to 40% at age 70) was found in various autopsy studies 
of men who were not diagnosed nor even suspected of having prostate cancer before 
they died.' Due to improved diagnostic methods and increased application of 
transurethral resection ofthe prostate (TURP), an increasing prop0l1ion of these 'latent' 
carcinomas may be detected, thereby spuriously increasing the incidence and 
improving survival. The marked improvement in survival in Sweden between 1960 
and 1980 is attributed to this phenomenon.3 Since diagnostic intensity and survival 
differ between countries, e.g. in the Nordic countries,. it is not clear whether the 
findings for Sweden are applicable to other industrialized countries where a large 
increase in incidence has been reported. In Southeastern Netherlands, the incidence 
increased by 53% between 1971 and 1989, the increase representing low grade and 
localized but partly also poorly differentiated and metastasized cancer.' Data on 
changes in survival according to stage and grade arc sparse in the literature, but may 
provide more insight into the cause of changes in survival. We studied stage-specific 
as well as grade-specific survival as of 1980 and investigated overall trends in survival 
since 1971. 
Patients and methods 
Study base 
In this study, survival of patients with prostate cancer registered in the Eindhoven 
Cancer Regishy was investigated. The registry covers a region with almost 1 million 
inhabitants in southeastern Netherlands with good access to specialized medical care. 
The methods of the regishy arc described in detail elsewhere.' Based on analysis of 
referral patterns and comparison with mortality data, the registry can be considered 
nearly complete for prostate cancer as of 1971.' Prostate cancer was usually diagnosed 
by meaIlS of histological examination of biopsies or tissue specimens obtained during 
TURP. TURP was the main treatment modality in the 1970s, often supplemented by 
hormonal or surgical castration. Radiotherapy has been prescribed increasingly since 
1980, but radical prostatectomy rarely before 1988. 
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Allalysis 
The Vital status of all cases was checked with municipal civil registries until I April 
1994. Of the 2583 patients registered between 1971 and 1989, 21 (0.8%) were 
untraceable (mainly due to repeated moving) and were, therefore, excluded from the 
survival analyses, resulting in a study cohort of 2562 patients. Another 28 (1.1 %) 
were lost to follow up before the closing date and were censored in the analyses. The 
survival rates were calculated according to the actuarial (life table) method. 
Differences in survival were tested with the log-rank test. A Cox proportional hazards 
model was used to test a possible interaction between age group and period of 
diagnosis. Relative survival was calculated as the ratio of the cl1lde to the expected 
survival. 7 The expected survival rates were calculated from life tables derived from 
the regional mOltalily statistics and compiled for five-year age groups and per calendar 
year for the regional male population. A software package from the Finnish Cancer 
Registry was used to calculate relative survival.' 
The study period was divided into four intervals: 1971-1974, 1975-1979, 1980-1984 
and 1985-1989. Survival was analyzed for the following IO-year age groups: 45-54, 
55-64, 65-74, 75-84 and 85-94 years of age. Stagc was recorded in the registty 
according to the TNM classification in use at thc timc: On the basis of the registered 
infonnation, we classified stage as localized and incidental finding (TI), localized and 
palpable (T2), locally advanced (T3-4), or as 'unknown' if not sufficient information 
was available for accurate staging. If lymph node involvement or distant metastases 
were recorded, stage was defined as metastasized. Because absence of metastases was 
not always rccorded explicitly, we included both MO and Mx in the non-metastasized 
categories. Since bone scans became widely available in the late 1970s, stage was 
reliably recorded as of 1980. In[onnation on histological grade was used when 
registered; it was scored by up to 10 pathologists of three departments of pathology 
according to the classification of the World Health Organization in use at that time and 
also usable as of 1980: Stratified survival analyses were perfonned on the basis of 
these categories since 1980 and for two age categories only: < 75 and ;0, 75 years of 
age. The chi-square test was used to test differences in proportions. 
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Figure 1 Trellds ill relative survival of patiellts with prostate callcer ill southeastern 
Netherlallds, 1971-1989. 
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Results 
The mean as well as the median age at diagnosis of the 2562 patients was 73 years, 
25% were aged 80 or over and 25% were aged 67 years or less. 
Both clllde and relative survival barely changed between 1971 and 1989 (Figure I). 
Five-year relative survival decreased slightly in the 1970s from 57% (95% confidence 
interval [eI] 50%, 64%) in 1971-1974 to 53% (CI 47%, 59%) in 1975-1979). 
Subsequently, it retul1led to the initial level, being 56% (CI 51, 61) in 1985-1989. 
Relative survival decreased for patients aged 55-64 years from 76% in 1971-74 to 57% 
in 1985-1989 as well as for patients aged 45-54 years since 1980 (Table I). A small 
improvement was observed for patients aged 75-84 years from 42% in 1971-74 to 48% 
in 1985-89. Cox regression analyses of crude survival indicated that the interaction 
between age group and period was not significant (p~O.l2). 
Table 1 Trends in 5-year survival (crude and relative) oj patients with prostate cancer diagnosed in southeastern Netherlands 
according to age group (standard error). 
45-54 years 55-64 years 65-74 years 75-84 years 85-94 years 
crude relative crude relative crude relative crude relative crude relative 
1971-74 43 (18) 45 (19) 67 (7) 76 (8) 48 (4) 64 (5) 23 (4) 42 (7) 13 (6) 48 (22) 
1975-79 45 (18) 47 (19) 64 (5) 72 (6) 43 (3) 57 (4) 25 (3) 47 (5) 8 (4) 28 (13) 
1980-84 53 (12) 55 (12) 53 (5) 59 (5) 44 (3) 58 (4) 31 (2) 58 (5) 7 (3) 41 (18) 
1985-89 42 (10) 44 (11) 52 (4) 57 (5) 50 (2) 65 (3) 26 (2) 48 (4) 10 (4) 44 (19) 
Table 2 Change in stage distribution Jor patients with prostate cancer in southeastern Netherlands between 1980 and 1989. 
< 75 years ;,; 75 J'ears 
1980-1984 1985-1989 1980-1984 1985-1989 
n % n % n % n % 
Localized incidental 100 25 147 29 85 26 123 31 
Localized palpable 59 14 126 24 53 16 66 17 
Locally advanced 26 6 54 10 22 6 36 9 
Metastasized 145 36 151 30 75 23 119 30 
Unknown 76 19 38 7 95 29 53 13 
Chi-square test 
including unknown cases: p=O.OOl p=O.OOl 
excluding unknown cases: p=0.002 p=0.8 
Table 3 Change in grade distribution for patients with prostate cancer in southeastern Netherlands between 1980 and 1989. 
< 75 ~ears > 75 ~ears 
1980-1984 1985-1989 1980-1984 1985-1989 
n % n % n % n % 
Well differentiated 131 32 164 32 103 31 94 24 
Moderately differentiated 124 31 204 40 81 25 167 42 
Poorly differentiated 72 18 101 20 60 18 85 21 
Unknown differentiation 68 19 31 9 71 26 31 13 
Chi-square test 
including unknown cases: p~O.OOI p~O.OOI 
excluding unknown cases: p~O.2 p~O.OOI 
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Survival by stage alld grade 
An increasing proportion of patients below 75 years were detected at an early stage 
during the 1980s (p~0.002) (Table 2), whereas the stage distribution for patients aged 
75 years or over improved only slightly (p~0.8). An increasing proportion of patients 
in this older age group were diagnosed with moderately differentiated tumours 
(p~O.OOI) with a conCUlTent decrease in the proportion well differentiated (Table 3). 
The changes in grade distribution of patients below 75 years were less noteworthy. 
Table 4 Challge ill 5-year relative survival of patiellts with prostate callcer 
diagllosed ill southeastem Netherlallds accordillg to stage (se ~ 
stalldard err0l1. 
< 75 years >~ 75 years 
1980-1984 1985-1989 1980-1984 1985-1989 
% (se) % (se) % (se) % (se) 
localized incidental 80 (6) 88 (4) 81 (10) 74 (9) 
Localized palpable 73 (8) 79 (5) 51 (11) 62 (12) 
Locally advanced 60 (12) 51 (8) 59 (20) 30 (I 1) 
Metastasized 31 ( 4) 24 (4) 16 (6) 20 (5) 
Unknown 66 (7) 61 (11) 67 (10) 45 (13) 
A total of 451 patients whose tumours were detected incidentally during TURP could 
be identified between 1980 and 1989, 245 of whom were below 75 years of age. 
Survival of these patients was shorter than that of the general male population, relative 
survival being 85% after 5 and 68% after 10 years. 
When we excluded patients recorded as Mx (metastasis status not known), relativc 
survival was nearly the same after 5 years (86%) and only slightly better after 10 years 
(70%). The majority (63%) of incidentally detected tumours was well differentiated, 
but 28% were moderately and 9% was poorly differentiated. 
Since 1980, the prognosis for patients below 75 years with localized tumours has 
improved modestly, but it has deteriorated for locally advanced and metastasized cases 
(Table 4). A small decrease in slllvival was obselved for patients aged 75 or over with 
incidentally detected tumours. 
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The prognosis improved for patients with well differentiated tumours but decreased for 
those with poorly differentiated tumours, especially for patients aged 75 years or over 
(Table 5). A small improvement was observed for patients with moderately 
differentiated tumours who were below 75 years but not for those who were 75 years 
of age or over. 
Table 5 Change ill 5-year relative s1l11Jival of patients with prostate cancer 
diagnosed in sOlllheaslem Nelherlands according 10 hislological grade 
(se ~ slandal'd el'l'ol/ 
< 75 years >~ 75 years 
1980-84 1985-89 1980-84 1985-89 
% (se) % (se) % (se) % (se) 
well differentiated 78 (5) 86 (3) 69 (9) 81 (10) 
moderately differentiated 47 (5) 64 (4) 61 (II) 45 (7) 
poorly differentiated 27 (6) 24 (5) 35 (9) 25 (7) 
unknown differentiation 69 (7) 42 (8) 48 (9) 37 (II) 
Discussion 
We observed no notable improvement in prognosis for patients with prostate cancer in 
Southeastem Netherlands between 1971 and 1989. An improvement in prognosis 
might be expected because 28% of incident cases between 1980 and 1987 were 
detected incidentally during TURP and stage distribution improved in this time 
period.' 
Our findings do not agree with data from Sweden, where the prognosis improved 
markedly between 1960 and 1985.3 A large improvement in survival was also repOtted 
in the USA between 1973 and 1989. 10 Several other reports concerning trends in 
survival since 1960 are available but unfortunately they cover several different time 
periods. Five-year relative sUlvival improved modestly in Scotland from 44% in 1968-
1972 to 47% in 1983-1987." In Norway,l2 it improved liOt11 42% in 1957-1961 to 
59% in 1982-1986 and in Vaud (Switzerland) from 44% in 1974-1978 to 52% in 1979-
1983. 13 In the Eurocare Study, a collaborative study of 45 cancer registries in 17 
European countries since 1978, a modest improvement in prognosis from 55% to 59% 
was found only between 1986 and 1989.14 
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In the present study, survival was initially higher than in subsequent periods. This may 
be explained by increasing completeness of the registry in the 1970s.5 Some of the 
more severe cases probably never underwent work-up in a hospital, because the 
number of urologists was still small in those days. (It increased from 3 per 400,000 
men in 1971 to 12 in 1978). This decreases the chances of registration by the cancer 
registlY, since this depends largely on notification by Pathology Departments and 
medical record departments in the hospitals. Selective loss to follow-up is not likely to 
be an issue, since migration rates are low in the region and all patients were actively 
followed up via municipal civil registries, resulting in only 1.9% lost to follow-up. 
Moreover, over 95% of cases were confirmed pathologically by histological 
examination of biopsies or tissue specimens obtained by TURP. A beneficial effect of 
treatment could probably not yet been expected, because most patients in the 1970s 
and a large proportion in the 1980s were treated conselvatively. The unexpected 
decline in survival in the youngest age groups is discussed in detail elsewhere. 15 
A small improvement in survival was observed for localized prostate cancer versus 
decreased survival for locally advanced and metastasized cases, although the rather 
large confidence intervals do not allow finn conclusions. Changes in the assessment of 
stage due to new diagnostic techniques (stage migration) cannot explain these 
divergent trends, because an improvement in all stages would then be expected. 16 
Furthermore, we used the clinical stage in our analyses, thereby minimizing the impact 
of staging procedures related to radical surgery. The cases detected incidentally during 
TURP exhibited a lO-year relative survival of 68%, which means that they also 
comprised lethal tumours. This was not due to the inclusion of patients with an 
unknown metastasis status (Mx), because survival was nearly the same after exclusion 
of these cases. Most of the incidentally detected cases were just classified as TI, not 
TlA or TlB. It is, however, not likely that many TI cases were miselassified as such, 
because whenever the registrars had a reasonable doubt, the tumour classification was 
coded as unknown. However, it is possible that the majority of these cases should be 
classified as TlB, which would mean a significantly worse survival than TlA.17 
Indeed, almost 40% of these cases were moderately or poorly differentiated. The 
unexpected finding of prostate cancer probably OCCUlTed largely in patients whose 
tumours would soon have become clinically apparent without this procedure. 
The lack of improvement in sUlvival in our study may be explained by an increased 
OCCUlTence of aggressive prostate cancer, which might have cancelled out the expected 
improvement due to earlier detection. Indeed, we did not obselve an improvement in 
the grade distribution but, in contrast, more moderately and to a lesser extent more 
poorly differentiated tumours were detected during the late 1980s. 
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In the USA, the proportion of patients with poorly differentiated tumours neither 
declined substantially afier the introduction of early detection measures in the 1990s, 
although an increased propOltion of these tumours was detected at an organ confined 
state. 18 An increased risk of aggressive prostate cancer is also suggested by the 
increasing risk of mortality due to prostate cancer for consecutive birth cohorts up to 
men bom around 1930 in most Europcan counlries,I9 although a cause for this 
development has not been found yet. Increased diagnosis of insignificant tumours, 
resulting in improved survival, such as reported for Sweden' did probably not occur in 
all countries to a similar extent. The effect of early detection by PSA testing and 
intervention by radical prostatectomy on survival could not yet be evaluated in our 
study, but early detection by PSA testing will produce improved survival even in the 
absence of treatment due to lead time bias.'o 
In conclusion, the lack of a notable improvement in survival of patients with pros late 
cancer between 1971 and 1989 in southeastern Nelherlands may indicate that earlier 
diagnosis conculTed with an increased incidence of aggressive prostate cancer. 
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4.2 Variation in survival of patients with prostate cancer in Europe 
since 1978: 
Abstract 
Since the incidence of prostate cancer has increased considerably over the past two 
decades in most European countries, knowledge of the variation in survival is 
pertinent. The collaboration across Europe in the Eurocare study has now been 
extended to 45 registries in 17 countries. We report on variation in relative survival 
according to age of 65728 patients diagnosed with prostate cancer between 1985 and 
1989 and also explore time trends since 1978 for most countries. 
Considerable variation in survival was found within and between countries with the 
highest survival in Switzerland (5-year relative survival 72%), followed by Germany 
(67%) and the Nordic countries (except Denmark). The lowest survival was found in 
Estonia (39%), preceded by Slovenia (40%), Denmark (41%) and England (45%). 
Between 1978 and 1986, relative survival barely changed over time, but it improved 
from 55% (95% confidence interval [Cl] 53-57) in 1984-1986 to 59% (Cl 56-61) in 
1987-1989. A small but unexpected deterioration of survival for patients aged 45-54 
from 61 % to 56% was observed in the early 1980s. 
It is likely that variation in both detection methods and treatment plays a role in the 
observed variation in survival, but more infOlmation is needed to assess each 
contribution . 
• Post PN, Damhuis RAM, van der Mcydcn APM and the Eurocare Working Group. Ellr J Callcer 
1998;34:2226-2231. Reproduced with pemlission from Elsevier Science. 
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Introduction 
In most European countries, the incidence of prostate cancer has increased morc than 
any other cancer over the past two decades.' Prostate cancer is mainly a cancer of old 
age. Being very uncommon at younger ages, the annual incidence increases steeply 
after age 50 to I per 100 men aged 80 and over. A velY high prevalence of so-called 
'latent' prostate cancer (of up to 40% at age 70) was found in various autopsy studies 
of men who had no clinical diagnosis or suspicion of prostate cancer before death.' 
An increasing propOliion of these latent cancers has been detected due to the increased 
use of transuretln'al resection of the prostate (TURP). Application of this surgical 
procedure for the treatment of symptoms of benign prostatic hyperplasia results in the 
unexpected diagnosis of prostate cancer in approximately 10% of cases.' Since 
increased detection of subclinical cases not only results in an increase in the 
incidence,4 but also in improved survival,s access to this surgical procedure in a 
region is an important determinant of the prognosis. Increased detection of 
insignificant tumours may be accelerated by the introduction of improved diagnostic 
techniques like transrectal ultrasound, ultrasound guided biopsy and prostate-specific 
antigen (PSA) testing (length time bias). Moreover, the diagnosis of prostate cancer 
following a positive PSA test appears to move the diagnosis forward by up to 5-10 
years," resulting in improved survival as well (lead-time bias). 
Stage at diagnosis is an impOliant detenninant of prognosis. Once the disease has 
metastasised, cure is not possible anymore and treatment is directed primarily on relief 
of symptoms. If prostate cancer is detected at an early stage, curative treatment by 
radical prostatectomy' or radiotherapy' is possible. However, watchful waiting appears 
to provide similar results for patients with low-grade tumours:,10 There is no 
consensus about the usefulness of screening for prostate cancer. Large trials that 
address this issue are clllTently carried out in the USA and Europe." Meanwhile, the 
incidence, mainly of low-grade cancer, has increased in several European countries 
following the introduction of opportunistic PSA testing.",13 Since there was no report 
on prostate cancer in the first pati of the Eurocare study,14 this is the first report on 
survival of prostate cancer across Europe. The collaboration across Europe in the 
Eurocare study has now been extended to 45 registries in 17 countries that have 
accumulated data on 3.5 million new patients most of them diagnosed between 1978 
and 1992. We now repoti on variation in relative survival of patients with prostate 
cancer according to age from 1985-1989 and we also explore time trends since 1978 
for most countries. 
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Patients and methods 
Survival analysis was ca!Tied out on prostate cancer cases diagnosed between 1985-
1989 in 17 countries recorded in 40 population-based registries. Some of these (in 
Finland, DelUuark, Estonia, Slovenia, Iceland, Scotland, Slovakia) cover the whole 
counlty, sOlUe a large prop0l1ion (England) and the rest up to 20% (Sweden, The 
Netherlands, Genuany, Austria, Switzerland, France, Italy, Spain, Poland). Cases 
discovered at autopsy (1.5%), patients known on the basis of a death certificate only 
(DCO) (4.6%) or patients first diagnosed with another ItmlOUf were not included 
(Table I shows percentages for each country). 
Table 1 Data quality by counll)' for patients with prostate cancer (Eurocare II). 
% DCOit % histologically % lost to follow up 
verified 
Iceland 0.2 93 0 
Finland 0.5 97 0.02 
Sweden . 0 99 0 
Denmark 0 92 0 
Scotland 2.3 84 0 
England 7.1 73 0.1 
Netherlands' 0 98 1.8 
Germany . 2.4 91 0 
Austria' 1.5 83 0 
Switzerland' 0.3 99 II 
France 0 97 0.4 
Spain" 15 89 0 
Italy' 3.6 79 0.6 
Slovenia 6.7 84 0.1 
Slovakia 8.1 81 0 
Poland' 0.9 60 7.1 
Estonia 0.1 66 0.7 
Europe 4.6 83 0.1 
. 
< 20% of the national population covered # % death certificate only 
The protocol specified a minimum follow-up of five years. With respect to time trends, 
the following 3-year periods were used: 1978-1980, 1981-1983, 1984-1986, and 1987-
1989. Age-specific survival was calculated for the following age groups: 55-64,65-74 
and 75-84 years of age. 
78 Chapter 4 
Relative survival was computed as the ratio between the obselved (crude) survival and 
the expected sUlvival, derived from generalmOliality data. 15 Age-standardised survival 
could not be calculated for Iceland, The Netherlands and Poland because, in the data of 
these registries, one of the age strata contained no cases, General European estimates 
of sUlvival were weighted according to the national incidence (reflecting the size of 
the population). Survival trends have also been computed as weighted rates. Changes 
in relative sUlvival over time were calculated for the following age groups: 15-44,45-
54,65-74 and 75-99 years of age. Only data from registries that could provide data for 
the entire period 1978-1989 were used for these calculations. Standard errors of 
sUlvival, used for calculation of 95% confidence intervals, were calculated according 
to Greenwood's method. 16 
Table 2 NI/lllber of patients with prostate cancer diagnosed between 1985 and 1989 in 
EI/rope by age grol/p and cOlli/II)' (EI/rocare 11). 
Age (years) Incidence per lOs 
15-54 55-64 65-74 75-84 85-99 Total in 1983-87' 
Iceland 6 73 147 165 47 438 52 
Finland 94 853 2101 2138 380 5566 36 
Sweden 
, 
41 436 1338 1473 292 3580 50 
Denmark 102 817 2597 2773 650 6939 30 
Scotland 85 638 2137 2159 457 5476 28 
England 375 3213 10202 11423 2398 27611 23 
Netherlands' 22 130 312 285 70 819 29 
Gennany 
, 
32 190 373 386 54 1035 29 
Austria' 3 49 130 163 19 364 52' 
Switzerland' 16 129 391 433 103 1072 51 
France 34 332 755 869 163 2153 32 
Spain' 31 234 670 738 133 1806 27 
Italy' 72 531 1496 1619 274 3992 26 
Slovenia 23 142 359 446 42 1012 19 
Slovakia 70 508 1004 1031 112 2725 20 
Poland' 13 105 167 127 25 437 12 
Estonia 23 121 295 243 21 703 19 
Europe 1042 8501 24474 26471 5240 65728 
• < 20% of the national population covered 
1 \Vorld Standardised Rate, adapted from llarkiu et al.25 
2 Incidence in 1988-1992 
Trends in prognosis 79 
Results 
Sun'ivai rates (age-standardised) witlzin each cOIllIIIJ' (including overall EU data) 
The number of patients with prostate cancer in the Eurocare database was 65512, of 
which 15% was below 65 years of age and 48% was aged 75 years or older (Table 2). 
Considerable variation in survival was observed between countries, which was 
apparent by I year (Figure I). Patients diagnosed in Switzerland had the highest 
survival (5-year relative survival 72%) followed by Germany and the Nordic countries, 
except Denmark. The lowest survival was observed in Estonia (39%), preceded by 
Slovenia and Denmark. Within Spain, Italy and France a geographical variation 
between different registries of up to 20% emerged, while hardly any variation in 
survival was found within England (data not shown; see Eurocare II monograph. 17 
Figure 1 
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Five -year relative sUl11ival of patieJlts with prostate cancer diagnosed 
between 1985 and 1989 in Europe. I 
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* < 20% of the national population covered 
I Age-standardised survival could not be calculated for Iceland, The Netherlands and Poland, because 
one of the age strata contained no cases, 
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Table 3 Age-specific 1- and 5-year relative sun'ival a/patients with prostate cancel' 
in Europe, 1985-1989 (Eurocare II) 
55-64 yrs 65-74 yrs 75-84 yes 
% % % % % % 
5 I 5 5 
Iceland 98 77 93 70 90 60 
Finland 92 58 93 64 89 63 
Sweden 95 66 94 68 91 64 
Denmark 87 40 87 45 80 39 
Scotland 88 54 83 50 77 45 
England 86 48 83 46 76 44 
Netherlands' 86 58 93 66 86 46 
Genllany 
. 94 71 91 73 87 58 
Austria' 89 72 95 64 78 48 
Switzerland' 95 64 94 73 92 77 
France . 90 58 92 68 85 56 
Spain' 86 54 87 50 81 45 
Italy' 88 55 87 53 78 43 
Slovenia 81 43 75 41 74 41 
Slovakia 84 52 80 55 75 64 
Poland' 74 43 71 42 60 25 
Estonia 75 33 74 40 68 41 
Europe 89 58 88 60 82 51 
. 
< 20% of the national population covered 
SlII1'ival rates depending on age distribution/or each CO/llltl)' 
Taking all participating countries together, 5-year relative survival of patients aged 
between 55 and 64 years was slightly lower than those aged between 65 and 74 years 
(58% vs. 60%), whereas survival of patients aged between 75 and 84 years was 
substantially lower (51%) (Table 3). The lower survival for the ages 55-64, which was 
generally already apparent within 1 year, was observed in most countries, except 
Iceland, United Kingdom, Italy and Slovenia. Five-year relative survival for patients 
aged between 75 and 84 years was by rar the lowest in Poland (25%), and the highest 
in Switzerland (77%), followed by Sweden and Slovakia (both 64%). 
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Challge ill survival over tillle 1978-1989 for each cOUlltl)' 
Overall, survival barely changed before 1986. Only between 1984-1986 and 1987-
1989 a modest but significant improvement was observed from 55% (95% confidence 
interval [CI] 53-57) to 59% (CI 56-61) and was mainly due to an improvement in 
survival for patients aged 65 or over (Table 4). 
Table 4 Challge ill 5-year relative sllJl'ival of patiellts with prostate callcer ill 
EI/rope over tillle by age grol/P, 1978-1989 (EI/racare II) 
15-44 45-54 55-64 65-74 75-99 aU ages . 
% % % % % % (95%CI) 
1978-80 56 61 57 52 61 56 (53-59) 
1981-83 47 56 61 53 43 55 (53-58) 
1984-86 49 58 60 50 48 55 (53-57) 
1987-89 57 60 61 55 59 59 (56-61) 
. 
age.standardized 
Table 5 Challge ill age-stalldardised 5-year relative sl/J1'ival for each COllJltl)''" 
1978-1989 (EI/rocare II) 
1978-80 1981-83 1984-86 1987-89 
% % % % 
Iceland 55 61 65 66 
Finland 55 56 60 63 
Sweden . 60 60 62 67 
Denmark 40 38 41 40 
Scotland 44 43 44 49 
England 44 44 46 43 
Netherlands· 52 60 55 56 
Gemmny 
. 
72 70 64 68 
Switzerland" 55 49 60 60 
France . 56 50 54 69 
Italy' 39 46 46 53 
Poland' 29 44 33 
Estonia 35 31 32 43 
Europe 56 55 55 59 
. 
< 20% of the national population covered 
# excludes Austria, Spain, Slovenia and Slovakia, where registries did not contribute data for the whole 
period 1978-1989. 
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This improvement OCCUlTed predominantly in France, Italy and Estonia and to a lesser 
extent in Sweden, Scotland and Gemlany (Table 5). Between 1978 and 1983, survival 
had already improved in Iceland, Finland and Italy. Relative survival of patients under 
the age of 55 years deteriorated unexpectedly in the early 1980s (Table 4), followed 
by a retulll to the initial value in 1987-1989. 
Discussion 
Variatioll ill s1lI1,ival 
Considerable variation was observed in survival of patients with prostate cancer in 
Europe. The lowest rates were found in East European countries (except Slovakia) 
and the United Kingdom, the highest in Switzerland and the Nordic countries (except 
Denmark). The velY high survival in Switzerland may be biased due to the high 
prop0l1ion that was lost to follow-up (11%) due to emigration [17]. BalTiers to 
specialised care, resulting in delayed diagnosis, played probably a role in the lower 
survival in the Eastem countries. Delayed diagnosis may also be caused by hesitance 
to consult a physician due to limited awareness of prostate cancer among the general 
public. However, intcmational differences in hmv and when to treat prostate cancer 
may result ill variation in survival as well. Increased inclusion of insignificant cases 
(e.g. detected unexpectedly by TURP) results in spuriously improved survival rates.' 
Similar m0l1ality rates for prostate cancer in the Nordic countries, but strikingly lower 
survival in Denmark could be explained by the rather reserved attitude of Danish 
physicians which appears to result in limited diagnosis of asymptomatic prostate 
cancer cases . 18 In Table 6, variation in survival is shown in relation to age-
standardised incidence for most pm1icipating countries. Countries at high incidence 
also exhibit relatively high survival, suggesting more intensive diagnostic activity 
leading to earlier stages. The low incidence and survival rates in the Eastern countries 
lIIay also indicate that the incidence only represented symptomatic cases. Although 
variation in the occurrence of cO M l11orbidity influences survival, 19 using relative 
survival (so correcting for expected survival) should have removed most of this 
variation. 15 Differences in treatment applied may explain pati of the variation in 
survival. Along with the reserved attitude of Danish physicians with respect to 
diagnosis, only a minority of patients used to receive curative treatment in Denmark. 20 
In Great Britain, radical prostatectomy has been advocated only for a small minority of 
patients. 2I Although early diagnosis makes curative treatment (radical prostatectomy 
or radiotherapy) accessible, the benefit of treatment of especially low-grade tumours is 
not undisputed. 10 Intelpretation of the intemational variation in sUlvival is difficult 
without proper information on the differences in the prop0l1ion of insignificant 
tumours, stage at diagnosis and treatment. 
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Standardised monitoring of staging procedures, tumour characteristics and treatmcnt 
by registries participating in the Eurocare study should provide a better understanding 
of the observed differences in survival. 
Table 6 Incidence (World Standardised Rate), adapted ji"O/l/ 3 volllllles of Cal/cer 
Incidence ill Five Continents25-27 ill relatioll 10 relative survival. 
Incidence (WSR) Relative survival * 
1978-82 1983-87 1988-92 1981-83 1987-89 
Iceland 36.2 52.4 61.0 H H 
Finland 34.2 36.1 41.3 H H 
Sweden 45.9 50.2 55.3 H H 
Denmark 27.7 29.9 31.0 L L 
Scotland 23.3 27.8 31.2 L L 
England 20.9 23.1 28.0 L L 
Netherlands (Eindhoven) 28.3 28.9 35.6 II H 
Gennany (Saarland) 28.7 28.9 35.9 H H 
Austria 51.6 H 
Switzerland 50 51 50 M H 
France (Calvados) 26.8 31.8 50.5 M H 
Spain (Navarra) 20.5 26.8 27.2 H 
Italy (Varese) 20.3 25.5 28.2 L H 
Slovenia 18.7 18.6 20.7 L 
Slovakia 15.8 19.9 22.0 L 
Poland (Warsaw) 11.5 11.9 15.7 L L 
Estonia 18.8 21.6 L L 
H: High survival (> 50%); L: Low survival « 50%); M (=50%). 
Trend ill s1I11,ival 
Overall, survival of prostate cancer patients barely changed in Europe. In Sweden, a 
marked improvement in survival was observed between 1960 and 1980, which was 
athibuted largely to increased diagnosis of insignificant ('nonlethal ') cases.5 A similar 
improvement might have occurred in other European countries between 1960 and 
1980, but this time period was not included in the Eurocare shldy. We observed only a 
modest improvement between 1978 and 1989, in contrast to the USA, where 5-year 
relative survival improved from 71% in 1978 to 83% in 1987." Therefore, increased 
diagnosis of insignificant tumours seems to playa limited role only in Europe in the 
time period studied. 
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Relative survival did not improve in the age band 45-54 years, as might have been 
expected, but even deteriorated (transiently) in the early 1980s. A large increase in 
incidence under age 60 lVas reported for Southeastern Netherlands and East Anglia 
(UK) without an improvement of prognosis.'] Multivariate analyses of m0l1ality 
between 1955 and 1992 revealed an increasing risk for consecutive birth cohorts up to 
men born around 1930 in most European countries (except France and Italy)." 
However, the assumption of an increased risk of fatal prostatc cancer has not yet been 
supportcd by evidence of a specific risk factor. 
In conclusion, a large variation in survival was observed within Europe, for which the 
role of early diagnosis, diagnosis of insignificant tumours and the variation in 
treatmcnt is difficult to disentangle. In spite of increased awareness of prostate cancer, 
survival improved only modestly since 1978. 
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Chapter 5 Detemlinants of treatment of localized prostate 
cancer 
5.l Trend and varIation in treatment of localized prostate cancer In the 
southern part of The Netherlands, 1988-1996. 
5.2 Co-morbidity in patients with prostate cancer and its relevance to 
treatment choice. 
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5.1 Trend and variation in treatment of localized prostate cancel' in 
the southel'll part of The Netherlands, 1988-1996: 
Abstract 
Objective. To investigate whether the large increase in incidence of early prostate 
cancer has led to subsequcnt increased application of curative treatment and whether 
similar pattems of treatment were observed in the various hospitals in the area of this 
investigation. 
Methods. Using the Eindhoven Cancer Regishy, all patients newly diagnosed with 
prostate cancer between 1988 and 1996 in the southem part of The Netherlands were 
included in the study. Initial treatment was analysed for 4073 patients, of whom the 
proportion with clinically localised prostate cancer (T1-T3, MO-Mx) increased from 
52% in 1988-1990 to 74% in 1994-1996. 
Results. The proportion of patients with localized prostate cancer treated with radical 
prostatectomy increased from II % to 34% among patients under age 70. Especially in 
1994-1996, a group of smaller hospitals with a rather low propOliion treated with 
radical prostatectomy (5%-52%: n~ll) could be distinguished from a group of larger 
hospitals with a large proportion treated with radical prostatectomy (35%-67%: IF5). 
Radiotherapy was a more frequent option in hospitals with low radical prostatectomy 
rates. The proportion of patients aged 70-74 years undergoing radiotherapy increased 
from 31% to 41%. Over 80% of the patients of 75 years or over were treated 
conservatively during the whole study period. 
COllclusioll. Increased detection of localized prostate cancer resulted in increased 
application of curative treatment for patients under 70 years of age, but a substantial 
variation was observed between hospitals in the application of radical prostatectomy 
and radiotherapy . 
• Post PN, Kil PJM, Hendrikx AJM, PoortIllans PMP, Crommelin MA, Coebergh JWW. Eur Ural (In press). 
Reproduced with pemlission from Karger AG Basel. 
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Introduction 
Different treatment options are available for patients presenting with localized prostate 
cancer. Long-term survival rates for untreated patients with small low-grade tumours 
of up to 87% at 10 years have been repOlied by several studies, as summarized by 
Chodak et aLl Nevertheless, the large increase in the incidence of early prostate cancer 
in the 1980s resulted in an even more pronounced increase in the use of radical 
prostatectomy in the USA,' In The Netherlands, the incidence, mainly of low grade 
prostate cancer, increased by almost 50% following the introduction of prostate 
specific antigen (PSA) testing in the 1990s. 3.4 Curative treatment is not necessarily the 
optimal treatment option for all of these patients, due to the protracted natural histOlY 
and the frequently occurring concomitant diseases with negative impact on the life 
expectancy of these patients.5 Perioperative mortality or other cardiopulmonaty 
complications of surgery occur in about 10% of patients aged 75 years or over and in 
up to 5% of patients aged 65-69: Application of curative treatment results in sexual 
dysfunction in the vast majority of patients, symptoms of urinary incontinence in 10-
30% of patients treated with radical prostatectomy and symptoms of bowel or bladder 
itTitation in up to 30% of patients undergoing radiotherapy.' No conclusive guidelines 
for the treatment of localised prostate cancer could be established by a 'guidelines 
panel' convened by the American Urological Association (AUA).' We were interested 
in the management of the increasingly at an early stage detected prostate cancer in our 
area. Since the Eindhoven Registry stalied to cover the whole southern part of The 
Netherlands in this year, we were able to describe the changes in treatment for the 
southern pali of The Netherlands sincc 1988. 
We investigated whether the observed exponential increase in incidence of early 
prostate cancer has led to subsequent increased application of curative treatment. We 
also assessed the variation in treatment between hospitals in the region. 
Patients and methods 
Data were obtained from the population-based Eindhoven Cancer Registry in the 
southern pali of The Netherlands. Initially, the regislty started in the southeastern part, 
as described in detail elsewhere' and can be considered viIiually complete for prostate 
cancer since 1971.4 Registration in the southwestern part, using similar methods as in 
the southeastern part, reached completeness in 1988. Nowadays, the regislty covers 
almost the whole southelll part of The Netherlands (excluding the province of Zeeland 
and the southern part of the province of Limburg) The region has a population of more 
than 2 million inhabitants and offers good access to specialised medical care supplied 
in 16 community hospitals and two large radiotherapy centres. The region does not 
include university or specialised cancer hospitals. 
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The distance to a hospital has always been less than 30 kilometres. In the 1970s, 
prostate cancer patients were usually treated symptomatically with transurethral 
resection of the prostate (TURP), frequently followed by honnonal or surgical 
eastration. Radiotherapy has been applied increasingly since the early 1980s, but 
radical prostatectomy was only rarely performed before 1988. 
Since 1988, initial treatment has been registered in more detail. We distinguished the 
following categories: radical prostatectomy (usually retropubic); prostatectomy 
followed by radiotherapy; radiotherapy; hormonal treatment only (including 
orchidectomy, anti-androgens and LH-RH-analogues); TURP only (mainly performed 
before the diagnosis of prostate cancer); expectant management; and a last categOlY 
containing patients with unknown treatment or patients with treatments other than 
those listed above. For some of the analyses, a more crude classification was used: 
radical prostatectomy (I), radiotherapy (2) or other treatment (3). In this classifieation, 
the few patients reeeiving radical prostatectomy followed by radiotherapy were 
included in the 'radical prostatectomy 'group. 
Because preliminaty analyses revealed large differenees in the application of radical 
prostateetomy, the hospitals were grouped in type A hospitals (with ~ 10 
prostatectomies per year: IFII) and type B hospitals (with more than 10 
prostatectomies per year: n=5). This division conesponds roughly to hospitals with 
less than 500 beds (type A) and hospitals with at least 500 beds (type B). 
Clinical and pathological stage is recorded in the registty according to the TNM 
classification in use. iO On the basis of the registered information, we simplified the T 
classification as Tl, T2 (includes since 1992 tumours that are not palpable, but visible 
on transrectal ultrasound, usually performed after a positive PSA test), iO T3 or T4. If 
lymph node involvement or distant metastases were recorded, stage was defined as 
metastasized. Because absence of metastases was not always recorded explicitly, we 
included both MO and Mx in the non-metastasized categories in case of a Tl-T3. 
Treatment patterns were described after exclusion of Ml, N1+ and T4 patients. The 
chi-square test was used to test differences in propOliions. 
Results 
Between 1988 and 1996, 5411 patients with prostate cancer were diagnosed in the 
southern part of The Netherlands, of whom 4073 had localized disease. The proportion 
of patients with advanced prostate cancer (MIIN1+/T4) decreased from 33% in 1988-
1990 to 19% in 1994-1996 (p=0.001), which was mainly attributable to the doubling 
of cases with T2 tumours (Figure I). 
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Figllre 1 Trend in stage distriblltion oj patients with prostate cancer diagnosed in the 
sOllthem part oJThe Netherlands between 1988 and 1996. 
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Figllre 2 Proportion oj patients treated Jor localized prostate cancer in the sOllthem 
part oJThe Netherlands by age grollI', 1988-1996. 
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Trelld ill treatmellt 
The increase in patients with potentially curable prostate cancer resulted in increased 
application of both radical prostatectomy (mainly under age 70) and radiotherapy 
(only for patients aged 70 or over) (Figure 2). The number of patients receiving 
radiotherapy remained almost twice as high as the number of prostatectomies (Figure 
3). The changes in treatment are displayed in more detail in table I. For patients under 
age 70, the proportion treated with radical prostatectomy increascd threefold from II % 
to 33%. The proportion of patients treated and usually detccted by 'TURP only' 
decreased considerably from 30% in 1988-1990 to 10% in 1994-1996. Radiotherapy 
remained the main curative treatment option in patients aged 70-74 years, in whom we 
also observed an increase in radical prostatectomies from 5% to 9%. Honnonal 
treatments were applied rather consistently through the years and especially among 
patients over 75 years of age, in whom the proportion detected by TURP also 
decreased. An increasing proportion received no initial treatment at all. 
Treatmellt according to T classification 
Radical prostatectomy was most frequently applied in patients under age 70 with T2 
tumours and infrequently for T3 tumours (Table 2). In contrast, radiotherapy was the 
most frequently applied treatment for paticnts under age 75 with T3 tumours and the 
sccond option in T3 patients over 75 years of age. 35% of clinical T2 and 15% ofTI 
tumours of the patients undergoing radical prostatectomy, were upstaged to T3, 
whereas a smaller proportion of clinical T3 was down staged (Table 3). Less than 5% 
of the patients regarded suitable for radical prostatectomy appeared to have positive 
lymph nodes. Hormonal treatment was the main option in patients over 75 years, 
except for Tl patients of whom the majority was detected and treated by TURP only. 
A considerable proportion ofTx patients under 75 received curative treatment. 
Variation ill treatment 
Substantial variation in treatment appeared to exist between large and smaller 
hospitals, cspecially in the most recent period, 1994-1996. Patients diagnosed in larger 
hospitals (type B) underwent radical prostatectomy more than twice as much than 
those diagnosed in smaller (type A) hospitals (Table 4). The proportion of patients 
under the age of 70 undergoing prostatectomy in 1994-1996 ranged from 5% to 52% 
in smaller hospitals (type A) from 37% to 67% in the larger hospitals (type B). 
Radiotherapy was more often applied in patients diagnosed in the smaller hospitals. 
No notable differences in age, stage or gradc distribution were observed between the 
two hospital categories. 
Table 1 Trend in treatment for patients with localized prostate cancer (MO-MX, TI -TJ) in the southern part of The Netherlands, 
1988-1996. 
< 70 years 70-74 years > 75 years 
88-90 91-93 94-96 88-90 91-93 94-96 88-90 91-93 94-96 
Number of patients 348 471 707 191 272 458 406 537 683 
% % % % % % % % % 
Radical prostatectomy 11 23 33 5 6 9 1 1 2 
Radiotherapy 39 29 35 31 37 41 11 16 16 
Hormonal treatment 15 20 14 20 22 25 35 45 42 
TURP only' 30 22 10 40 29 11 45 28 17 
Expectant management 1 2 4 3 3 9 5 6 17 
Unknown/other 3 5 3 1 4 5 2 4 5 
• Usually the mode of incidental diagnosis 
Table 2 Treatment of patients with localized prostate cancer (MO-MX, T1-T3) in relation to Tumour classification in the southern 
part of The Netherlands, 1988-1996, 
< 70 years 70-74 years ;0, 75 years 
Clinical stage Tl T2 T3 TX Tl T2 T3 TX Tl T2 T3 TX 
Number of patients 561 688 121 156 327 417 67 110 579 664 99 284 
% % % % % % % % % % % % 
Radical prostatectomy 21 31 8 17 9 7 0 7 1 1 0 
Radiotherapy 29 39 58 15 30 41 58 13 10 22 24 5 
Prostatectomy and radiotherapy 0 2 2 3 0 2 2 3 0 0 0 1 
Hormonal treatment 10 17 24 26 16 26 39 24 30 50 61 36 
TURP only" 36 6 5 18 43 9 6 24 48 14 7 25 
Expectant management 4 1 2 8 6 4 1 15 8 9 5 19 
Unlmown! other 2 3 2 14 1 1 1 22 2 3 3 13 
• Usually the mode of incidental diagnosis 
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Figure 3 Number oj patiellts with prostate callcer treated curatively ill the southern part oj 
The Netherlallds, 1988-1996. 
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Table 3 Comparisoll oj clillical alld pathological T- alld N-classiJicatioll ill patiellts 
treated with radical prostatectomy ill the southern part oj The Netherlallds, 
1988-1996. 
T classification N classification 
ETl ET2 ET3 ET4 eTx ENO ENI EN2 2Nx 
% % % % % % % % % 
eTI 28 50 15 1 6 eNO 83 4 1 12 
eT2 1 51 35 1 12 eNx 65 2 1 32 
eT3 0 8 84 0 8 
eTx 13 54 27 2 4 
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Table 4 Variation in treatlllent oj patients under age 70 with localized prostate cancer 
(MO-MX, TJ- T3) in the southern part oj The Netherlands, 1994-1996. 
Type A hospital 1/ Type B hospital 1/ 
n % n % 
Radical prostatectomy 77 19 149 47 
Prostatectomy and radiotherapy 4 I 10 3 
Radiotherapy 176 44 73 24 
Hormonal treatment 64 16 36 12 
TURF only' 27 I I 43 9 
Expectant management 16 4 I I 3 
Unknown/other 18 5 5 2 
• Usually the mode of incidental diagnosis 
I:Type A: < 10 radical prostatectomies per year; Type B: ~ 10 per year 
Discussion 
The large increase in the propOliion of patients with localised prostate cancer since 1990 in 
the southern part of The Netherlands was followed by an increased application of radical 
prostatectomy and curative radiotherapy. The increased application of radical prostatectomy 
was restricted largely to 111en under 70 years of age. In contrast, the almost six-fold increase 
in radical prostatectomy rates in the USA extended to men over 75 years of age" As far as 
we know, no repOlis fi'om other European countries are available for comparison. In the 
Amsterdam region in The Netherlands, the proportion of patients under age 60 treated with 
radical prostatectomy increased from 11% in 1991-1992 to 42% in 1993-1994. The 
proportion of patients aged 60-74 who underwent radical prostatectomy increased from 4% 
to 11%, for whom the proportion undergoing radiotherapy increased from 14% to 22%." 
Although increased detection of prostate cancer at an earlier stage is a likely cause of 
increased application of curative treatment in our region, it may also (partly) be due to the 
fact that an increasing number of urologists were trained to perf 01111 this procedure. 
Indeed, a questionaire among all 28 urologists in the southe1l1 part of The Netherlands in 
1995 (response 68% ) showed that 70% of the respondents performed radical prostatectomy 
and that the majority statied doing this between 1988 and 1992. 
The proportional increase in localized tumours is most likely due to increasing opporhmistic 
PSA testing, which resulted in an increase in the age-adjusted incidence in southeastern 
Netherlands from 55 perlO' in 1990 to 80 per 10' in 1995, the incrcase representing mainly 
localized cases.4 This would explain why T2 tumours increased in pm1icuiar: besides small 
palpable tumours, this category represents tumours that were not palpable, but visible on 
transrectal ultrasound, e.g. performed after a positive PSA test. 10 A similar exponential 
increase in the incidence of localized prostate cancer was observed in other countries like 
the USA 2 and the Isere region in France." 
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The majority of prostatectomies in our region was applied in five large community hospitals 
(to which almost half of the patients with prostate cancer were admitted). Since 
radiotherapy was a more common treatment option in the other hospitals, the proportion of 
patients treated with curative intent in 1994-1996 did not ValY substantially between 
hospitals (74% of patients under age 70 in the five large hospitals and 64% in the smaller 
hospitals). Such valiation in the application of radical prostatectomy was also observed 
between but not within states in the USA (twice as low in New England and Mid-Atlantic 
regions compared to Pacific and Mountain regions).' No conclusive evidence of superiority 
of one of the options is cun-ently available,8 although most patient series suggest a better 
outcome for surgically treated patients i3•I4 than for irradiated patients. I6 However, these 
comparisons are hampered, because candidates for radiotherapy generally appear to have 
more concomitant discases I5 and the lymph node status is usually not known in these 
patients. In contrast, radical prostatectomy is generally cancelled if lymph node metastases 
are discovered before or during opcration. Indeed, radiation series provide fairly similar 
survival rates as the radical prostatectomy series at 10 years, if all patients are staged with 
pelvic lymphadenectomy and those with positive lymph nodes are excluded from the 
analyses. 17 Unfortunately, evidence from randomized trials is very sparse. When population-
based outcomes for patients with well and moderately differentiated tumours were analysed 
retrospectively by an intention to treat principle, the differences in outcomes for 
prostatectomy, radiotherapy or conservative treatment appears to be veIY small after 10 
years. Patients with poorly differentiated tumours are more likely to bcnefit by curative 
treatment. IS The A.U.A. guidelines panel recommended to offer radical prostatectomy or 
radiotherapy to patients with a life expectancy of at least 10 years. Surveillance is 
recommended for those with a limited life expectancy and/or a low-grade tumour.' A wait 
and see policy may not be accepted casily by the last category of patients, especially if 
prostate cance.' is detected through PSA testing. In our region, most of these patients were 
offered some kind of non-aggressive treatment, which raises the question whether these 
patients should have undergone a PSA test in the first place. I" 
The regional variation in the application of radical prostatectomy and radiotherapy seemed 
largely dependent on the preference of the consulted urologist. However, since treatment-
related morbidity varies between the different modalities,' the patient's appreciation of the 
risks and expected benefits will becomc more important. 
Monitoring of treatment and follow-up of patients with localized prostate cancer seems 
important, in order to be able to inform future patients well-considered of the actual risks 
and benefits of the different treatment options. However, randomized trials remain the 
preferred source of evidence. 
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5.2 Co-morbidity in patients with prostate cancel' and its relevance 
to treatment choice. 
Abstract 
Objective. Since prostate cancer has become a frequently occUlTing disease in elderly 
men and an increasing proportion is offered curative treatment, the benefits and risks 
of the different treatment options have to be balanced taking the patient's age and 
concomitant diseases into account. We assessed the prevalence of co-morbidity among 
patients with prostate cancer in relation to tumour and patient characteristics. We also 
analyzed if co-morbidity was a detennining factor in the treatment choice for patients 
with localized prostate cancer. 
Patients and methods. Serious co-morbidity was recorded in the Eindhoven Cancer 
Regishy (according to Charlson's list of serious diseases) for all patients with prostate 
cancer newly diagnosed between 1993 and 1996 in the southel11 part of The 
Netherlands (n=2941). We also assessed with logistic regression which factors 
determined the choice of treatment. 
Resu/ts. The prevalence of at least one serious concomitant disease was 38% for 
patients aged 60-69 years, 48% for 70-74 years and 53% for those aged 75 years or 
over, cardiovascular and chronic obstmctive lung diseases being most frequent. 
Patients aged 60-69 years were more likely to be treated with radical prostatectomy in 
case of a moderately differentiated tumor confined to the prostate, when younger of 
age and when diagnosed in a hospital with a high case load. Presence of co-morbidity 
was of little influence. 
Conclusion. Co-morbidity was frequently present in patients with prostate cancer, but 
the decision of urologists in southern Netherlands to apply radical prostatectomy was 
determined largely by the patient's age and the urologist's experience. 
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Introduction 
Increased detection of localized prostate cancer after the introduction of prostate-
specific antigen (PSA) testing'" has led to increased application of radical 
prostatectomy in the U,S.A.,3 and also in the southem part of The Netherlands: 
However, controversy exists about the need to treat these patients aggressively, since 
several studies reported high lO-year survival rates of up to 87% for low grade prostate 
cancer managed expectantly.5 Therefore, radical prostatectomy is advocated by many 
urologists only if the estimated remaining life expectancy of the patient is more than 
10 years.6 The presence of concomitant diseases is impOliant in the appraisal of the life 
expectancy of a patient with prostate cancer,7,8 
Although co-morbidity has received increasing attention, the exact prevalence of 
serious concomitant diseases in patients with prostate cancer is not known generally. 
The Eindhoven Cancer Registry in the southem part of The Netherlands has been 
collecting infollnation about serious co-morbidity in all patients with newly diagnosed 
prostate cancer since 1993. We report here the age-specific prevalence of serious co-
morbidity in patients with prostate cancer. Furthermore, we investigated which factors 
determined the decision of urologists in the southem part of The Netherlands to apply 
radical prostatectomy for patients with localized prostate cancer between 1993 and 
1996, with special reference to co-morbidity. 
Patients and methods 
Data were extracted from the Eindhoven Cancer Registry. This registty statied 
originally in the southeastern part of The Netherlands. Since 1988, it covers almost the 
whole southem pmi of The Netherlands (only excluding the province of Zeeland and 
the southern part of the province of Limburg) with a population of more than two 
million inhabitants. The area offers good access to specialized medical care supplied in 
16 community hospitals and two large radiotherapy institutes. The registry may be 
considered nearly complete for prostate cancer since 1971.' Presence of co-morbidity 
is recorded for every patient with a newly diagnosed cancer since 1993, Registration 
clerks extract information on co-morbidity from the medical records along with the 
registration of details of diagnosis and treatment of cancer (usually within 3-6 months 
after diagnosis), Co-morbidity was recorded using a slightly adapted list of serious 
diseases developed by Charlson and associates (Table 1).9 Only diseases with possible 
impact on the prognosis are recorded. 
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Table 1 C1assificatioll of co-morbidity, accordillg to all adapted list of Char/soli et 
al! 
Cardiovascular diseases 
(myocardial infarction, heart failure, angina pectoris, intermittent claudication, 
abdominal aneurysm) 
Cerebrovascular diseases (cerebrovascular accident, hemiplegia) 
Diabetes Mellitus (medically treated) 
Other malignancies (except basal skin carcinoma) 
Chronic obstructive pulmonary diseases (COPD) 
Dementia 
Tuberculosis and other chronic infections 
Cormcctive tissue diseases 
(Besnier Boeck's disease [sarcoidosis], systemic lupus erythematosus [SLE], 
Wegener's granulomatosis) 
Rheumatoid arthritis (only severe) 
Kidney diseases (chronic glomerulonephritis, chronic pyelonephritis) 
Bowel diseases (Chrolm's disease, colitis ulcerosa) 
Liver diseases (cirrhosis, hepatitis) 
Gastric disease 
(patients who received major surgery for ulcerative disease (BIl) 
A validation study was undertaken among 150 patients diagnosed in 1995 to determine 
if the registration clerks extracted co-morbidity conectly from the medical records 
(Intemal report Eindhoven Cancer Registry, 1997). Registration of the number of 
serious concomitant diseases was cOlTect for 87% of the patients. When the type of co-
morbidity was examined in more detail, 20% of diseases was registered inconectly. In 
most of these cases, serious co-morbidity was usually present, but an enol' was made 
in classifying the disease (e.g. cardiovascular instead of cerebrovascular disease). 
Another part of this misclassification was due to unfamiliarity of the registrars with 
tenns such as CABG (Coronmy Artery Bypass Grafting), PTCA (Percutaneous 
Transluminal Coronmy Angioplasty), when used without a mentioning of the 
underlying disease. This resulted in an underestimation of the prevalence of 
cardiovascular disease by 28%. We could not cOlTect this type of (supposedly random) 
misclassification in the cutTent study. 
Clinical stage is recorded in the registty according to the TNM classification in use.1O 
On the basis of the registered information, we simplified the T classification as Tl, T2, 
T3 or T4. If lymph node involvement or distant metastases were recorded, stage was 
defined as metastasized. Because absence of metastases was not always recorded 
explicitly, we included both MO and Mx in the non-metastasized categories TI-T3. 
However, this category may be mixed with patients who did not undergo staging 
procedures, because their high PSA level indicated a velY high probability of 
104 Chapter 5 
metastases. I I Histological grading recorded according to the TNM classification of 
malignant tumors' was scored by up to 20 pathologists of six Departments of 
Pathology. Poorly and undifferentiated tumors were considered as one category in our 
analyses. Treatment was classified in three categories: radical prostatectomy (usually 
retropubic) (I), radiotherapy (2), or other (non-curative) treatment like honnonal 
treatment and expectant management (3). Patients undergoing both radical 
prostatectomy and radiotherapy (n~21) were included in the radical prostatectomy 
group. 
Trends and vmiation in treatment are reported in more detail elsewhere.' Because the 
substantial variation in application of radical prostatectomy between hospitals (only 
general hospitals in this region), the hospitals were grouped in type A hospitals (n~9) 
(with < 200 newly diagnosed patients with prostate cancer during the study period and 
type B hospitals (IF7) (with;" 200 newly diagnosed patients per year). 
The role of various patient and tumor characteristics was investigated in relation to the 
application of curative treatment for patients aged 60-69 years with localized (Tl-T3 
MO-Mx) prostate cancer. This age group was chosen, because most urologists do not 
apply radical prostatectomy for patients aged over 70 years of age. Logistic regression 
was applied to determine the independent impact of age, co-morbidity, tumour 
characteristics and hospital size, taking radical prostatectomy as the dependent 
variable. 12 The likelihood-ratio test was used to test models against each other. 
Results 
The study consisted of 2941 patients diagnosed with prostate cancer between 1993 and 
1996 in the southern pmi of The Netherlands. The prevalence of the various 
concomitant diseases by age group is presented in table 2. The most fj'equent!y 
occurring concomitant diseases were cardiovascular diseases, chronic obstl1lctive 
pulmonary diseases (COPD), and other cancer. Most frequent combinations were 
cardiovascular disease and COPD ( 2.7%) and cardiovascular disease and diabetes 
(2.1 %). As expected, the prevalence of co-morbidity increased strongly with age, but it 
did not vary appreciably with respect to grade or stage (data not shown). The 
prevalence of at least one concomitant disease was 38% for patients below aged 60-69 
years, 48% for those aged 70-74 and 53% for patients aged 75 or over. 
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Table 2 Prevalellce of co-morbidity ill patients with prostate callcer by age group ill 
the southern part of The Netherlallds, 1993-1996. 
< 60 years 60-69 years 70-74 years ;0,. 75 years 
n~227 n~904 n~699 n~1111 
% % % % 
No co-morbidity 78 62 52 47 
One co~morbidity 17 30 32 37 
~ 2 co~morbidities 5 8 16 16 
Cardiovascular 8 16 19 18 
CVA 2 3 3 7 
Diabetes 2 5 8 8 
Other cancer 8 7 9 12 
COPD 5 8 17 14 
TBC I 3 
Dementia 0 0 2 
Billroth 11 I 2 3 
Other 0 2 2 
Application of curative treatment 
These analyses were restricted to patients aged 60-69 years with clinically localized 
prostate cancer (n~736). Radical prostatectomy was less commonly applied for 
patients aged 65-69 years (Table 3). Older patients more frequently underwent 
radiotherapy, but also other treatment without curative intent. Most patients recorded 
as Mx underwent other than curative treatment (such as hormonal treatment and 
expectant management). Treatment practices did not vary substantially over co-
morbidity. 
The logistic regression analyses (Table 4) indicate that for every year of age increase, 
a patient was 0.9 times less likely to undergo prostatectomy as a younger one (OR per 
year increase ~ 0.9; CI ~ 0.8, 0.9). For example, according to the multiplicative 
logistic model, a 65 year old is (0.9) 5 ~ 0.6 times less likely to undergo prostatectomy 
than a 60 year old man. Furthermore, radical prostatectomy was carried out more 
often when patients had a small tumour (T2) that was moderately differentiated and 
when diagnosed in a hospital with a high case load. 
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Year of incidence did not have additional influence. Patients with at least one co-
morbidity were 0.8 times less likely to undergo radical prostatectomy, but this was not 
significant (p=0.2). 
Neither did presence of 2 or more concomitant diseases contribute significantly to the 
choice of treatment. 
Table 3 Applicatioll of treatmellt of localized prostate callcer (Tl-T3, MO-Mr) for 
patients aged 60-69 years (n=736) ill reiationto tllmor- and patiellt characteristics. 
prostatectomy radiotherapy other treatment l 
% % % 
age (years) 
60-64 32 31 37 
65-69 22 37 41 
metastasis 
unknown 13 II 76 
no 29 41 30 
grade 
well diff. 21 38 41 
moderately 35 33 32 
poorly 23 31 46 
unknown 4 46 50 
tumor size 
Tl 13 26 51 
T2 30 37 33 
T3 6 62 32 
Tx 28 22 50 
co-morbidity 
0 28 33 39 
23 38 41 
;0,2 25 37 38 
hospital' 
A 14 45 41 
B 37 25 37 
I Other treatment includes honnonal treatment, TURP only and expectant management 
2 hospital A: < 200 newly diagnosed patients, Type B : ;:: 200 patients. 
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Table 4 Ulladjusted alld adjusted odds-ratios for receivillg radical prostatectomy for 
patiellts aged 60-69 years wilh localized prostate callcer (Tl-T3, MO-M'). 
Univariate Multivariate 
OR CI p-value OR CI p-value 
Age 0.9 0.8- 0.9 0.0001 0.9 0.8 -0.9 0.0001 
Metastasis 0.0001 0.0005 
Unknown (ref.) 
No 2.8 1.7 - 4.7 2.6 1.5 -4.6 
Grade 0.0002 0.0002 
Well diff(ref.) 
Moderately 2.0 1.4 - 2.9 2.3 1.5 - 3.5 
Poorly 1.1 0.7-1.7 1.2 0.7 -2.0 
Unknown 0.1 0.02 - 1.03 0.2 0.02 - 1.2 
Tumor size 0.002 0.0007 
Tl (rcr.) 
1"2 1.5 1.0-2.1 1.2 0.8-1.9 
T3 0.2 0.1-0.7 0.1 0.04-0.4 
TX 1.3 0.7 -2.6 1.9 0.9-4.0 
Co-morbidity 0.2 OJ 
No (ref.) I I 
I 0.7 0.5 - 1.0 0.7 0.5 - 1.1 
;,2 0.9 0.5-1.6 1.0 0.5-1.9 
HospItal type' 0.0001 0.0001 
A (ref.) 
B 3.7 2.6-5.3 4.1 2.8-5.9 
OR ~ odds ratio; CI - 95% confidence interval 
I hospital A: < 200 newly diagnosed patients; B: ;;:.: 200 patients 
108 Chapter 5 
Discussion 
In this population-based study of almost 3000 patients with newly diagnosed prostate cancer 
in the southem part of The Netherlands, up to 38% of patients under age 60-69 and 53% of 
those aged 75 years or older had at least one serious concomitant disease Because all serious 
concomitant diseases were recorded, our results are likely to provide a realistic picture of 
the burden of co-morbidity relevant to the treatment choice. Our prevalence estimates of co-
morbidity may be underestimated slightly, since the prevalence of cardiovascular disease 
was underestimated in a sample of 150 patients diagnosed in 1995. This may indicate that 
the overall prevalence of co-morbidity was 1-3% higher than we report here. Random 
misclassification caused by incorrect registration of co-morbidity (in about 10% of patients) 
may have confounded our estimates as well. Although comparisons with other studies may 
be hampered because of differences in definitions, age range and selection, some data are 
presented for comparison. The prevalence of chronic diseases in Dutch general practices 
was lower: the overall prevalence of one or more chronic diseases in men aged 65 or over 
was 23%. The prevalence of diabetes mellitus was 3%, of chronic ischemic heart disease 
8% and COPD 4%.13 The prevalence ofCOPD among elderly Finnish men was estimated to 
be 12.5%," which is fairly similar to our estimates. 
Choice oftreatlllellt 
Patients most likely to undergo radical prostatectomy were of younger age, had moderately 
differentiated and clinically localized tumors and were usually admitted to a hospital with 
urologists performing radical prostatectomy frequently. Patients with a T2 tumour probably 
underwent radical prostatectomy more fequently because TI tumours partly represented 
patients whose tumours were detected incidentally during TURP who did not receive further 
treatment and because patients with T3 tumours underwent radiotherapy more frequently.4 
Age was an imp0l1ant decisive factor, even in the age range 60-69 years. This seems 
justifiable, because radical prostatectomy provides better results for a younger man.- In spite 
of its impact on life expectancy,' co-morbidity was not a significant factor in the decision to 
apply radical prostatectomy in our region between 1993 and 1996. In a cohort of 261 
consecutive prostate cancer patients treated with radical prostatectomy betwecn 1989 and 
1995 in Nashville Tn, 20% had an estimated life expectancy ofless than 10 years due to co-
morbidity." In a cohort of 276 patients treated consecutively with curative intent between 
1980 and 1991 in a Veteran Affairs Medical Center in the USA, patients undergoing radical 
prostatectomy had significantly less co-morbidity than those undergoing radiotherapy.'6 
Urologists may recently have become increasingly aware of the role of co-morbidity after 
two studies emphasizing its impact on survival were published.7•8 However, we did not 
observe a different result for the more recent years. More evidence on the impact of co-
morbidity on survival might change the attitude of physicians. The imp0l1ance of hospital 
size in the treatment choice suggest a cl1lcial role for the urologist's experience. 
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Since other population-based estimates of factors influencing treatmcnt choice are to our 
knowledge not available for compatison, we do not know to what extent our results are 
applicable to other regions. 
In conclusion, serious co-morbidity appeared to be present in about half of the patients with 
prostate cancer in our population-based series. It barely influenced the choice of treatment 
of patients aged 60-69 years and diagnosed between 1993 and 1996 in the southern part of 
The Netherlands, which was detellnined largely by the patient's age, tumour characteristics 
and the urologist's experience. 
Refel'ences 
1. Polasky AL, Miller BA, Albertsen PC, Kramer OS. The role of increasing detection in the rising 
incidence of prostate cancer. JAMA 1995;273:548-552. 
2. Post PN, Kit PJM, Crommelin MA, Schapers RFM, Coebergh JWW. Trends in incidence and mortality 
rates for prostate cancer before and after prostate-specific antigen introduction. A registry-based study in 
Southeastern Netherlands, 1971-1995. EliI' J Cal/cel' 1998;34:705-709. 
3. Lu-Yao GL and Greenberg R. Changes in prostate cancer incidence and treatment in the USA. Lancet 
1994; 343: 251-254 
4. Post PN, Kil PJM, Hcndrikx AJM, Poortmans PMP, Crommclin MA, Coebergh J\VW. Trend and 
variation in treatment of localised prostate cancer in the southern part of The Ncthcrlands, 1988-1996. 
Elfr Ural. (In press) 
5. Chodak GW, 'Thisted RA, Gerber OS, et al. Recent results of conservative management of clinically 
localized prostate cancer. N EI/gi J Med 1994;330:242-248. 
6. \Valsh PC, Partin AW, Epstein n. Cancer control and quality of life following anatomical retropubic 
prostatectomy: results at 10 years. J Uro11994; 152: 1831-1836. 
7. Albertsen PC, Fryback DO, Storer BE, Kolon TF, Fine J. Long-ternl survival among -men with 
conservatively trcatcd prostate cancer. JA_MA 1995;274:626-631 
8. Albertsen PC, Fryback DO, Storer BE, Kalan TF, Fine J. The impact of co-morbidity on life expectancy 
among mcn with localised prostate cancer. J Uro11996; 156: 127-132. 
9. Charlson ME, Pompei P, Ales KL, Mackcnzic CR. A new method of classifying prognostic co-
morbidity in longitudinal studies: development and validation. J Chrall Dis 1987;40:373-383. 
10. IDCe. TNM atlas illustrated guide to the TNM/pTNM classification of malignant tumours, 4th edtion, 2nd 
revision. Berlin: Springer, 1992, pp. 141-144. 
II. Badalcment RA, O'Toole RV, Young DC, Drago JR. DNA ploidy and prostate-specific antigen as 
prognostic factors in clinically rcsectable prostate cancer. Cancer 1990;67:3014-3023. 
12. Clayton 0 and Hills M. Statistical models in cpidcmiology. New York: Oxford University Press, 1993. 
13. ScheIlcvis FG, van der Velden J, van de Lisdonk E, van Eijk K.T.M, van Weel C. Comorbidity of 
chronic diseases in general practice. J Clin Epidemiol 1993;46:469·473. 
14. Isoaho R, Puolijoki H, Huhti E, et al. Prevalence of chronic obstmctive pulmonary disease in elderly 
Films. Res!, Med 1994;88:571-80. 
15. Koch MO, Miller DA, Butler R, Lebos L, Collings D, Smith JA. Are we selecting thc right patients for 
treatment of localized prostate cancer? Results of an actuarial analysis. Urology 1998;51: 197-202. 
16. Fowler JE, Terrel FL, Renfroe DL. Co-morbidities and survival of men with localized prostate cancer 
treated wilh surgery orradiation therapy. J. Uro11996; 156: 1714-1718. 

Chapter 6 Determinants of survival 
6.1 Long-term survival of prostate cancer in southeastern Netherlands. 
6.2 Independent prognostic value of co-morbidity among men aged < 75 
years with localized prostate cancer: a population-based study. 
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6.1 Long-term survival of prostate cancer in southeastel'll 
Netherlands. 
Abstract 
Being detected increasingly at an early stage, few and conflicting results have been 
rep0l1ed for the long-teml outcome for prostate cancer beyond 10 years. The vast 
majority of the prostate cancer patients diagnosed between 1955 and 1984 in 
Southeastern Netherlands, with a population of almost I million inhabitants, did not 
receive curative treatment. We calculated the prognosis for lO-year survivors of 
prostate cancer diagnosed in the era preceding prostate-specific antigen (PSA) testing 
to detennine how long these patients exhibited excess mortality. 
All patients under age 70 diagnosed with prostate cancer and registered in the 
population-based Eindhoven Cancer Registry between 1955 and 1984 were included in 
the study. Relative survival was calculated for those who survived for at least 10 years 
(IFI74). Initially, these patients still exhibited an almost 25% mortality risk in excess, 
but this decreased and no excess m0l1ality was found after IS years. 
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Introduction 
Whilst the incidence of localized prostate cancer has been increasing rapidly,I,2 much 
controversy exists about the optimal management of patients with early detected 
prostate caneer, Survival rates of up to 87% at 10 years for conservatively managed 
patients led to doubts on the need for radical surgery in these cases",4 because it results 
in treatment related morbidity in a considerable proportion of patients,5 Therefore, 
radical prostatectomy is advocated by many urologists only if the estimated remaining 
life expectancy of the patient is more than 10 years, Extended follow-up of 
conservatively managed patients revealed only slightly lower survival rates at 15 years 
(81 %) in one,' but a continuing risk of death due to prostate cancer beyond \0 years in 
two other recent studies.6,7 In view of these conflicting results, it remains unccliain 
whether patients who survived for 10 years or more remain at risk of death due to 
prostate cancer and would benefit from curative treatment. If prostate cancer carries a 
notable mortality risk after \0 years, radical treatment might be justifiable for those 
patients with an estimated remaining life expectancy of at least \0 years, In 
Southeastell1 Netherlands, the region of the Eindhoven Cancer Regisfly, most prostate 
cancer patients were treated conservatively in the seventies. An increasing proportion 
underwent radiotherapy since 1985,' but radical prostatectomy was not performed 
more than incidentally before 1988, This makes this cancer registry also suitable to 
study the prognosis for long-tenn survivors of prostate cancer who still had a 
considerable life expectancy at diagnosis, because their outcome closely resembled 
that of untreated disease, Because infonnation about stage and grade was lacking for a 
large number of eases diagnosed before 1980, we could not define subcohorts on the 
grounds of stage or grade, We calculated relative survival rates for patients under age 
70 at diagnosis who had survived for at least 10 years and were diagnosed between 
1955 and 1984, 
Patients and methods 
Stlldy Poplliatioll 
Patients were identified t1uough the Eindhoven Cancer Regisfly, This registry covers 
Southeastern Netherlands, a region with a population of approximately two million 
inhabitants, The development and methods of this regis!ty, which started in 1955 in an 
area with 300,000 inhabitants, are dcscribed in detail elsewhere: Analyses of referral 
pattell1s and comparison with regional mortality data indicated that the regis!ty can be 
considered nearly complete for prostate cancer as of 1971.10 We also included cases 
diagnosed between 1955 and 1970 in the s!tldy, 
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However, the incompleteness of the registry before 1971 may have been selective, 
because the more severe cases, which probably never received work up in a hospital, 
were more likely to be missed by the cancer registry in those days. 
Nevertheless, since we selected only those patients who survived 10 years or more, it 
is unlikely that this would have resulted in significant bias. Nevertheless, we did a 
separate analysis after exclusion of patients diagnosed before 1971. 
Over 95% of cases were identified through pathology repOlis, which were always sent 
to the registry. Less than 5% were identified by medical record administrations in the 
regional hospitals or the regional radiotherapy institute, because they were diagnosed 
on clinical evidence only. The pathological diagnosis was established by histological 
examination of biopsies or tissue specimens obtained by TURP. Cases identified by 
'death celiificate only' cannot be registered in The Netherlands. Early diagnosis by 
PSA testing was not introduced until 1990. 
Allalysis 
All patients with prostate cancer diagnosed between 1955 and 1984 in Southeastern 
Netherlands and under age 70 at diagnosis were included in the study. The initial 
cohort consisted of 643 patients. The vital status of all patients was checked with 
municipal civil registries until April I 1994. 9 patients (1.4%) were untraceable 
(mostly due to repeated moving home) and were, therefore, excluded from the 
analyses, resulting in a study cohort of 634 patients. Another 10 patients (1.5%) were 
lost to follow up before the closing date and were censored in the analyses. Survival 
rates were calculated according to the actuarial (life-table) method. Relative survival 
was calculated as the ratio of the observed to the expected survival, II using a software 
package from the Finnish Cancer Registry." Expected survival rates were calculated 
from life tables derived from the regional mortality statistics and compiled for five-
year age groups and per calendar year for the regional male population. The expected 
survival rates were adapted during the course of the follow-up according to the 
changing age distribution of the patients (Ederer II option). Patients who died or were 
censored before 10 years were not included and so did not affect the cumulative 
relative survival beyond 10 years. 
Results 
The mean age of the cohort was 64 years (median age 65). Table I shows the age 
distribution and period of diagnosis of the COhOli. A total of 437 patients died within 
the first 10 years of diagnosis so that the COhOli of 10-year survivors represented 30% 
of the original cohort (Table 2). 
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Table 1 Characteristics of the cohort ofpatiellts with prostate callcer IIl1der age 70 
at diagllosis. 
Patient characteristics Number % 
Age at diaguosis (yrs) 
< 55 39 6.2 
55-59 92 14.5 
60-64 174 27.4 
65-69 329 51.9 
Year of diagnosis 
1955-1959 9 1.4 
1960-1964 25 3.9 
1965-1969 55 8.7 
1970-1974 113 17.8 
1975-1979 188 29.7 
1980-1984 244 38.5 
Table 2 Experiellce of the cohort of patiellts IIl1der age 70 at diagllosis ill the first 
10 years afier diagllosis. 
Interval no. at start interval no. of deaths 110. withdrawn Cumulative observed 
(year) during interval alive survival 
1-5 634 287 5 55% 
6-10 342 150 18 30% 
The mean age of the 174 patients who survived at least 10 years was 63 years (median 
age 64). Characteristics of these patients at diagnosis are displayed in table 3. 
Most patients were between 60 and 69 years of age. Most 10-year survivors received 
only symptomatic treatment by TURP or honnona! treatment (including castration). A 
minority underwent radiotherapy. 
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Table 3 Characteristics of of patients with prostate cancer under age 70 at 
diagnosis who survived for 10 years or more ill southeastern 
Netherlallds, 1955-1984. 
Patient characteristics Number % 
Age at diagnosis (yrs) 
50-54 11 6.3 
55-59 38 21.8 
60-64 48 27.6 
65-69 77 44.3 
Year of diagnosis 
1955-1959 2 1.1 
1960-1964 8 4.6 
1965-1969 19 10.9 
1970-1974 37 21.3 
1975-1979 59 33.9 
1980-1984 49 28.2 
Initial trcatment 
TURP only 75 43.1 
hormonal 16 9.2 
TURP + honnonal 42 24.2 
radiotherapy (RT) 11 6.3 
TURP+RT 23 13.2 
honnonal + RT 2 1.2 
TURP + RT + hormonal 3 1.7 
unknown 2 1.1 
Relative survival of the lO-year survivors decreased by about 20% (Figure 1). 
Subsequently, the death rate of the cohort was similar to that of the general male 
population of the same age, relative survival leveling off at approximately 75%-80%. 
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Figl/re 1 Obselwd (OS), expected (ES) alld relative slllvival (RS) of patients with 
prostate cancer aged below 70 years at diagnosis (1955-1984) who 
slllvived 10 years or //lore. 
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When we excluded patients diagnosed before 1971, the results barely changed: relative 
survival leveled off at 80% after 15 years (data not shown). 
Because it is not unlikely that radiotherapy would have altered the prognosis, we 
performed separate analyses after exclusion of the 39 patients who received 
radiotherapy. The death rate of this COhOli was initially higher than was found for the 
whole COhOli, relative survival being 70% at 15 years (Figure 2). Subsequently, 
relative survival leveled off, indicating no deaths in excess from this point. When 
patients aged 70 years or over were included in the analyses, relative survival 
exceeded 100% 18 years after diagnosis (data not shown), suggesting a lower risk of 
mortality in the COhOlt of prostate cancer survivors than the general male population of 
the same (old) age. 
Figure 2 Obsen'ed (OS), expected (ES) aud relative slIrvival (RS) of patiellts with 
prostate caucer aged below 70 years at diagllosis (1955-1984) who 
slIrvived 10 years or II/ore after excllsiou of patieuts who lIuden"eut 
radiotherapy. 
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Discussiou 
Patients diagnosed with prostate cancer in southeastern Netherlands between 1955 and 
1984 exhibited only a small increased risk of mortality if they had survived 10 years or 
more. About 15 years after diagnosis, the death rate among IO-year survivors barely 
differed from that found for the general age-matched male population. 
Adolfsson et al. found an excess mortality up to approximately 18 years after diagnosis 
in their study of IO-year survivors" Although application of radiotherapy might 
explain the better survival in our study, it is unlikely that this would have had a 
substantial effect on survival, because it was only applied for a minority of patients. In 
fact, exclusion of the 22% of patients who received this treatment resulted in a slightly 
lower relative survival at 15 years but no increased mortality hereafter. We do not 
know on what grounds patients were selected to undergo radiotherapy. Most patients 
underwent TURP or honnonal treatment, which is not considered to be curative. We 
have no evidence that awareness of prostate cancer resulting in earlier detection 
occurred earlier in the Netherlands than in Sweden. Although southeastem 
Netherlands has been an area with a large proportion of smokers since the I 960s, 13 
differences in co-morbidity cannot be an explanation of the difference between our 
study and the Swedish study, since the survival rates were corrected for background 
mOliality. We did not try to correct the expected survival rates for socioeconomic 
status, but a previous analysis of socioeconomic variations in survival of prostate 
cancer in Southeastern Netherlands revealed hardly any differences between the 
highest and the lowest socioeconomic levels, when the same expected survival 
probabilities were used (5-year relative survival 61% vs. 59%).14 Patients with low 
grade, localized prostate cancer diagnosed in Orebro county in Sweden had a corrected 
survival of 85% at IO years and 81 % at 15 years, indicating few deaths due to prostate 
cancer beyond IO years.' Hugosson et al found a continued risk of mortality due to 
prostate cancer beyond IO years, which decreased with extended follow-up.' Relative 
survival of American patients diagnosed with prostate cancer between 1974 and 1991 
continued to decline up to 15 years after diagnosis. IS We found only a small excess 
mortality beyond IO years. However, patients in our study cohort are likely to be 
different from patients nowadays detected with prostate cancer. Whilst patients 
diagnosed in the 1970s usually consulted their physician because of symptoms of 
cancer, most patients are nowadays detected on the basis of a positive PSA test before 
symptoms arise. 
Since PSA testing appears to advance the diagnosis of prostate cancer by up to 5- IO 
years,I6 these patients might carry an increased mOliality risk up to 15 years after 
diagnosis. So, our results do not justify a modification of the rule to offer radical 
prostatectomy only if a patient has a life expectancy of at least 10 years. Further study 
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is needed to identify those patients who are at risk of progression and may benefit 
fl'0111 curative treatment. 
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6.2 Independent prognostic value of co-morbidity among men aged 
< 75 years with localized prostate cancel': a population-based 
study. 
Abstract 
COJltext. Co-morbidity has been shown to have significant prognostic value for 
patients who were diagnosed with localized prostate cancer in the 1970s. However, the 
impact of co-morbidity might be different for those diagnosed by means of a positive 
prostate-specific antigen (PSA) test. 
Objective. To investigate which prognostic factors apply for patients with localized 
prostate cancer diagnosed in the era ofPSA testing. 
DesigJl. Population-based cohort study with 2.9 years (1.5-4.5) offollow-up 
SettiJlg. Eindhoven Cancer Registry 
PatieJlts. All 894 patients < 75 years with localized (T1-T3 MO) prostate cancer 
diagnosed between 1993 and 1995 in southem Netherlands. 
Main outcome measures: Three-year overall and relative survival; Cox regression 
analyses of overall survival. 
Results. co-morbidity was the most important prognostic factor, especially for those 
below 70 years (n~579): patients with one concomitant disease were 1.9 times more 
likely to die than those without co-morbidity (95% Confidence interval [CI) 1.4-3.6), 
whereas the hazard ratio (HR) was 3.7 (CI 2.0-6.9) for two or more diseases. This was 
not due to age or reduced application of curative treatment for these patients. Poor 
differentiation of the tumor was also an important prognostic factor; this became 
increasingly apparent 2 years after diagnosis (HR 3.4, CI 1.5-7.7). 
COJlclusioJls. Co-morbidity had decisive influence on the prognosis for patients with 
localized prostate cancer. However, a poorly differentiated tumor was also a highly 
significant factor, even within 3 years of diagnosis. 
ImplicatioJls. It seems more appropriate to look at the patient's co-morbidity rather 
than age when evaluating the risk of early death. 
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Introdnction 
Whilst prostate cancer is being detected with increasing frequency at an early stage in 
the ageing population",2 unce11ainty about optimum primary management still exists, 3 
Although prostate cancer can be a potentially fatal disease, the high prevalence of co-
morbidity in the elderly population' raises the question of which disease puts the 
patient at the highest risk, his malignant process or his co-morbidity, Moreover, when 
patients with low grade prostate tumors are managed conservatively, they exhibit only 
a low probability of dying due to prostate cancer within 10 years of diagnosis,5 Co-
morbidity had a major impact on the prognosis of such patients when diagnosed in the 
1970s,6 However, it is unclear whether these findings apply to today's practice, Some 
have argued that tumors diagnosed following a positive PSA test or rectal examination 
are more aggressive than those detected incidentally during transurethral resection of 
the prostate,7,8 which comprised a considerable prop0l1ion of cases in the study by 
Albertsen, On the other hand, survival may be underestimated, because diagnosis of 
prostate cancer on the basis of a positive PSA test appears to advance the diagnosis by 
an average of 5-10 years:,lO,J] Serious co-morbidity has been recorded routinely for 
all patients registered in the Eindhoven Cancer Registry since 1993, giving us the 
rather unique opportunity to study its impact on survival independent of other patient 
and tumor characteristics, PSA testing was introduced in this area between 1990 and 
1993,2 We studied survival in a population-based cohort of 1337 patients below 75 
years of age with prostate cancer diagnosed between 1993 and 1995,894 of whom had 
localized disease, 
Patients and methods 
Study populatioll 
Data were extracted from the Eindhoven Cancer Registry, This registry was started 
originally in the southeastern pm1 of The Netherlands, Since 1986, it covers almost the 
entire southern part of The Netherlands (excluding only the province of Zeeland and 
the southern part of the province of Limburg) with a population of more than two 
million inhabitants, The area offers good access to specialized medical care supplied in 
16 community hospitals and two large radiotherapy institutes, PSA assays were 
introduced between 1990 and 1993 in the regional hospitals and PSA testing has been 
applied increasingly by general practitioners since 1992,2 
However, no formal screening program exists in The Netherlands, as its potential 
benefit is currently assessed in a large randomized screening tria!. '2 
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The increase in the propOliion of patients with a clinically localized tumor (from 52% 
in 1988-1990 to 74% in 1994-1996) in southem Netherlands resulted in a threefold 
increase in the proportion treated by radical prostatectomy." Curative radiotherapy 
has been another frequent treatment option in the 1990s. The large variation in the 
proportion of patients undergoing radical prostatectomy or radiotherapy between the 
various regional hospitals could be related to the experience of the urologists involved. 
The regishy may be considered nearly complete for prostate cancer since 1971.2 
Presence of serious co-morbidity has been recorded for evelY patient with a newly 
diagnosed cancer since 1993.4 Registration clerks extract infollnation on co-morbidity 
from the medical records along with the registration of details of diagnosis and 
treatment of cancer, usually within 3-6 months of diagnosis. Co-morbidity was 
recorded, using a slightly adapted list of serious diseases developed by Charlson and 
associates (Table I ).14 Only diseases with a possible impact on the prognosis are 
recorded. 
Table 1 Classification of co-morbidity, according to an adapted list of Charlson et 
al" 
Cardiovascular diseases 
(myocardial infarction, heart failure, angina pectoris, intennittent claudication, abdominal 
aneurysm) 
Cerebrovascular diseases (cerebrovascular accident, hemiplegia) 
Diabetes Mellitus (medically treated) 
Other malignancies (except basal skin carcinoma) 
Chronic obstructive pulmonary diseases (COPD) 
Dementia 
Tuberculosis and other chronic infections 
COimective tissue diseases 
(Besnier Bocek's disease [sarcoidosis), systemic lupus erythematosus [SLEl, Wegener's 
granulomatosis) 
Rheumatoid arthritis (only severe) 
Kidney diseases (chronic glomerulonephritis, chronic pyelonephritis) 
Bowel diseases (Chrohn's disease, colitis ulcerosa) 
Liver diseases (cirrhosis, hepatitis) 
Gastric diseases (patients who underwent major surgery for ulcerative disease: Billroth II) 
A validation study was undertaken among 150 patients diagnosed in 1995 to determine 
whether the registration clerks extracted co-morbidity correctly from the medical 
records (Post et aI, internal report, 1997). Registration of the number of serious 
concomitant diseases lVas correct for 87% of the patients. 
When the type of co-morbidity was examined in detail, 20% of the diseases were 
registered incorrectly. 
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In most of these cases, serious co-morbidity was usually present, but an error was 
made in classification of the disease (e.g. cardiovascular instead of cerebrovascular 
disease). Another reason for misclassification was unfamiliarity of the registrars with 
tem1S such as CABG (Coronary Artery Bypass Grafting), PTCA (Percutaneous 
Transluminal Coronary Angioplasty), if used without mentioning the underlying 
disease. This resulted in an underestimation of cardiovascular disease by 28%. We 
could not correct this type of (presumably random) misclassification in the CUlTent 
study. The number of co-morbidities was used as main covariate, distinguishing the 
following categories: No co-morbidity; I co-morbidity or ;0,2 co-morbidities. 
Additional analyses were done for the most frequent specific types of co-morbidity. 
Clinical stage is recorded in the regishy according to the TNM classification in use. l5 
On the basis of the registered information, we simplified the clinical tumor 
classification as Tl, T2, T3 or T4. If lymph node involvement or distant metastases 
were recorded, stage was defined as metastasized. If infonnation on staging was 
lacking, stage was coded as unknown. Histological grading recorded according to the 
TNM classification of malignant tumors l5 was scored by several pathologists of six 
Departments of Pathology. Patients with undifferentiated tumors «1%) were included 
in the categOlY poorly differentiatcd tumors in our analyses. Treatment was separated 
in three categories: radical prostatectomy (usually retropubic) (J), radiotherapy (2), 
and other (non-curative) approaches such as hOlmonal therapy and expectant 
management (3). Patients undergoing both radical prostatectomy and radiotherapy 
(n~13) were included in the radical prostatectomy group. 
Analysis 
Vital status of all patients was checked at least up to I July 1997. In addition to passive 
follow-up, this information was also supplied by regional urologists and the two 
Departments of Radiotherapy. Vital status of the remaining patients was checked with 
their general practitioners and the Central Bureau of Genealogy, an institution that 
registers every death of a Dutch citizen via the municipal civil registries. We could not 
trace 26 patients (1.9%) in this way. Because the Central Bureau of Genealogy is 
unlikely to miss deaths occurring in The Netherlands, these patients were censored 
alive at the closing date, I July 1997. Overall sUlyival was assessed with the Kaplan 
Meier method. Deaths OCCUlTing after the closing date were disregarded. In addition to 
overall survival, relative survival was calculated for the various strata. Relative 
survival is the ratio of the obselyed to the expected sUlyival. 16 The expected sUlyival 
probabilities were calculated from life tables derived from the regional mOltality 
statistics. Relative sUlyival is an estimate of the mOltality attributable to the diseases 
shldied, unless the study COhOlt differs from the general population in some aspect 
distinct from the index disease. 
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Hence, relative survival for patients with different co-morbidity levels should not be 
interpreted as estimates of mortality due to prostate cancer, because relative survival 
for patients with co-morbidity is also determined by the difference in co-morbidity 
between these patients and the general age-matched population. Differences in 
survival were tested with the log rank test. Cox proportional hazard regression analysis 
was used to estimate simultaneously the contributions of various explanatory variables 
to overall survival. 17 Significance of terms in the models was tested with the 
likelihood-ratio test. Cox proportional hazards regression analysis is a valid approach 
only if the hazard rate (risk of death) can be assumed to be constant over time. The 
validity of this assumption was checked for all covariates in the model and a time 
dependent variable was introduced in the model for the variable with varying hazard 
over time. 
To estimate the result of excluding eases recorded with an unknown metastasis status 
(Mx), we perfonned separate analyses including these cases. Because knowledge of 
prognostic factors is particularly important for patients who are generally considered 
to be fit to undergo radical prostatectomy, we performed separate analyses for patients 
below 70 years of age. 
Results 
Almost 70% of patients had a tumor confined to the prostate (Table 2). The survival 
analyses involved 894 patients registered as MO and clinical stages Tl-T3. The mean 
age of these patients was 67 years (median age 68; range 45-74.9). Characteristics of 
this subcohort are presented in table 3. Most patients had Tl or T2 tumors of low 
grade malignancy. Serious co-morbidity was present in 40% of the patients, whereas 
10% had two or more serious diseases. Most of the patients underwent curative 
treatment. The remainder received hormonal treatment, TURP only, unknown or no 
treatment. The mean age did not differ notably over the various strata, except for 
treatment and co-morbidity. Patients treated with radical prostatectomy were younger 
than those treated otherwise (63 vs. 68 years of age). Patients with <: 2 concomitant 
diseases were older than those with one and those without co-morbidity (69 vs. 67 vs. 
65 years of age). Prevalence of co-morbidity did not vary significantly over either 
stage or grade. 
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Table 2 Distributioll of c1illical stage witlzill the cohort. NUII/ber of cases (%) per T 
alld M combillatioll. 
TI T2 T3 T4 Tx all T 
MO 281 (31) 492 (54) 77 (8) 14 (2) 44 (5) 908 (68) 
Mx 98 (42) 73(31) 13 (6) 5 (2) 46 (19) 235 (18) 
MI 24 (12) 100 (52) 28 (14) 18 (9) 24 (12) 194 {I 5) 
AllM 403 (30) 665 (50) 118 (9) 37 (3) 114 (8) 1337 {I 00) 
Survival analyses 
During a median follow-up of 2.9 years (range 1.5-4.5) , 137 patients died. Overall 
survival was 85% at 3 and 78% at 4 years, relative survival 94% and 89% respectively. 
A total of 21 patients died within I month of diagnosis. All of them had received 
noncurative treatment and most of them (67%) were aged 70-74 years. 
Patients without co-morbidity (3-year survival 89%) had a better prognosis than 
those with one (80%) or those with two or more concomitant diseases (73%) (Table 3). 
Patients with poorly differentiated tumors exhibited a significantly lower survival rate 
(3-year survival 74%) than those with moderately (86%) and well differentiated 
tumours (88%). Relative survival was also significantly shorter for patients with 
poorly differentiated tumors (p~O.OOI). Patients with a tumor coded as T3 seemed to 
have a worse prognosis than other patients, but the difference was not significant 
(p~Oo4). 
Multivariate analyses 
In the Cox regression analysis, survival decreased with increasing age, when co-
morbidity was present or when the tumor was poorly differentiated. Because the strong 
effect of a poorly differentiated grade was unexpected, we examined this effect by 
interval. Since the hazard was not constant over time, a time-dependent variable for 
poorly differentiated grade was introduced. Poorly differentiated cancer appeared to be 
significant only after I year and the hazard ratio increasing to 3.6 after 2 years of 
observation (Table 4). The risk of death for a patient with moderately differentiated 
cancer (not significant) was constant over time as was the hazard for the other co-
variates. Co-morbidity was the most impOltant prognostic factor (p~O.OOOI): hazard 
ratio for one concomitant disease was 104 (CI 1.0-2.0) and for two or more 2.3 (CI 1.4-
3.6). The hazard ratio for patients with 3 or 4 concomitant diseases (n~23) was not 
significantly different when considered as a separate categOlY. The hazard ratio (RR) 
for co-morbidity decreased slightly when all significant factors were modelled 
together. 
Table 3 Characteristics of and univariate survival rates for the cohort of patients with localized prostate cancer. 
Variable n % No. of 3-year survival p-value log 3-year relative p-value 
deaths (95% CD rank test survival (CD 
All 894 100 137 85 (83-87) 94(91-97) 
Age 0.003 0.9 
< 60 years 128 14 15 88 (82-94) 90 (83-97) 
60-64 171 19 18 92 (88-96) 95 (90-100) 
65-69 280 31 42 85 (79-91) 95 (90-100) 
70-74 315 35 62 80 (76-84) 94 (77-111) 
Tumor size 0.4 0.3 
Tl 281 31 40 86 (82-90) 96 (91-101) 
T2 492 55 73 85 (81-89) 94 (90-98) 
T3 77 9 17 77 (65-89) 88 (76-100) 
Tx 44 5 7 82 (68-96) 92 (78-106) 
Grade 0.002 0.001 
Gl 331 37 37 88 (84-92) 99 (97-101) 
G2 346 39 50 86 (82-90) 95 (91-99) 
G3 182 20 44 74 (66-82) 83 (75-91) 
Gx 35 4 6 85 (71-99) 94 (78-110) 
No. of concomitant diseases 0.0001 0.03 
0 538 60 64 89 (85-93) 97 (94-100) 
1 261 29 46 80 (74-86) 90 (84-96) 
,,2 95 11 27 73 (63-83) 84 (73-95) 
Treatment 0.0003 0.06 
radical prostatectomy 221 24 18 90 (84-96) 99 (95-103) 
curative radiotherapy 365 41 52 85 (81-89) 96 (91-101) 
hormonal treatment 170 19 
TURPonly 88 10 67' 79 (73-85) • 87 (79-95)' 
no initial treatment 33 4 
unknown/other 18 2 
-All noncurative treatments together 
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The negative impact of co-morbidity was independent of treatment: when treatment 
was included in this model, the hazard ratio for co-morbidity did not change further. 
Neither did the hazard ratio change for patients with poorly differentiated tumors, 
although they underwent curative treatment to a lesser extent than those with 
moderately differentiated tumors. Inclusion of cases recorded as Mx did not change 
the results (data not shown). The most important concomitant diseases with an 
independent impact on survival were a second cancer, COPD, renal disease and to a 
lesser extent cardiovascular disease (Table 5). 
Because the effect of co-morbidity varied over different age strata (the only significant 
interaction), a separate Cox analysis was performed for patients below 70 years, the 
age group that is of particular interest with respect to treatment choice. Stage and 
grade distribution were similar in this age group. Within this subcohort, age did not 
contribute significantly to the model, the presence of co-morbidity being more 
important (Table 6). Inclusion of cases coded as Mx did not change the results for this 
age categoty notably (data not shown). 
Discussion 
In this large population-based study of patients diagnosed with localized prostate 
cancer between 1993 and 1995, co-morbidity was the most significant prognostic 
factor in the first three years afier diagnosis, followed by histological grade. Unlike 
other studies, our study has the advantage that it included patients diagnosed in the era 
of PSA testing, so that the results should be applicable to patients diagnosed today. 
Compared to the study of patients diagnosed in the 1970s: we conclude that the 
impact of co-morbidity has become even more impot1ant. This finding agrees with 
studies linking selllm banks to subsequent diagnosis of prostate cancer: diagnosis of 
prostate cancer on the basis of a positive PSA test may advance the diagnosis by up to 
5-10 years:· IO•1l The negative impact of co-morbidity on survival might be caused by 
holding these patients back from curative treatment. 4 However, we found that the co-
morbidity itself produced an adverse effect on survival regardless treatment. The 
rather frequently OCCUlTing cardiovascular diseases, another cancer and COPD 
contributed the most to this effect on survival. Two concomitant diseases had the 
largest impact on survival, whereas the infrequent occurrence of 3 or more diseases did 
not contribute further. In a cohort study of patients treated with either surgery or 
radiotherapy, highly significant hazard ratios (adjusted only for age) were found for 
patients with two or more concomitant diseases; these ratios increased significantly as 
the number of concomitant diseases increased." 
Table 4 Results of cox regression analyses of non-metastasized cases (n=894). 
age (per year ) 
1.08) 
cT classification 0.27 
Tl (reference) I 
T2 l.l (0.7-1.6) 
T3 1.6 (0.9-2.9) 
Tx 1.0 (0.5-2.2) 
Grade 0.002 0.0009 0.001 
GI (reference) I I I 
G2 1.3 (0.9-2.0) 1.4(0.9-2.1) 1.5 (1.0-2.3) 
G3 (0-1 year) 1.0 (0.4-2.3) 1.0 (0.4-2.3 1.0 (0.4-2.3) 
G3 (1-2 years) 2.4 (1.3-4.6) 2.3 (1.2-4.4) 2.3 (1.2-4.3) 
G3 (:<: 2 years) 5.1 (2.3-11.2) 3.6 (1.9-6.7) 3.5 (1.9-6.6) 
Gx 1.6 (0.7-3.7) 1.5 (0.6-3.5) 1.5 (0.6-3.5) 
No. of concomitant diseases 0.0003 0.002 0.002 
o (ret) I I I 
I 1.5 (1.04-2.2) 1.4 (1.0-2.0) 1.3 (0.9-2.0) 
:<:2 2.7(1.7-4.2) 2.3 (1.4-3.6) 2.3 (1.4-3.7) 
Treatment 0.002 
noncurative (ref) I 
prostatectomy 0.4 (0.3-0.7) 
radiotheraEJ.: 0.6 (0.4-0.9) 
HR - hazard ratio; eI = confidence interval 
Table 6 Results of cox regression analyses of non-metastasized cases (only < 70 years at diagnosis: n=579) 
variable 
age (per year ) 
cT classification 
Tl (reference) 
T2 
T3 
Tx 
Grade 
GI (reference) 
G2 
G3 (0-1 year) 
G3 (1-2 years) 
G3 (2: 2 years) 
Gx 
No. of concomitant diseases 
o (ref) 
I 
2:2 
Treatment 
noncurative (ref) 
prostatectomy 
radiotherapy 
univariate 
HR(95%CI) 
1.1 (1.0-1.1) 
I 
1.2 (0.7-2.1) 
2.1 (1.0-4.6) 
0.8 (0.2-2.6) 
I 
1.3 (0.7-2.3) 
0.6 (0.1-2.6) 
3.0 (1.3-7.0) 
5.0 (1.8-14.0) 
2.6 (1.1-6.6) 
I 
1.9 (1.2-3.2) 
4.2 (2.3-7.9) 
HR = hazard ratio; CI = confidence interval 
p~va1ue 
0.05 
0.2 
0.004 
0.0001 
multivariate multivariate + treatment 
HR (95% CI) p-value HR (95% CI) p-value 
1.03 (1.0.-1.1) 0.2 1.03 (1.0-1.1) 0.4 
0.008 om 
I I 
1.3 (0.7-2.4) 1.4 (0.8-2.6) 
0.6 (0.1-2.5) 0.6 (0.1-2.5) 
2.8 (1.2-6.6) 2.8 (1.2-6.7) 
3.4 (1.5-7.7) 3.3 (1.5-7.6) 
2.6 (!.I-6.6) 2.5 (1.0-6.2) 
0.0002 0.0004 
I I 
1.8 (!.I-2.9) 1.7 (1.02-2.8) 
3.7 (2.0-6.9) 3.6 (1.9-6.8) 
0.1 
I 
0.5 (0.3-0.97) 
0.9 (0.6-1.5) 
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Table 5 Type of co-morbidity alld its impact Oil slln'ival (11=894) 
type of co· morbidity n % no. of deaths univariate HR (el) multivariate HR (el)l 
none 538 60 64 I I 
cardiovascular disease 146 16 65 1.7 (1.2-2.6)" 1.5 (1.0-2.2)' 
eVA 21 2 13 1.7 (0.7-4.1) 1.8 (0.7·4.5) 
Diabetes mellitus 54 6 22 1.4 (0.8·2.6) 1.3 (0.7-2.4) 
Other cancer 71 8 41 2.0 (1.3-3.3)" 1.9 (1.2-3.1)" 
eOPD 104 12 54 2.1 (1.4-3.1)" 1.7 (1.1-2.7) • 
Dementia 2 0.2 2 
Kidney diseases 3 0.3 3 11 (3.4-33.8)" 11 (3.4-35.5)" 
Bowel diseases 2 0.2 0 
Liver diseases 6 0.7 2 1.3 (0.2-9.2) 1.2 (0.2-8.8) 
Billrolh II 15 1.7 6 1.4 (0.4-4.4) 1.7 (0.5-5.2) 
I adjusted for age and grade 
• p<0.05 .. p<O.O 1 'p~0.06 
Co-morbidity had a greater impact in our study among paticnts aged < 70 years. Since 
age did not contribute significantly, it may be betel' to look at co-morbidity instead of 
age in this age group when evaluating the patient's risk of early death. 
Established prognostic factors 
Clinical T-classification did not have a significant prognostic value. Pathological T 
classification has a strong prognostic value/9 but the ovcrall agreement between 
clinical and pathological stage has been shown to be weak.8 In our study population, 
about 25% of the patients with Tl-T2 tumors were upstaged to T3 after pathological 
examination of thc radical prostatectomy specimens. 13 We only examined the role of 
clinical T classification in the current study, because its influence would be rclevant to 
treatment choice. Moreover, pathological T classification is generally only known for 
patients undergoing radical prostatectomy. In a cohort of 938 hradiated patients with 
clinically localized prostate cancer diagnosed in the PSA era, both grade and clinical T 
classification (Tl-T2 vs. T3-T4) were independent prognostic factors, whereas 
pretreatment PSA level had an additional strong prognostic value after a follow-up of 
3.5 years.'o Patients with clinical T4 tumors were not included in our analyses, which 
might also explain why we could not demonstrate a significant prognostic valuc for T 
classification. Pretreatment PSA levels were not readily available for our cohort and 
thus were not included in our analyses. 
Patients with poorly differentiated cancer exhibited a substantial risk of dying, even 
within 3 years of diagnosis. Poor differentiation had an increasing adverse effect on 
survival, when patients survived more than one year. This would mean that the 
estimated lead time of 5-10 years does not apply for patients with this type of cancer. 
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Hence, our findings do not agree with the only study differentiating between 
aggressive (metastasized or poorly differentiated) and non-aggressive tumors, in which 
no difference in lead time distributions between the two types was found? 
Nevertheless, a more rapid growth of poorly differentiated tumors is likely to be 
responsible for our observations. 
Although definite conclusions cannot be drawn after a follow-up period of only 3 
years, our results show that early m0l1ality was not negligible in this interval, making 
knowledge of prognostic factors for this interval relevant to treatment choice. Whereas 
any effect of curative treatment on well differentiated tumors is questionable,'! 
patients with moderately differentiated tumors may benefit from radical treatment." 
However, if these patients have at least two other diseases, the uncertain beneficial 
effect should be balanced against its perioperative risks as well as other treatment-
related morbidity such as urinaty incontinence, impotence and disturbances in rectal 
function.23 
In southeastem Netherlands, survival decreased for patients with poorly differentiated 
tumors (their proportion having increased) between 1980 and 1989, i.e. the period 
preceding the introduction of PSA testing.24 In the USA, survival improved for 
patients with poorly differentiated tumors after the introduction of early detection 
measures in the 1990s." This discrepancy might be explained by less extensive PSA 
testing in The Netherlands, where no formal screening program takes place. Moreover, 
the adverse effect of poor differentiation in the current study may be amplified by 
inadequate treatment. Radical prostatectomy can cure these patients, if thc tumor is 
confined to the prostate.26 In case of a locally' advanced tumor, radiotherapy with 
adjuvant hormonal treatment seems preferable.27,28 About one-quarter of the patients 
with poorly differentiated cancer was treated with radical prostatectomy, but 
radiotherapy was not combined with honnonal treatment in the period studied, 
Patients treated with curative intent exhibited a better survival than those treated 
othenvise. However, the effect of radiotherapy seemed stronger for patients over 70 
years of age than those of younger age (patients over 70 were barely treated with 
radical prostatectomy), Since it is unlikely that radiotherapy has a better effect for 
older patients, this is likely to be the effect of confounding by indication rather than a 
real treatment effect. This may be caused by selecting patients for curative treatment 
on the basis of other (unknown) factors than we corrected for, e,g, the clinical 
presentation of the patient at diagnosis, Moreover, it is unlikely that a treatment effect 
would be apparent within 3 years of diagnosis. 
Issues a/validity 
Charlson's method of classifying prognostic co-morbidity was used to score co-
morbidity in our study/4 but diseases were not subdivided according to severity. 
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However, only serious co-morbidity is considered by the Eindhoven Cancer Regishy. 
For example, diabetes mellitus is recorded only if under active management. 
Misclassification of co-morbidity will be limited, since the concomitant diseases are 
taken directly from the medical records of the patients. Moreover, a validation study 
among patients with prostate cancer diagnosed in 1995 showed that 87% of the 
patients were registered with a correct number of diseases. Since the number of 
diseases was our main co-variate, random misclassification (likely only for 13% of 
patients) has at most diluted the prognostic impact of co-morbidity. 
The histological grade of biopsies was scored by several pathologists from six 
Departments of Pathology. Although inter-observer variation is likely to have 
occulTed in this way, we feel that this would not have weakened our study. On the 
contraty, it makes the results applicable in daily practice. 
Since oU!' study was population-based, selection bias will be limited to a minimum. 
The only exclusion criteria were age (75 years or over) and positive (MI) or unknown 
(Mx) evidence of metastases. Some of the patients recorded as Mx may have been 
excluded unjustly, because staging procedures were omitted due to the poor general 
condition of the patient. However, exclusion ofthese cases did not change the results. 
COllclusions 
Although a longer study period is needed to draw definite conclusions, our results 
underscore the imp0l1ant role of co-morbidity in early mortality among men with 
localized prostate cancer. It seems more appropriate to look at the patient's co-
morbidity rather than age when evaluating the risk of early death. Patients with serious 
co-morbidity and well or moderately differentiated tumors may be unlikely to benefit 
from curative treatment. However, poor differentiation was a strong determinant of 
early mortality, even within 2 years of diagnosis. Since this observation is not 
compatible with a lead time of 5-10 years, poorly differentiated tumors seem to 
represent fast-growing tumors. Patients with these tumors may benefit from curative 
treatment, regardless of concomitant diseases. 
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Chapter 7 General discussion 
Main findings of the thesis 
The main finding of this thesis is the observation that the incidence of prostate cancer 
increased considerably between 1971 and 1989 (before the introduction of PSA 
testing) in southeastern Netherlands, the sole region with a long-standing cancer 
regishy in The Netherlands. Initially, the increase in incidence (in the 1970s) was 
probably related to the increase in the number of urologists who performed 
transurethral resection of the prostate with increasing frequency. However, between 
1980 and 1989, the increase not only represented low-grade tumours but also high 
grade and even metastasized cancer. After the introduction of PSA testing, the 
incidence further increased, but mainly for low-grade localized prostate cancer. 
Survival did not improve between 1971 and 1989, confirming that the increase was 
unlikely to represent mainly 'insignificant' tumours. To increase the sample size, 
incidence and survival for men aged < 60 years were investigated in a collaborative 
study with the East Anglian Cancer Registry, which uses similar methods of data 
collection. Both incidence and mortality increased in this age group between 1971 and 
1989, whereas survival of these patients decreased or remained unaltered, indicating 
an increased incidence of fatal prostate cancer among men below 60 years. A decline 
in survival at this age was also observed in analyses with the Eurocare Study, a 
collaborative effort of 45 cancer registries in 17 countries. Mortality due to prostate 
cancer increased to a lesser extent and may pat11y be caused by decreases in mortality 
due to other major causes of death I.' and benign prostatic hyperplasia.3 However, 
analyses of national m0l1ality data revealed an increased risk for consecutive bil1h 
COh011s for men bom in 1875 up to those born around 1930. This observation as well 
as the increased incidence of both low and high grade prostate cancer and the lack of 
improvement in slllvivaJ point to an increased incidence of fatal prostate cancer, in 
particular for those bom between 1925 and 1934. Introduction of PSA testing and 
other diagnostic tools resulted in a fm1her increase in incidence that appeared to be due 
largely to advanced diagnosis and probably also a higher detection rate for formerly 
undiagnosed cases. 
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International comparisons 
Studies of trends in the incidence of prostate cancer before the introduction of PSA 
testing indicate an increase in low grade and/or localized tumours in the USA 4 and 
Sweden,S which resulted in a marked improvement in survival between 1960 and 
1980.6•7 In Norway, the incidence of more aggressive prostate cancer increased as well, 
although survival improved between 1957 and 1986.8 In the USA, 5-year relative 
survival improved from 70% in 1973-77 to 95% in 1988-1993, but the improvement 
among men aged < 60 years was very limited before 1988.' In view of the rather small 
improvement that was observed in the EUROCARE study (chapter 4.2), it seems 
reasonable to conclude that increased detection of insignificant tumours was fairly 
limited, but may valY between countries. 
Introduction of (oppOltunistic) PSA testing in southeastern Netherlands resulted in a 
pronounced increase in the incidence between 1991 and 1995, the increased incidence 
representing solely low-grade and localized tumours during this period. A similar and 
even exponential increase was observed in the USA' between 1986 and 1992 and in 
the Isere region in France, II also after the introduction of PSA testing. This increase is 
most likely an artifact caused by advanced diagnosis, based on the fact that a high PSA 
level may precede clinical prostate cancer by up to 5-10 years. 12. I ' This assumption 
was suppOlied by fluctuating trends in several areas in the USA: after a peak in 
incidence was reached, the incidence dropped to the level recorded a few years before 
the peak. 15.17 Part of the recent increase in incidence may be due to increased diagnosis 
of insignificant tumours that fonnerly remained undetected. However, there is no 
convincing evidence that this has OCCUlTed to a large extent, since most tumors 
detected by screening are moderately differentiated tumours (Gleason 5_7).15.18 On the 
other hand, increased use of multiple core biopsies and detailed examination of radical 
prostatectomy specimens might have resulted in 'up-grading' of tumours formerly 
classified as well differentiated. 19 Nevertheless, pathological findings on impalpable 
tumours of patients who underwent radical prostatectomy point into the same 
direction: only 17% of these tumours may be considered insignificant (on the basis of 
small tumour volume and low grade), whereas 37% was classified as advanced 
(capsular penetration, seminal vesicle invasion, etc.).20 However, 22% of tumours 
detected in cystoprostatectomy specimens of men not suspected of having prostate 
cancer (which would closely resemble latent prostate cancer) wcre also advanced.21-n 
Therefore, conclusions about the significance of diagnosed tumours on the basis of 
pathological findings are tentative. 
Furthennore, clinical significance is deternlined not only by pathological but also by 
patient characteristics, such as age and co-morbidity.2] 
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An increased risk of (fatal) prostate cancer bctween 1970 and 1990 can be assumed to 
have occurred in The Netherlands, but also in other European countries.'4 
However, too little is known about the aetiology of prostate cancer to be able to 
attribute the increase to a specific risk (;1ctOr. Only old age, black race and a positive 
family history are established risk indicators." However, the putative risk factor(s) 
responsible for the assumed increased risk of fatal prostate cancer should have 
occurred with increasing prevalence over the past decades and should affect men born 
between 1925 and 1934 in particular. This putative risk factor Illay initiate prostate 
cancer at young age, but Illay also (as suggested by Carter and coworkers )'6 promote 
the transition frolll latent to invasive cancer at an older age. Studies adressing putative 
risk factors might be more successful if the focus is on poorly differentiated cancer, 
since it represents potentially fatal disease. 
Management of localized prostate cancer 
From the increase in incidence of mainly localized prostate cancer, we now turn to the 
optimal and actual management of this type of cancer, which includes curative 
radiotherapy and radical prostatectomy. 
A few years ago, a guidelines panel of the American Urologic Association (AUA) 
concluded that no conclusive evidence of the superiority of one of the treatment 
options for clinically localized prostate cancer existed." Since radical treatment is 
associated with undesirable side effects such as impotence and urinary incontinence in 
up to 30-50% of patients, 28·29 ovelireatment should be avoided. 
The recent increase in the incidence of prostate cancer in the southem part of The 
Netherlands resulted in increased curative treatment, but mainly for patients under age 
70. The propOliion of patients in this age group who underwent radical prostatectomy 
ranged from 5% to 67% in the various general hospitals. Radical prostatectomy was 
perfornled more often in larger hospitals. Presence of co-morbidity had little influence 
on the physician's decision to perform radical prostatectomy, which was determined 
largely by age, tumour characteristics and the urologist's experience. Co-morbidity 
should influence the treatment choice, because most urologists consider radical 
prostatectomy only if a patient has a life expectancy of at least 10 years. 30 This is not 
easy to assess at the individual level, but co-morbidity remains an important 
determinant of the life expectancy of these patients. 31 For curative radiotherapy, such 
a rule does not exist probably because there is not a notable risk of mOliality. The 10-
year rule was based on the obselvation that cause-specific survival is very high for 
patients with localized and low grade prostate cancer.32 Patients with prostate cancer 
diagnosed in southeastern Netherlands between 1955 and 1984 cxhibited a small 
excess risk of death compared to the gcneral age-matched population, if they had 
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survived for 10 years, but no excess after 15 years. This obselvation, as well as the 
results from other recent studies,33-34 suggests that the risk of death from prostate 
cancer is still present 10 years after diagnosis, but it fades away with increasing 
follow up. Moreover, a recent study of American patients managed conservatively in 
the 1970s and 1980s (in which all pathology specimens were reviewed) showed that 
patients with well differentiated tumours (Gleason 2-4) are virtually not at risk of 
dying from prostate cancer, even IS years after diagnosis.3' Co-morbidity had a 
substantial impact on the risk of death from all causes,31 but not on prostate cancer-
specific survival for these patients.35 It is, however not clear whether these findings 
apply to patients diagnosed on the basis of a positive PSA test. The routine registration 
of co-morbidity in the Eindhoven Cancer RegistlY gave us the rather unique 
opportunity to address this issue in a population-based setting. In agreement with the 
estimated lead time of 5-10 years for PSA detected tumours, 12-14 co-morbidity had 
decisive impact (which was stronger than age) on 3-year slllvival of patients with 
prostate cancer diagnosed between 1993 and 1995, especially below 70 years of age. 
Intermediate grade tumours did not incur a significantly worse sUlvival than a well 
differentiated tumour in the first 3 years following diagnosis. However, poor 
di fferentiation was a highly significant prognostic factor, becoming increasingly 
impOliant 2 years after diagnosis. 
Although the benefit of curative treatment for patients with well differentiated tumours 
is doubtful,35 its role for patients with moderately differentiated tumours has yet to be 
defined. Since co-morbidity appeared to be an important determinant of early 
mortality, it should be taken into account in the choice of treatment of these patients. 
Hoewever, it is probably of less impOtiance for patients with well differentiated 
tumors (who do not seem to need curative treatment) and patients with poorly 
differentiated tumors (who need proper treatment). 
Methodological considerations 
Most of the studies in this thesis are based on data from the Eindhoven Cancer 
Registry in the southem part of The Netherlands. The methods of the East Anglian 
Cancer Regislty and the other registries participating in the Eurocare study (chapter 
4.2) are comparable to those used in the Eindhoven Cancer Registry and comply with 
the standards required by the IARC.J6 Since this registry used to cover a relatively 
small region, one may wonder whether inference from this region is generalizable to 
other regions. As described in chapter 2, the region is characterized with good access 
to medical care. Since access to specialized medical care is supposed to be an 
important determinant of both incidence and survival, the inferences have to be 
considered in relation to the specific customs and traditions of a country. A striking 
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feature of the region of southeastern Netherlands is the high proportion of smokers, 
especially among males.' This has resulted in a high incidence of lung cancer and 
cardiovascular diseases. Although smoking is not associated with an increased risk of 
prostate cancer,37 the adverse effect of smoking on sUlvival may lead not only to lower 
sUlvival, but also to higher m0l1ality rates for prostate cancer.38 Therefore, an increase 
in the propol1ion smokers over time might lead to increased mortality due to prostate 
cancer. However, this is not a likely explanation becausc, on the contrary, the 
proportion of smokers has decreased since 1960.' 
An imp0l1ant feature of the Eindhoven Cancer Registry is the high quality of data on 
stage and grade. Due to rather shict coding rules, misclassification of stage is unlikely, 
because stage was coded as unknown whenever the registrars had a reasonable doubt. 
Stage data were not used for the period when the proportion unknown was> 25% (i.e. 
before 1980). Grade data are of similar high quality and are based on judgements of 
several pathologists from three Depm1ments of Pathology in the eastern part and for 
one study (chapter 6.2) three other Depal1ments of Pathology in the western part as 
well. Since histology was not reviewed, intcrobserver variation is likely to have 
occuned in this way.39 However, systematic misclassification is unlikely. Moreover, 
no changes in the mOlphological intelpretation of histological specimens have 
occurred during the study period and there is no reason to assume that Dutch 
pathologists score histological grade differently from those from othcr countries. 
The assessment of co-morbidity, described in detail in chapter 2, can be assumed to be 
of fairly high quality. However, although co-morbidity is responsible for the main 
selection bias, any real effects of treatment can only be estimated whcn patients are 
randomized over different treatment options. Residual confounding is likely in 
nonrandomized studies. This may be caused by selecting patients for curative 
treatment on the basis of other factors than co-morbidity, e.g. the clinical presentation 
of the patient at diagnosis. 
The prognostic studies in this thesis did not have prostate cancer speci fie slllvival as 
main outcome but overall or relative survival. When a specific disease is studied, one 
is usually interested only in mortality attributable to the disease studied. Hence, overall 
survival would not be an approporiate outcome. Relative survival (the ratio of the 
crude [observed] to the expected survival) is an estimate of mortality attributable to the 
disease studied, unless the study COh0l1 differs from the general population apart from 
the index disease.'o Relative survival is an appropliate outcome when studying 
survival for population~based cohorts, as in this thesis. Moreover, when relative 
survival is used, noncancer deaths among cancer patients (e.g. related to treatment) are 
also counted.'1 
However, the life tables used for expected slllvival probabilities are stratified for age 
and gender, but not for other factors associated with longevity such as socio-economic 
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status and co-morbidity. Therefore, relative survival was not the main outcome in the 
chapter on co-morbidity. It is, however, not likely that correction for socio-economic 
status would have modified our findings, since specialized medical care is equally 
accessible for all socio-economic classes in The Netherlands. Moreover, a previous 
analysis of socio-economic variations in the survival of prostate cancer in Southeastem 
Netherlands barely revealed any differences between the highest and the lowest 
socioeconomic levels, when the same expected survival probabilities were used (5-
year relative survival 61 % vs. 59%).42 
COllclusiolls and implications 
The increase in the incidence of prostate cancer between 1971 and 1989 can be 
attributed to a higher detection rate related to the increased supply of urologists, but 
also to an increased risk of fatal prostate cancer. Early detection of prostate cancer by 
PSA testing since 1990 has resulted in an additional increase in the incidence of 
mainly low-grade tumours due largely to advanced diagnosis. A causal factor for the 
assumed increased risk of fatal prostate cancer has yet to be demonstrated. 
The management of localized prostate cancer is still sUlTounded with many 
uncertainties. A result of this thesis is the importance of co-morbidity among patients 
with localized prostate cancer, especially for those aged below 70 years. The excess 
risk of death appears to decrease over time for patients with prostate cancer. 
The role of curative treatment was not addressed in this thesis. Randomized trials of 
radical prostatectomy versus observation are under way in Sweden43 and the USA,44 
but results will not be available for many years. Simultaneously, randomized trials 
adressing the benefit of early detection and treatment are currently being calTied 
QUt.45,46 
Pending these trials, follow-up studies of patients with localized prostate cancer are 
necessary. Cancer registries can supply a feasible framework for such studies, 
provided that representatives of all involved medical disciplines play an active role. 
These studies may provide insight in quality of care for all patients, including those 
excluded from trials. Furthenllore, such a study setting facilitates studies of 
determinants of recurrence and survival. Stage and grade should then uniformly be 
assessed and side effects of treatment recorded as well. 
Furthermore, the vital status of all patients should be followed up and prefen'ably the 
cause of death recorded using unambiguous criteria. 
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PSA testing outside the research setting should only be done once the man is engaged 
in the decision process and after he is informed about the current state of uncertainty 
and the risks and theoretical benefits. 
When prostate cancer is diagnosed, patients with well differentiated tumours should be 
infollllcd of the unlikely benefit of radical treatment. The possible benefit of radical 
treatment of moderately differentiated tumours and its side effects should be discussed 
with the patient. It seems more appropriate to look at the patient's co-morbidity rather 
than age when evaluating the risk of early death. Since poorly differentiated cancer 
entails a high risk of early death, when possible, radical treatment is prefelTed for 
patients presenting with these tumours. A search for a noninvasive screening test 
specific for high grade cancer deserves priority in research. Intensive investigation of 
risk factors for this fatal form of prostate cancer is another way of dealing with this 
disease. 
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A large number of papers describing an increase in the incidence of prostate cancer 
have been published over the past two decades. However, a high prevalence of so-
called 'latent' prostatc cancer of up to 30% was found in several autopsy studies of 
men aged 70 or older without a clinical diagnosis or suspicion of prostate cancer 
before death. Therefore, it is generally assumcd that the increase is partly due to 
increased detcction of these latent tumours by improved urological teclmiques such as 
TURP, PSA testing and fine needle biopsies. However, it is unclear whether this 
would explain the whole increase in incidence or that an increased risk of prostate 
cancer has occurred as wcll. This qucstion was addressed in this thcsis. 
Most of the studies are based on data from the Eindhoven Cancer Regishy, which 
collects infOlmation on every newly diagnosed cancer in a defined area in the southern 
part of The Netherlands with since 1987 approximately two million inhabitants. For a 
few studies, collaboration with other European cancer registries took place. 
In southeastem Netherlands, the age-adjusted incidence increased from 36 per 10' in 
1971 to 55 per 105 in 1989 (i.e. before introduction of PSA testing). This increase 
represented after 1980 not only low grade but also poorly differentiated and 
metastasized prostate cancer (chapter 3.1) 
The conclusion that an increase in the incidence of significant prostate cancer occurred 
in this period was confirmed by studies of trends in survival: survival barely changed 
between 1971 and 1989 in southeastern Netherlands. 
Five-year relative survival (an estimate of cause-specific survival) improved in Europe 
only from 55% in 1984-1986 to 59% in 1987-1989, according to a collaborative study 
of 45 European cancer registries (the Eumcnre study), although relative survival varied 
substantially between countries (chapter 4.2). A marked improvement in survival 
would be expected if increased diagnosis of latent cancer (which should not result in 
death of the patient) had occurred to a large extent. 
Special attention was directed to men aged below 60 years in a collaborative study 
with the East Anglian Cancer Registry. In this age group (in which fewer diagnostic 
procedures take place), both incidence and mortality due to prostate cancer increased 
by about 50% between 1971 and 1989, whereas relative survival barely changed or 
even decreased during the study period (chapter 3.3). In addition, no improvement in 
relative survival was found for this age group in the Eurocare study. 
An increased risk of fatal prostate cancer could explain this observation, which was 
further investigatcd in an age-period-cohOlt analysis of national mortality data (chapter 
3.2). Mortality due to prostate cancer increased for all age groups fmm 55 years up to 
1989 and for men aged 65 or over up into the 1990s. Furthermore, the age-cohOlt 
model but not the age-period model described the data satisfactorily, which showed an 
150 
increased risk for each subsequent bhih cohort from men bom between 1870 and 1879 
up to men born between 1925 and 1934. This suggests increased exposure to an 
hitherto unknown risk factor. 
Introduction of opportunistic PSA testing in southeastern Netherlands resulted in a 
fhrther increase (up to 80 per 10' ) in mainly low grade localized prostate cancer 
presumably due to advanced diagnosis and probably also increased detection of 
insignificant tumours. However, compared to e.g. the USA, where PSA testing has 
been widely propagated and used, the increase was rather modest (chapter 3.1). 
The second part of the thesis concell1S the mangement of localized prostate cancer. An 
increasing proportion of patients (mainly < 70 years) with localized tumours were 
treated with radical prostatectomy, although radiotherapy remained an impOliant 
altemative (chapter 5.1) A striking variation in the proportion treated with radical 
prostatectomy (ranging from 5% to 67% in the various general hospitals) was present. 
Whereas no conclusive evidence of superiority of one of these treatment options is 
cUITently available, the choice of treatment was detenuined largely by the patient's 
age, tumour characteristics and the urologist's experience. Co-morbidity was barely 
taken into account, although this was present in about 50% of patients aged 70 or over 
(chapter 5.2). 
Patients with prostate cancer diagnosed between 1955 and 1984 in southeastern 
Netherlands (largely treated without curative intent) only exhibited a small excess 
mortality if they had survived 10 years after diagnosis, whereas no excess was 
observed at 15 years (chapter 6.1). 
Co-morbidity had a large impact on survival for patients diagnosed between 1993 and 
1995 (in the era ofPSA testing), especially for patients below 70 years of age (chapter 
6.2). This was of more impOliance than age. A poorly differentiated tumour was the 
second most important prognostic factor, even after the rather ShOli mean follow-up 
period of3 years. 
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Sinds 1970 hebben onderzoekers uit talloze landen een toename in de incidentie van 
prostaatkanker gerappOlieerd. Wanneer echter op systematische wijze lijkschouwingen 
worden velTicht bij oudere mannen bij wie gedurende hun leven geen aanwijzingen 
waren voor prostaatkanker, wordt bij ongeveer 30% van de mannen van 70 jaar en 
ouder een latente voml van prostaatkanker aangetroffen. Aangezien de afgelopen 
decennia diverse verbeterde urologische technieken (zoals transurethrale resectie van 
de prostaat, PSA bepalingen en dunne naald biopsieen) zijn ge"introduceerd, wordt 
algemeen aangenomen dat de toename in incidentie voor een deel is veroorzaakt door 
een toename in de diagnose van deze latente gevallen van prostaatkanker. Het is echter 
onduidelijk of dit de hele toename in de incidentie kan verklaren of dat er daarnaast 
een werkelijk verhoogd risico op prostaatkanker is opgetreden. Dit was de 
belangrijkste onderzoeksvraag in dit proefschrift. 
Hierbij werd in hoofdzaak gebruik gemaakt van gegevens die verzameld zijn door de 
kankelTegistratie van het Integraal Kankercentrum Zuid, waarin aile nieuw ontdekte 
gevallen van kanker zijn geregistreerd voor een nauw omschreven gebied in het zuiden 
van Nederland met sinds 1987 ongeveer 2 miljoen inlVoners. Voor enkele studies werd 
samengewerkt met andere Europese kankcrregistraties. 
In Zuidoost Nederland nam de voor de leeftijd gestandaardiseerde incidentie toe van 
36 per 10' in 1971 tot 55 per 10' in 1989 (dus voor de introductie van PSA 
bepalingen). Deze toename betrofna 1980 ook slecht gedifferentieerde en bij diagnose 
gemetastaseerde tumoren (hoofdstuk 3.1). 
De conclusie hiel1lit dat er een toename in de incidentie van klinisch belangrijk 
prostaatkanker is opgetreden, werd bevestigd door studies betreffende trends in de 
prognose: de prognose veranderde nauwelijks tussen 1971 en 1989 in zuidoost 
Nederland (hoofdstuk 4.1). 
De 5-jaars relatieve overleving (een benadering van de prostaatkanker specifieke 
overlevingskans) verbeterde in Europa slechts van 55% in 1984-1986 naar 59% in 
1987-1989 in een samenwerkingsproject van 45 Europese kankerregistraties (de 
Eurocare studie), hoewel de relatieve overleving sterk varieerde tussen de 
verschillende landen (hoofdstuk 4.2). 
Speciale aandacht werd geschonken aan mannen onder de 60 jaar. In deze 
leeftijdsgroep (die minder prostaat gerelateerde diagnostiek ondergaat) namen zowcl 
de incidentie als de sterfte aan prostaatkanker met 50% toe tussen 1971 en 1989, 
terwijl de relatieve overleving niet veranderde of zelfs verslechterde gedurende deze 
periode (hoofdstuk 3.3). Er werd ook cen kleine verslechtering in de relatieve 
overleving waargenomen in de Eurocare shldie. 
Een toegenomen risico op een fatale VOlln van prostaatkanker zou deze bevindingcn 
kunnen verklaren, hetgeen nader werd bestudeerd door middel van een leeftijd-
periode-geboortecohort analyse (hoofdstuk 3.2). De sterfte ten gevolge van 
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prostaatkanker nam in heel Nederland sinds 1955 toe voor aile leeftijdsgroepen vanaf 
55 jaar tot aan 1989 en voor mannen van 65 jaar en ouder tot aan 1994. V00l1s bleken 
de sterftegegevens adequaat besclueven te kUlmen worden met een leeftijd-cohort 
model, hetgeen een toegenomen risico Iiet zien voor elk opeenvolgend geboortecohort 
van mannen geboren tussell 1870 en 1879 tot aan mannen geboren tussen 1925 en 
1934. Dit suggereert een toegenomen blootstelling aan een totnogtoe onbekende 
risicofactor. 
De introductie van PSA bepalingen in zuidoost Nederland leidde tot een verdere 
toename in de incidentie (tot 80 per 10' ) van hoofdzakelijk laaggradige en tot de 
prostaat beperkte tumoren als gevolg van vervroegde diagnose en mogelijk ook 
toegenomen detectie van latente tumoren. Vergeleken met bijvoorbeeld de Verenigde 
Staten, waar screening met behulp van PSA wijdverspreid wordt gepropageerd en 
lIitgevoerd, was de toename echter bescheiden. (hoofdstuk 3.1) 
Het tweede deel van dit proefscluift gaat over detelluinanten van behandeling en 
prognose van lokale prostaatkanker. 
Een toegenomen dee! van de patienten (vooral onder de 70 jaar) met deze tumoren 
onderging een radicale prostatectomie, hoewel curatieve radiotherapie een belangrijk 
altematief bleef (hoofdstuk 5.1). Er werd een opmerkelijke variatie tussen de 
verschillende regionale ziekenhuizen waargenomen in het percentage patienten dat een 
radicale prostatectomie onderging (dit varieerde van 5% tot 67%). 
De keuze van behandeling werd in belangrijke mate bepaald door de leeftijd van de 
patient, tumor kenmerken en de ervaring van de uroloog. Emstige bijkomende ziekten 
(co-morbiditeit) kwamen bij ongeveer de helft van de patienten van 70 jaar en ouder 
voor, maar speelden bij de behandelingskeuze een ondergeschikte rol. (hoofdstuk 5.2). 
Oversterfte bleef bij patienten die tussen 1955 en 1984 met prostaatkanker waren 
gediagnostiseerd in zuidoost Nederland na 10 jaar nog te bestaan, maar werd niet 
waargenomen na 15 jaar (hoofdstuk 6.1). 
Co-morbiditeit had grote invloed 01' de overleving van patienten met lokale 
prostaatkanker gediagnostiseerd tussen 1993 en 1995 (de periode na introdllctie van 
PSA testen), vooral bij patienten onder de 70 jaar (hoofdstuk 6.2). Dit was van meer 
belang dan de kalenderleeftijd van de patient. Een slecht gedifferentieerde tumor was 
ook een zeer belangrijke prognostische factor, ze1fs al na de vrij k0l1e studieperiode 
van gemiddeld 3 jaar. 
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Sunt 1970 hawwe undersikers ut withae folie lamlCn beskreaun, dat it tal nij untdutsen 
gefallen (ynsidinsje) fan prostaatkanker tanammen is. As ap systematyske wize 
lykskogingen dien wurde by aldere manlju, by wa't dae't se naeh libben, gjin 
prostaatkanker kanstateaITe waard, wurdt by likernoeh 30% fan de manlju fan 70 jier 
of alder prastaatkanker aantroffen. Der wurdt aer it generaal understeld, dat dizze 
latinte tumaaren faker apspaard wurden troeh de ferbettere uralagyske teehniken lykas 
TURP, PSA-hifking en biapsysk undersyk mei fine nullen. It is lykwals net dudlik, of 
dit de hiele taname yn ynsidinsje ferkleatje kin, of dat der sprake weze kin fan in 
glUtter risika ap prastaatkanker. Op dit prableem giet dit proefskrift neier yn. 
Hjirby waard yn haadsaak gebruk makke fan gegevens dy't sammele binne troeh de 
kankerregistraasje van het IKZ, weryn aile ny untdutsen gefalIen fan kanker 
registrealTe binne faar in nau amskreaun gebiet yn Zl,d Nederlan mei sunt 1987 sa 
Iikern6ch twa mi1joen ynwenncrs. Foar in stikmanllich sttldzjes waard gearwurke mei 
aare Europeeske kanke'l'egistraasjes. 
De ynsidinsje naam yn Sudeast Nederlan ta fan 36 de 10' yn 1971 en ta aan 55 de 10' 
yn 1989 (faar de yntroduksje fan PSA-hiIking). Dit tanimmen nei 1980 wiist net 
allinnieh ap in lege gl'aad fan, mar ek ap in net batte diffel'inseaITe en titsaaide 
prostaatkanker (haadstik 3.1). 
De kankll,zje dat del' yn dizze periaade in wiehtige taname pleats fUn fan de ynsidinsje 
fan prostaatkanker, waard berestige traeh stUdzjes aangeande trends yn de prognaaze: 
yn Sudeast Nederlan feroat'e tusken 1971 en 1989 de prognaaze amper. 
Relatyf aerlibjen (in skatting fan de aarsaak foal' spesifYk ael'libje fan prostaatkanker) 
ferbettere neffens in mienskiplike stUdzje fan 45 Eurapeeske kankerregistraasjes (de 
Euraeare stl,dzje) inkeld fan 55% yn 1984 aan 59% ta yn 1987-1989, alhaewal't dat 
relatyf aerlibjen wal gans farieaITet tusken de lannen (haadstik 4.2). In gruttere 
ferbettering yn aerlibjen kin ferwaehte wurde, as tanimmende diagnaaze fan latinte 
kanker (dy't net liedt ta de dea fan de pasjint) yn in gruttere am fang pleats fine sao. 
Spesjale aandaeht waard skanken aan manlju under de 60 jier. Yn dit aldel'damsskift 
(der't minder diagnastysk undersiik yn dien wurdt) namen sawal de ynsidinsje as it 
aantal deaden as gefaleh fan prostaatkankel' tusken 1971 en 1989 ta, wylst it relatyf 
aerlibjen amper feroare, earder minder waard yn dizze periaade (haadstik 3.3). Yn de 
Euraeare stUdzje waard yn dit alderdamsskift ek gjin ferbettering waamammon yn it 
relatyf aerlibjen. Dizze waarninllning soc te forkleatjen weze troeh in tanammen risika 
fan fatale prostaatkanker, dy't yn de aIderdams-periaade-skift analyze neier undersaeht 
waard mei gegevens fan alle deaden yn Ncderlan as gefaleh fan prostaatkanker 
(haadstik 3.2). 
As gefaleh fan prostaatkanker naam de stierte foal' alle alderdall1sskiften fanOf 55 jier 
aan 1989 ta en faar manlju fan 65 jier of illder aant yn de njaggentiger jierren. 
Bappedat bliek net it alderdams-periaade-madel, mar it illderdall1sskift-madel dizze 
gegevens befredigjend te beskriuwen, dat in tanimll1end risika sjen liet foal' elk 
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opinoar folgjend berte-skifl fan manlju berne tusken 1870 en 1879 en manlju berne 
tusken 1925 en 1934. Dit suggerearret in tan ommen bleatstelling oan in risiko-faktor, 
dy't oant no ta unbekend is. De yntroduksje fan de opportunistyske PSA-hifking 
resultearre yn in fierder tanimmen (boppe 80 de 10') fan yn haadsaak lokalisearre 
prostaatkanker fan lege graad as gefolch fan, nei aile gedachten, betidere diagnoaze en 
it tan ommen opspoaren fan unbetsjuttende tumoaren. 
Yn ferliking mei bygelyks de USA, dUt PSA-hifking wiidferspraat propagearre en 
brukt waard, wie it tanimmen Iykwols bcskicdcn.It twadde diel fan dit proefskrift giet 
oer de behanneling fan beheind lokalisearre prostaatkanker. In gllltter tal pasjinten 
(benammen dy fan under de 70 jier) mei 10kalisemTe tumoaren waard behannele mei 
radikale prostatektomy (it radikaal fuorthcljcn fan dc prostaa!), alhocwol't radioterapy 
(bestrieling) oerbleau as in wichtich alternatyf (haadstik 5.1). Del' bestic in opmerklike 
fariaasje yn it persintaazje behannelingen fan pasjinten (benammen dy finder de 70 
jier) mei lokalisearrc tumoaren dy't behannele wam'den mci prostatcktomy (yn de 
ferskate sikehUzen in skaal fan 5% oant 67%). Wylst op't heden net foldwaande dlIdlik 
is, hokker bchanncling de beste is, waard de kar fan de behanneling meast bepaald 
troch de filderdom fan de pasjint, de tumor-karakteristiken en de underfiningen fan de 
urolooch. Eamstigc ko-morbiditeit (bykommende sykten) waard by likern6ch 50% fhn 
dc pasjinten yn de alderdom boppe 70 jier oantroffen, mar del' waard kwealik rekken 
mei halden by de kar fan behanneling (haadstik 5.2). 
By pasjinten dy't tusken 1955 en 1984 mei prostaatkanker, diagnostisearre wienen 
(meast behannele sunder utsicht op betterskip), koe in Iytsc ferheging fan it stjertesifer 
konstatcarrc wurde, as hja langer as 10 jier nei de behanneling libben, wylst dat fan nci 
15 jier net sein wurde kin (haadstik 6.1). Ko-morbiditeit hie in gmtte ynfloed op it 
oerlibjcn fan pasjinten dy't diagnostisealTe wienen tusken 1993 en 1995 (yn it tiidrck 
fan PSA-hifking), benanunen foal' pasjinten under de 70 jier (haadstik 6.2). Oat wie 
wichtiger as de filderdom. In botte differensearre tumor wic ck in tigc wichtige 
prognoastyske faktor, sels al yn dizze srudzje fan 3 jier. 
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